Document:

EX-10.13

 Exhibit 10.13 

Confidential Treatment Requested by MeiraGTx Holdings plc 

LICENCE AGREEMENT 
 between

 UCL Business Plc 
 and

 MeiraGTx UK II Limited 

and 
 MeiraGTx Limited 

Dated: 15 March 2018 

Ref: 
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

  

	INDEX	

							
			
	1.	  	Definitions	  	 	2	 
			
	2.	  	Grant of Rights	  	 	7	 
			
	3.	  	Know-how and Confidential Information	  	 	10	 
			
	4.	  	Consideration	  	 	12	 
			
	5.	  	Commercialisation	  	 	17	 
			
	6.	  	Access to Medicines and Ethical Licensing	  	 	20	 
			
	7.	  	Compliance with Laws	  	 	21	 
			
	8.	  	Intellectual Property	  	 	22	 
			
	9.	  	Warranties and Liability	  	 	24	 
			
	10.	  	Duration and Termination	  	 	29	 
			
	11.	  	General	  	 	32	 
		
	Schedule 1 Licensed Technology	  	37	 
		
	Schedule 2 Appointment of Expert	  	38	 
		
	Schedule 3 Definition of Tobacco Industry Funding (Revised 2009)	  	39	 
		
	Schedule 4 Initial Development Plan	  	40	 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	THIS	AGREEMENT is made                     15 March
,             2018 

  

	BETWEEN:	

  

	(1)	UCL BUSINESS PLC, a company incorporated in England and Wales under company registration number 02776963 whose registered office is The Network Building, 97 Tottenham Court Road, London W1T 4TP
(“UCLB”); 

 and 
  

	(2)	MEIRAGTX UK II LIMITED, (FORMERLY ATHENA VISION LIMITED), a company incorporated in England and Wales with registered number 09348737 and having its registered office at 92 Britannia Walk, London, United Kingdom,
N1 7NQ (the “Licensee”); and 

  

	(3)	MEIRAGTX LIMITED (FORMERLY KADMON GENE THERAPY HOLDINGS LIMITED), a company incorporated in England and Wales with registered number 09501998 and having its registered office at 92 Britannia Walk, London, United
Kingdom, N1 7NQ (“Meira”). 

  

	WHEREAS:	

  

	A.	University College London (“UCL”), through the Principal Investigators, has developed certain technology and owns certain intellectual property rights relating to a gene therapy for [***], including the
Patents, the Know-how and the Materials. 

  

	B.	UCL has assigned to UCLB all of its right, title and interest in and to such property. 

  

	C.	The Licensee wishes to acquire rights under the Patents and to use the Know-how and the Materials for the development and commercialisation of Licensed Products in the Field and
in the Territory, all in accordance with the provisions of this Agreement. 

  

	D.	The Licensee aims to develop and commercialize the Licensed Product in the Field and in the Territory. 

  

	E.	Meira wishes to issue shares in the capital of Meira in consideration for the grant of rights set out in this Agreement and is a party to this Agreement solely for this purpose. 

 

	F.	It is the policy of UCLB that its activities in licensing intellectual property take into consideration ethical and socially responsible licensing principles, including ensuring that Licensed Products are made available
to fulfil unmet needs in Developing Countries, and the Licensee acknowledges and agrees to carry out its activities under this Agreement in a manner which complies with ethical and socially responsible licensing principles and which is designed to
fulfil such needs, all in accordance with the provisions of this Agreement. 

  

	NOW	IT IS AGREED as follows: 

  

	1.	DEFINITIONS 

  

	1.1	In this Agreement: 

 Agreement means this agreement (including the Schedules);

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

2 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 Affiliate in relation to a Party, means any entity or person that Controls, is
Controlled by, or is under common Control with that Party; 
 At-Cost Markets means those
markets in Developing Countries [***]; 
 Claims means all demands, claims and liability (whether criminal or civil, in contract, tort
or otherwise) for losses, damages, costs and expenses of any nature whatsoever and all costs and expenses (including legal costs) incurred in connection therewith; 

Commencement Date means the date of this Agreement; 

Commercial Third Party means a commercial entity that is not a Party of this Agreement; 

Competing Product means any product, whether ready for marketing or in development that competes, or is likely to compete once
developed, with any Licensed Product; 
 Confidential Information means the Know-how, the
Materials and all other technical or commercial information that: 
  

	 	a)	in respect of information provided in documentary form or by way of a model or in other tangible form, at the time of provision is marked or otherwise designated to show expressly that it is imparted in confidence or
which a reasonable person would expect to be confidential; and 

  

	 	b)	in respect of information that is imparted orally, any information that the Disclosing Party or its representatives informed the Receiving Party at the time of disclosure or which a reasonable person would expect to be
confidential; 

 Consideration Shares means the Convertible Preferred C Shares of £0.00001 each in the capital of
Meira to be allotted and issued to UCLB in accordance with Clause 4.1.2(a). 
 Control means direct or indirect beneficial ownership
of 50% (or, outside a Party’s home territory, such lesser percentage as is the maximum permitted level of foreign investment) or more of the share capital, stock or other participating interest carrying the right to vote or to distribution of
profits of that Party, as the case may be; 
 Cost-Based Price means, in respect of each Licensed Product, [***]; 

Developing Country or Developing Countries refers to those countries that are: 

 

	 	a)	[***]; and 

  

	 	b)	to the extent not included in a); 

  

	 	i)	defined as of the Commencement Date [***]; and 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

3 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	ii)	all other countries that may be mutually agreed to by UCL and Licensee from time to time; 

Developing Country Manufacturer means a manufacturer of pharmaceutical products that is able to efficiently manufacture (either within
or outside the Developing Country in which the At-Cost market exists), distribute and supply the Licensed Product in an At-Cost market at a Cost-Based Price; 

Diligent Efforts means exerting such efforts and employing such resources as would normally be exerted or employed by [***], when
utilizing sound and reasonable scientific, medical and business practice and judgment in order to develop the product in a timely manner and generate an economic return to the Parties from its commercialisation; 

Disclosing Party has the meaning given in Clause 3.3; 

Field means ocular gene therapy; 

First Commercial Sale means the first sale to a third party of a Licensed Product in a given regulatory jurisdiction after all
regulatory and marketing approvals have been obtained for such Licensed Product in such jurisdiction. A sale shall not be deemed to have occurred if a Licensed Product is provided pursuant to an early access or compassionate use; 

Indemnitees has the meaning given in Clause 9.7; 

Intellectual Property means any and all patents, utility models, registered designs, unregistered design rights, copyright, database
rights, rights in respect of confidential information, rights under data exclusivity laws, rights under orphan drug laws, rights under unfair competition laws, property rights in biological or chemical materials, extension of the terms of any such
rights (including supplementary protection certificates), applications for and the right to apply any of the foregoing registered property and rights, and similar or analogous rights in any part of the Territory; 

Know-how means: 
  

	 	a)	the inventions claimed in the Patents; and 

  

	 	b)	the technical information relating to the inventions claimed in the Patents and data described in the Part B of Schedule 1; 

Licensed Products means any and all products that are developed, manufactured, used, or sold by or on behalf of the Licensee or its
Affiliates or Sub-licensees and which (a) are within (or are manufactured using a process described in) any claim of the Patents; and/or (b) incorporate, or their development or manufacture makes use
of, any of the Know-how and/or the Materials; 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

4 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 Licensed Technology means the Patents, the
Know-how and the Materials set out in Schedule 1; 
 Materials means any and all of the
materials referred to in Part C of Schedule 1; 
 Net Sales Value means in respect of the Licensed Products after their First
Commercial Sale: 
  

	 	a)	the gross invoiced price of Licensed Products sold by the Licensee or its Affiliates or Sub-licensees in arm’s length sales of Licensed Products for cash consideration; and/
or 

  

	 	b)	where the sale is not at arm’s length and/ or is for or includes a non-cash consideration, or if Licensed Products used or subject to Clause 5.9, disposed of for free by the
Licensee or its Affiliates the relevant open market price for the Licensed Product in the country or territory in which the sale, use or disposal takes place or if the relevant open market price is not ascertainable, a reasonable price, assessed on
an arm’s length basis therefor, 

 after deduction of all documented: 

 

	 	i)	normal trade discounts (but excluding early payment discounts) actually granted and any credits actually given for rejected or returned Licensed Products; 

 

	 	ii)	costs of packaging, insurance, carriage and freight, provided in each case that the amounts are separately charged to the purchaser on the relevant invoice; 

 

	 	iii)	deductions for actual bad debt in connection with sales of Licensed Product (provided that Licensee will use Diligent Efforts to obtain payment of such bad debt); 

 

	 	iv)	value added tax or other sales tax; and 

  

	 	v)	import duties or similar applicable government levies charged to the purchaser on the relevant invoice. 

provided that such deductions do not exceed reasonable and customary amounts in the markets in which such sales occurred. Sales of Licensed
Products between the Licensee and its Affiliates shall not be taken into account for the purposes of calculating “Net Sales Value” unless there is no subsequent sale to a third party in an arm’s length transaction for a cash
consideration; 
 Parties means UCLB, the Licensee and Meira, and “Party” shall mean either of them; 

Patent Costs means [***]. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

5 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 Patents means any and all of the patents and patent applications referred to in Part A
of Schedule 1; 
 Principal Investigators means [***]. 

Reasonable Developing Country Licence Terms means terms that meet the requirements of both UCL’s ethical and socially responsible
licensing policy, which is at: (http://www.ucl.ac.uk/enterprise/about/policies/files/Global_access-final.pdf) and the following principles: 
  

	 	a)	the Licensee shall [***]; 

  

	 	b)	the Developing Country licence terms [***] that shall not [***]; 

  

	 	c)	if the Developing Country Manufacturer is granted any exclusive rights, the continued grant of those rights shall be conditional upon the Developing Country Manufacturer supplying
At-Cost Markets at a Cost-Based Price and meeting market demand in that market; and 

  

	 	d)	the Licensee may impose reasonable conditions, including as to use of trademarks, trade dress, format and pack size, to differentiate the Licensed Product when sold in the At-Cost
market from Licensed Products sold in other markets and to prohibit their export into other markets and territories, provided that such conditions or their implementation do not act as an unreasonable barrier to the prompt and efficient supply of
Licensed Product in the At-Cost market; 

 Receiving Party means has the meaning
given in Clause 3.3; 
 Regulatory Exclusivity means, with respect to a Licensed Product, any exclusive rights or protection which are
recognised, afforded or granted by any Regulatory Authority in any country or region with respect to the Licensed Product other than through patent rights; 

Sub-licensee means any third party (other than an Affiliate) to whom the Licensee grants a
sub-licence of its rights under this Agreement in accordance with Clause 2.3; 
 Territory means Worldwide; 

Valid Claim means a claim of a patent or patent application that has not been abandoned or allowed to lapse or expired or been held
invalid or unenforceable by a court of competent jurisdiction in a final and non-appealable judgment. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

6 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	2.	GRANT OF RIGHTS 

  

	2.1	Licence 

 UCLB hereby grants to the Licensee and its Affiliates, and the Licensee hereby
accepts on its own behalf and on behalf of its Affiliates, subject to the provisions of this Agreement: 
  

	 	2.1.1	an exclusive (even as to UCL) licence under the Patents, with the right to sub-license, subject to Clause 2.3, to develop, commercialise, manufacture, have manufactured, use, sell
and have sold Licensed Products only in the Field and in the Territory; and 

  

	 	2.1.2	an exclusive (even as to UCL) licence to use the Know-how and the Materials, with the right to sub-license, subject to Clause 2.3, to
develop, commercialise, manufacture, have manufactured, use, sell and have sold Licensed Products only in the Field and in the Territory. 

  

	2.2	UCLB shall at the Licensee’s request and cost execute such formal licences as may be necessary to enable the Licensee to register the licences granted to it under this Agreement with the Patent Offices in
the relevant Territory. Such formal licence will reflect the terms of this Agreement where possible and for the avoidance of doubt if there is a conflict in the terms of such formal licence and this Agreement, the terms of this Agreement shall
prevail. The Licensee shall ensure that this Agreement shall not form part of any public record, except where disclosure of the terms of this Agreement are required by applicable law, rule or regulation (including the rules or regulations of a stock
exchange upon which the Licensee’s shares are sold). 

  

	2.3	Sub-Licensing 

 The Licensee shall have the right
to grant sub-licences under the licence in Clause 2.1 to its Affiliates or other third parties through one or more levels of Sub-licensees except that the Licensee may not grant such a sub-licence to any person or the Affiliates of any person
involved in: the tobacco industry (as defined by the Cancer Research UK Code of Practice on Tobacco Industry Funding to Universities detailed in Schedule 3); arms dealing; gambling operations; the promotion of violence; child labour or any other
illegal activity. A grant of any sub-licence shall be conditional on the following: 
  

	 	(a)	The Licensee shall enter into a written agreement with each Sub-licensee and shall ensure that the provisions of each sub-licence are consistent with the provisions of this
Agreement, and the Licensee shall ensure that: 

  

	 	(i)	the sub-licence sets out all the proposed terms agreed between the Licensee and the Sub-licensee, including, in particular, all terms as to remuneration; 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

7 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	(ii)	the Sub-licensee will maintain complete and accurate records in sufficient detail to permit UCLB to confirm the accuracy of the calculation of royalty payments under this
Agreement; and 

  

	 	(iii)	the sub-licence imposes obligations of confidentiality on the Sub-licensee which are no less onerous than those set out in Clause 3.3. 

 

	 	(b)	The Licensee shall procure that each Sub-licensee complies fully at all times with the provisions of its sub-licence. 

 

	 	(c)	The Licensee shall be liable for all acts and omissions of its Sub-licensees that, if committed by the Licensee, would constitute a breach of any of the provisions of this
Agreement. 

  

	 	(d)	The Licensee shall provide UCLB with a copy of any sub-licence [***] ([***]) days after execution of such sub-licence, provided that the Licensee may redact confidential or proprietary terms from such copy, including
financial terms. 

  

	 	(e)	Each sub-licence shall terminate automatically upon termination of this Agreement for any reason (but not expiry of this Agreement under Clause 10.1) except where: 

 

	 	(i)	the Sub-licensee was not implicated in or at fault in any circumstances which led to the termination of this Agreement; 

 

	 	(ii)	the benefit (but not the burden) of the sub-licence agreement is validly assigned to UCLB in writing within [***] ([***]) days following the date of termination of this Agreement; and 

 

	 	(iii)	following assignment, the Sub-licensee observes in full the terms of the sub-licence agreement including paying all sums due to the Licensee under the sub-licence agreement
directly to UCLB in a timely manner, 

 in which case the Sub-licensee’s rights to
use the Patents and the Know-how and/or the Materials shall continue in full force and effect in accordance with the terms of the relevant sub-licence agreement. 

 

	2.4	Reservation of Rights 

  

	 	2.4.1	UCLB reserves for itself and UCL the non-exclusive, irrevocable, worldwide, royalty-free right to: 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

8 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	(a)	Use the Patents and the Know-how and the Materials in the Field solely for academic research, publication and teaching; and 

 

	 	(b)	Grant licences to academic third parties to use the Patents and the Know-how and the Materials solely in academic research collaborations with UCL; and 

 

	 	(c)	Grant licences of the Patents and the Know-how and the Materials to post graduate students of UCL solely for the purpose of conducting a programme of post graduate academic
research. 

 In exercising the rights described in Clause 2.4.1(b) and (c), UCL and UCLB shall comply with the provisions of
Clause 3 as regards confidentiality of the Know-how. 
  

	 	2.4.2	UCL and UCLB will refer a request from a third party for a licence to use the Patents in clinical trials or for diagnostic purposes involving human subjects to the Licensee, and the Licensee shall liaise directly with
such third party. 

  

	 	2.4.3	Except for the licences expressly granted by this Clause 2, UCLB grants no rights to the Licensee under this Agreement to or under any intellectual property other than the Patents, the
Know-how and the Materials and hereby reserves all rights under the Patents, the Know-how and the Materials outside the Field. 

 

	 	2.4.4	Nothing in this Agreement shall limit or otherwise affect UCL’s ability to apply for noncommercial grant funding or comply with such grant terms and conditions. In the event that any terms of this Agreement
conflicts with the terms of any non-commercial grant funding, the Parties shall negotiate in good faith to amend the terms of this Agreement to allow UCL to access such funding provided that nothing herein
shall require the Licensee to agree to alter or modify the scope of the licence granted to it in this Clause 2. 

  

	2.5	Affiliates 

 The Licensee shall: 

 

	 	2.5.1	ensure that its Affiliates comply fully with the terms of this Agreement; 

  

	 	2.5.2	be responsible for any breach of or non-compliance with this Agreement by its Affiliates as if the breach or non-compliance had been a
breach or non-compliance by the Licensee; 

  

	 	2.5.3	indemnify in accordance with Clause 9.7 each of the Indemnitees against any Claims which are awarded against or suffered by any of the Indemnitees as a result of any breach of or
non-compliance with this Agreement by its Affiliates; and 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

9 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	2.5.4	ensure that if any Affiliate ceases to be an Affiliate as a result of a change of Control or otherwise, that unless a sub-licence agreement in accordance with Clause 2.3 is entered into with such an Affiliate, such
former Affiliate immediately upon such cessation: 

  

	 	(a)	ceases developing, manufacturing, having manufactured, using, selling and/ or having sold Licensed Products and ceases all use or exploitation of the Licensed Technology, for as long as any of the relevant Patents
remains in force and/or the Know-how remains confidential; 

  

	 	(b)	returns to the Licensee or destroys any documents or other materials in the former Affiliate’s possession or under its control and that contain Confidential Information provided under this Agreement relating to the
Licensed Technology and/ or Licensed Products; 

  

	 	(c)	to the extent possible, takes all action necessary to have any product licences, marketing authorisations, pricing and/ or reimbursement approvals (and any applications for any of the foregoing) which relate to Licensed
Products transferred into the name of the Licensee. 

  

	3.	KNOW-HOW AND CONFIDENTIAL INFORMATION 

  

	3.1	Provision of Know-how and Materials 

 Within
[***] ([***]) days following the Commencement Date, UCLB shall deliver to the Licensee the Materials and a copy of the Know-how. 
  

	3.2	Confidentiality of Know-how and Materials 

 The
Licensee undertakes that for so long as the Know-how and/or the Materials remains confidential, it shall (and shall ensure that its Affiliates and Sub-licensees) take
all reasonable precautions to prevent unauthorised access to the Know-how and the Materials and protect the Know-how and the Materials in the same manner as it (or they)
protect(s) its (or their) own proprietary information, and shall not (and shall ensure that its Affiliates and Sub-licensees do not) use the Know-how or the Materials
for any purpose, except as expressly licensed hereby and in accordance with the provisions of this Agreement. For the avoidance of doubt, to the extent that any Materials, Know-how or information relating to
the Patents falls within the public domain (without any breach of this Agreement or any other obligation of confidentiality), then UCL, the Principal Investigators and UCLB shall be free to use such information without restriction in the same way
that any third party would have the freedom to use it. 
  

	3.3	Confidentiality Obligations 

 Each Party (“Receiving Party”) undertakes: 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

10 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	3.3.1	to maintain as secret and confidential all Confidential Information obtained from, in the case of UCLB, the Licensee or Meira as applicable, and in the case of the Licensee and Meira, UCLB (“Disclosing Party”)
in the course of or in anticipation of this Agreement and to respect the Disclosing Party’s rights therein; 

  

	 	3.3.2	to use such Confidential Information only for the purposes of or as permitted by this Agreement; and 

  

	 	3.3.3	subject to Clause 3.4, to disclose such Confidential Information only to those of its employees, contractors, Affiliates, and Sub-licensees (if any) to whom and to the extent that
such disclosure is reasonably necessary for the purposes of this Agreement. 

  

	3.4	Permitted Disclosure 

  

	 	3.4.1	The Licensee shall have the right to disclose Confidential Information received from UCLB to: 

  

	 	(a)	potential or actual customers of Licensed Products to the extent reasonably necessary to promote the sale or use of Licensed Products and provided that the customer has agreed to confidentiality provisions at least as
restrictive as set forth herein; 

  

	 	(b)	to existing or potential Sub-licensees, collaborators, investors or lenders provided that such third parties have agreed to confidentiality provisions at least as restrictive as
set forth herein; and 

  

	 	(c)	to its Board of Directors (or similar governing body) and its counsel, accountants and other professional advisers. 

  

	3.5	Exceptions to Obligations 

 The provisions of Clause 3.3 shall not apply to Confidential
Information which the Receiving Party can demonstrate by reasonable written evidence: 
  

	 	3.5.1	was, prior to the Commencement Date, in the possession of the Receiving Party and at its free disposal and was not obtained or otherwise acquired directly or indirectly from the Disclosing Party or its Affiliates or
their respective employees, students or representatives; or 

  

	 	3.5.2	is subsequently disclosed to the Receiving Party without any obligations of confidence by a third party; or 

  

	 	3.5.3	is or becomes generally available to the public through no act or default of the Receiving Party or its agents, employees, Affiliates or Sub-licensees; or 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

11 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	3.5.4	the Receiving Party is required to disclose by or to the courts of any competent jurisdiction, or to any government regulatory agency or financial authority, provided that the Receiving Party shall: 

 

	 	(a)	inform the Disclosing Party as soon as is reasonably practicable; 

  

	 	(b)	at the Disclosing Party’s request and cost seek to persuade the court, agency or authority to have the information treated in a confidential manner, where this is possible under the court, agency or
authority’s procedures; and 

  

	 	(c)	where the disclosure is unavoidable, limit the disclosure of Confidential information to the minimum extent required by law; or 

  

	 	3.5.5	which a Party is advised by its information officer that it is required to disclose under the Freedom of Information Act 2000 or the Environmental Information Regulations 2004. 

 

	3.6	Disclosure to Employees 

 The Receiving Party shall procure that all of its employees,
contractors, Affiliates and Sub-licensees who have access to any of the Disclosing Party’s Confidential Information to which Clause 3.3 applies, shall be made aware of the obligations of confidence and
enter into written undertakings of confidentiality at least as restrictive as those set forth herein (which it undertakes to enforce and for which it is legally responsible) and the Receiving Party shall only disclose the Disclosing Party’s
Confidential Information to those of its subsidiaries, employees, and officers as need to have access thereto wholly necessarily and exclusively for the purposes of this Agreement. 

 

	4.	CONSIDERATION 

  

	4.1	Initial Payment and Allocation of Shares 

 On or before the Commencement Date in
consideration for the rights granted by UCLB under this Agreement: 
  

	 	4.1.1	the Licensee shall pay to UCLB £6,994 (six thousand nine hundred ninety-four pounds only) (exclusive of VAT) in terms of Patent Costs up to the Commencement Date, which payment shall be non-refundable and non-deductible; and 

  

	 	4.1.2	Meira shall: 

  

	 	(a)	allot and issue to UCLB such number of fully paid-up (and credited as fully paid-up) Consideration Shares ranking pan passu with the
existing Convertible Preferred C Shares of £0.00001 each in the capital of Meira that have the equivalent cash value of £[***], which the Parties agree is [***] Consideration Shares; 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

12 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	(b)	deliver to UCLB a copy or extract of the resolutions adopted by the board of directors of Meira approving the allotment and issue of the Consideration Shares to UCLB; and 

 

	 	(c)	enter UCLB’s name in Meira’s register of members as the holder of the Consideration Shares and deliver to UCLB a duly executed share certificate in respect of the Consideration Shares.

  

	4.2	Milestone Payments 

 Within [***] ([***]) days following achievement of each of the
following milestone events by Licensee, its Affiliates or Sub-licensees, the Licensee shall notify UCLB in writing that the relevant milestone event has been achieved, provide documentary evidence of such
achievement as appropriate and pay to UCLB, within a period of [***] days, the amount(s) set out next to such milestone event below: 
  

			
	 Milestone Event
	  	Amount to be paid
	 [***]
	  	£[***]
	 [***]
	  	£[***]

  

	4.3	Annual Management Fees 

 On each date referred to in the following table, the Licensee
shall pay to UCLB the annual management fee set out next to such date in the table. 
  

			
	 Date
	  	Amount to be paid
	 Upon each anniversary of the Commencement Date until [***]
	  	£50,000

  

	4.4	Sales Linked Milestone Payments 

 Upon achievement of each of the sales linked milestones
set out in the following table by the Licensee, its Affiliates or Sub-licensees, the Licensee shall notify UCLB in writing that the relevant sales linked milestone has been achieved, provide the relevant
documentary evidence and pay to UCLB the amount(s) set out next to such event in the table: 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

13 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

			
	 Sales Linked Milestones
	  	Amount to be paid

  

					
	 When Net Sales Value reaches £[***]
	  	£	[	***] 
		
	 On the next £[***] of Net Sales Value (when sales cumulatively reach £[***])
	  	£	[	***] 
		
	 On the next £[***] of Net Sales Value (When sales cumulatively reach
£[***])
	  	£	[	***] 
		
	 On the next £[***] of Net Sales Value (when sales cumulatively reach £[***])
	  	£	[	***] 
		
	 On the next £[***] of Net Sales Value (when sales cumulatively reach £[***])
	  	£	[	***] 
		
	 On the next £[***] of Net Sales Value (when sales cumulatively reach
£[***])
	  	£	[	***] 

  

	4.5	Royalties on Net Sales 

 For each Licensed Product in each country, the Licensee shall
pay to UCLB a royalty of [***]% ([***] per cent) being a percentage of the Net Sales Value of all Licensed Products sold by Licensee, its Affiliates or Sub-licensees. The Licensee’s obligations to pay
such royalty for a given Licensed Product in a given country shall begin after the First Commercial Sale of such Licensed Product in such country and shall end on the later to occur of the following: (a) expiration of the last Valid Claim of a
Patent claiming such Licensed Product in such country; or (b) the tenth (10th) anniversary of the date of such First Commercial Sale in such country; or (c) the expiration of any
Regulatory Exclusivity with respect to all Licensed Products in the relevant country. 
  

	4.6	Combination Products 

 If any Licensed Products are incorporated in any other product
(“Combination Product”) sold by the Licensee or its Affiliates and the Licensed Product is not priced separately from the Combination Product, the Net Sales Value of such Licensed Product shall be deemed to be the fair market value of the
Licensed Product in the country of sale when sold separately or if not sold separately in the country of sale, in comparable countries and territories or if neither of the foregoing apply, a reasonable amount which fairly reflects the value of the
Licensed Product within the Combination Product assuming the Licensed Product is not being sold as a loss leader. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

14 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	4.7	Payment Frequency 

 Royalties due under this Agreement, except for the payments due under
Clauses 4.1.1, 4.2, 4.3 and 4.4 , which are payable upon the date/time specified in Clauses 4.1.1, 4.2, 4.3, and 4.4 as appropriate, shall be paid within [***] ([***]) days following the end of each calendar quarter ending on 31 March,
30 June, 30 September and 31 December in each year, in respect of sales of Licensed Products made during such quarter, and within [***] ([***]) days following the termination of this Agreement. 

 

	4.8	Payment terms 

 All sums due under this Agreement: 

 

	 	4.8.1	are exclusive of Value Added Tax which where applicable will be paid by the Licensee to UCLB in addition; 

  

	 	4.8.2	shall be paid in pounds sterling in cash by transferring an amount in aggregate to the following Account name: UCL Business Plc, Sort Code: 20 10 53, Account number: 30782270, Address: Barclays Bank Plc, PO Box 11345,
London, W12 8GG, and in the case of income or amounts received by the Licensee or its Affiliates in a currency other than pounds sterling, the royalty shall be calculated in the other currency and then converted into equivalent pounds sterling at
the relevant daily spot rate for that currency as quoted in the Financial Times newspaper on the last business day of the quarter in relation to which the royalties are payable; 

 

	 	4.8.3	will be made without any set-off, deduction or withholding except as may be required by law. If the Licensee is required by law to make any deduction or to withhold any part of
any amount due to UCLB under this Agreement, the Licensee will give to UCLB proper evidence of the amount deducted or withheld and payment of that amount to the relevant taxation authority, and will do all things in its power to enable or assist
UCLB to claim exemption from or, if that is not possible, to obtain a credit for the amount deducted or withheld under any applicable double taxation or similar agreement from time to time in force; and 

 

	 	4.8.4	shall be made by the due date, failing which UCLB may charge interest on any outstanding amount on a daily basis at a rate equivalent to 3% above the Bank of England pound sterling base rate then in force in London.

  

	4.9	Royalty Statements 

 The Licensee shall send to UCLB, at the same time as each royalty
payment is made in accordance with Clause 4.5, a statement setting out for the relevant calendar quarter: 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

15 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	4.9.1	in respect of each territory or region in which Licensed Products are sold; 

  

	 	4.9.2	the types of Licensed Product sold; 

  

	 	4.9.3	the quantity of each type sold; 

  

	 	4.9.4	the total invoiced price for each type of Licensed Product sold; 

  

	 	4.9.5	where relevant, details of any Licensed Products that have been sold other than on arm’s length terms for a cash consideration, including the relevant open market price or (if not available) the reasonable price
attributed thereto; 

  

	 	4.9.6	the amounts deducted from the Net Sales Value as referred to in paragraph (i) to (iv) of that definition (broken down on a product by product and category by category basis); and 

 

	 	4.9.7	the aggregate royalties on Net Sales Value due to UCLB; 

 in each case expressed both in local
currency and pounds sterling and showing the conversion rates used, during the period to which the royalty payment relates. 
  

	4.10	Records 

 The Licensee shall keep at its normal place of business detailed and up to date
records and accounts showing the quantity, description and invoiced price or non-cash consideration for all Licensed Products sold by it or its Affiliates or on its or its Affiliates’ behalf, broken down
in each case on a country by country basis, and being sufficient to ascertain the payments due to UCLB under this Agreement. 
 The Licensee
shall make such records and accounts available, on reasonable notice, for inspection during business hours by an independent chartered accountant nominated by UCLB for the purpose of verifying the accuracy of any statement or report given by the
Licensee to UCLB under this Clause 4.10. The Licensee shall co-operate reasonably with any such accountant, and shall promptly provide all information and assistance reasonably requested by such accountant.
The accountant shall be required to keep confidential all information learnt during any such inspection, and to disclose to UCLB only such details as may be necessary to report on the accuracy of the Licensee’s statement or report. UCLB shall
be responsible for the accountant’s charges unless the accountant certifies that there is an inaccuracy of more than [***]% ([***] percent) in any royalty statement, in which case the Licensee shall pay his charges in respect of that
inspection. 
 The Licensee shall ensure that UCLB has the same rights as those set out in this Clause 4.10 in respect of the Licensee’s
Affiliates and Sub-licensees. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

16 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 The Licensee shall co-operate with UCLB in good faith to resolve any
discrepancies identified during any such inspection and shall pay any shortfall in the amounts paid to UCLB under this Agreement, together with interest on late payment as specified in Clause 4.8.4, within 30 days following receipt of a copy of the
independent chartered accountant’s report. 
  

	4.11	Accounting Standards 

 Where this Agreement requires a financial calculation to be made or an action to
be taken, such calculation or action will be made or taken in accordance with the generally accepted accounting principles from time to time approved by the United Kingdom’s Financial Reporting Council, or any successor body, applicable as at
the date on which such calculation or action is made or taken. 
  

	5.	COMMERCIALISATION 

  

	5.1	General Diligence 

 The Licensee shall use Diligent Efforts to develop and commercially
exploit Licensed Products throughout the Territory (including obtaining all and any regulatory approvals which may be required to market and sell the Licensed Products) and to maximise sales for the benefit of both Parties. 

 

	5.2	Competing Activities 

 The Licensee shall notify UCLB in confidence if it or any of its
Affiliates or its Sub-licensees commences any marketing, sale or commercialisation of any Competing Product or enters into an agreement with any other person with respect to any such activities. 

 

	5.3	Development Plan 

 The Licensee’s initial plan for developing and commercialising
Licensed Products is set out in Schedule 4 (the “Initial Development Plan”). The Licensee shall provide to UCLB on each anniversary of the Commencement Date a written update to the Initial Development Plan that shall: 

 

	 	5.3.1	report on all activities conducted under this Agreement by the Licensee and its Affiliates and Sub-licensees since the Commencement Date or the date of the previous update (as
appropriate); 

  

	 	5.3.2	(where applicable) set out the milestone events achieved since the Commencement Date or the date of the previous update (as appropriate) and the Licensee’s reasonable estimate of the dates for achieving any future
milestone events; 

  

	 	5.3.3	set out the current and projected activities being taken or planned to be taken by the Licensee and its Affiliates and Sub-licensees to bring Licensed Products to market, and to
maximise the sale of Licensed Products in the Territory; and 

  

	 	5.3.4	set out the Licensee’s projected sales of Licensed Products (based on the Licensee’s current forecasts) for each of the next [***] ([***]) years following the date of the report. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

17 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 UCLB’s receipt or approval of any update to the Updated Development Plan shall not be
taken to waive or qualify the Licensee’s obligations under Clause 5.1. 
  

	5.4	Annual Meeting 

 In respect of the Licensed Technology, the Licensee will on UCLB’s
request meet with UCLB at least once per calendar year, following the submission of the update to the relevant Development Plan pursuant to Clause 5.3, to discuss progress with development and commercialisation of the Licensed Technology and where
relevant the Licensee’s efforts to maximise sales of Licensed Products. 
  

	5.5	Reporting of First Commercial Sale 

 The Licensee will, for each Licenced Technology,
promptly notify UCLB in writing of the First Commercial Sale of each Licensed Product on a commercial basis in each country within the Territory. 
  

	5.6	Reporting for Impact Purposes 

  

	 	5.6.1	The Licensee acknowledges that part of UCLB’s purpose in licensing the Patents, Know-how and the Materials to the Licensee pursuant this Agreement is to ensure that the
Patents, Know-how and the Materials are made available for use and commercial exploitation with the intention of benefitting society and the economy. In order to enable UCLB and UCL to monitor the benefit that
they are providing, and to enable UCL to demonstrate the impact of its research activities, to society and the economy, the Licensee will upon request provide to UCLB [***], a written report describing in reasonable detail how it has used the
Patents, Know-how and the Materials and the societal and economic benefits generated therefrom. 

  

	 	5.6.2	UCLB shall notify and seek permission from the Licensee in advance, in writing if it wishes to use any written reports received from the Licensee (and the information contained therein) pursuant to Clause 5.6.1 in
applications for research or other grant related funding and in submissions to Higher Education funding bodies such as HEFCE and/ or HEIF (or any replacements for either of those entities) and like entities, supplying a written copy of the
application for research or other grant related funding or submission (or the relevant sections thereof). The Licensee will respond to UCLB in writing within [***] ([***]) days of receipt of such written information and subject to the removal of any
confidential information as notified in such written request by the Licensee, UCLB and UCL shall be entitled to submit the approved applications for research or other grant related funding and in submissions to Higher Education funding bodies such
as HEFCE and/ or HEIF (or any replacements for either of those entities) and like entities. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

18 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	5.7	Quality 

 The Licensee shall ensure that all of the Licensed Products marketed by it and
its Affiliates and Sub-licensees are of satisfactory quality and comply with all applicable laws and regulations in each part of the Territory. 

 

	5.8	Marking of Licensed Products 

 To the extent permitted under the laws of any country, the
Licensee shall mark and cause its Affiliates and Sub-Licensees to mark each Licensed Product with the number of each issued Patent which applies to the Licensed Product and a statement that such Licensed
Products are sold under licence from UCL Business plc. 
  

	5.9	Disposals of Licensed Products for Free 

 Notwithstanding the terms of Clause 5.1, the
Licensee shall be entitled to supply a reasonable number of Licensed Products to third parties free of charge as promotional items for the purpose of establishing a market for the Licensed Products in the relevant country or territory or for
research, evaluation and testing purposes, or for clinical development, provided that the quantity of Licensed Products supplied for free (or for the cost of manufacture) in each country or territory is not excessive and is in line with normal
industry practice in such country or territory. Any Licensed Products disposed of to third parties in accordance with this Clause 5.9 shall not be taken into account for the purposes of calculating Net Sales Value. 

 

	5.10	Referral to Expert 

 If UCLB considers at any time during the period of this Agreement
that the Licensee has failed to comply with its obligations under Clause 5.1 or 5.3, then the matter shall be referred to an independent expert to answer the following questions: 

 

	 	5.10.1	whether the Licensee has complied with its obligations under Clause 5.1 or 5.3; and if not 

  

	 	5.10.2	what specific action the Licensee should have taken and/or now needs to take (“Specific Action”) in order to fulfil such obligations and within what period the Specific Action should be taken (“Action
Period”). 

 The independent expert shall be appointed in accordance with the provisions of Schedule 2 and his decision
shall be final and binding on the Parties. 
  

	5.11	Consequences of Expert’s Decision 

 If the expert determines that the Licensee has
failed to comply with its obligations under Clause 5.1 or 5.3, and if the Licensee fails to take the Specific Action within the Action Period, UCLB shall be entitled, by giving, at any time within [***] ([***]) months after the end of that Action
Period, not less than [***] ([***]) months’ notice, to (a) convert the licence granted under Clause 2.1.1 into a non-exclusive licence or (b) terminate this Agreement. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

19 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	6.	ACCESS TO MEDICINES AND ETHICAL LICENSING 

  

	6.1	General Diligence 

 The Licensee agrees to use Diligent Efforts to develop and
commercially exploit Licensed Products in a manner consistent with ethical and socially responsible licensing principles, including requiring all Sub-licensees and other parties involved in the development and
commercial exploitation of Licensed Products to agree in writing to comply with ethical and socially responsible licensing principles. 
  

	6.2	Supply to Developing Countries 

  

	 	6.2.1	Supply by the Licensee 

 The Licensee shall use Diligent Efforts to supply the Licensed
Products to customers in At-Cost Markets at a Cost-Based Price and to meet market demand for the Licensed Products in those markets. 
  

	 	6.2.2	Sub-Licensing in Developing Country markets 

 If
the Licensee is unable to supply the Licensed Product at a Cost-Based Price in any At-Cost Market and to meet market demand for the Licensed Products in those markets, it shall use Diligent Efforts to license
one or more Developing Country Manufacturers on Reasonable Developing Country License Terms to manufacture, distribute and sell the Licensed Product at a Cost-Based Price in that At-Cost Market. 

 

	6.3	Reporting 

 The Licensee shall keep UCLB regularly updated regarding the Licensee’s
efforts to supply the Licensed Products in accordance with the requirements outlined in Clauses 6.1 and 6.2. 
  

	6.4	Step In Rights 

  

	 	6.4.1	If at any time UCLB acting reasonably considers that the Licensee is not meeting its obligations under Clauses 6.1 and 6.2 in relation to the supply of the Licensed Products to customers in At-Cost Markets, UCLB may be written notice require the Licensee to seek one or more third parties to develop, commercialise and supply the Licensed Products to customers in
At-Cost Markets. 

  

	 	6.4.2	If the Licensee following a written requirement from UCLB refuses to grant a sublicense to or is unable to identify a third party to develop, commercialise and supply the Licensed Products to customers in At-Cost Markets, then UCLB notwithstanding the rights granted to the Licensee under this Agreement shall have the right to seek a third party and/ or to grant to a third party a license to manufacture, have
manufactured, use, sell, offer for sale and import the Licensed Products for supply in the At-Cost market on Reasonable Developing Country License Terms. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

20 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	7.	COMPLIANCE WITH LAWS 

  

	7.1	General Compliance with Laws 

 The Licensee will at all times (and will ensure its
Affiliates and Sub-licensees) comply with all legislation, rules, regulations and statutory requirements applying to and obtain any consents necessary for its use of the Patents, the Know-how and the Materials, the development, manufacture, and sale of Licensed Products in any country or territory. 
  

	7.2	Bribery Act 

 The Licensee shall (and shall procure that any persons associated with it
engaged in the performance of this Agreement including its Affiliates and Sub-licensees shall): 
  

	 	7.2.1	comply with all applicable laws and codes of practice relating to anti-bribery and anti-corruption including the Bribery Act 2010 and without prejudice to the foregoing generality, shall not engage in any activity,
practice or conduct which would constitute an offence under sections 1, 2 or 6 of the Bribery Act 2010 or do or omit to do any act that will cause or lead UCLB to be in breach of the Bribery Act 2010; 

 

	 	7.2.2	comply with UCLB’s ethics, anti-bribery and anti-corruption policies as notified to the Licensee from time to time and have, maintain in place and enforce throughout the term of this Agreement adequate procedures
to ensure compliance with Clause 7.2.1; and 

  

	 	7.2.3	promptly report to UCLB any request or demand for any undue financial or other advantage of any kind received in connection with the performance of this Agreement. 

For the purpose of this Clause 7.2, the meaning of adequate procedures and whether a person is associated with another person shall be
determined in accordance with the Bribery Act 2010 (and any guidance issued under section 9 of that Act). Breach of this Clause 7.2 shall be deemed a material breach of this Agreement entitling UCLB to terminate under Clause 10.2.1. 

 

	7.3	Export Control Regulations 

 The Licensee shall ensure that, in using the Patents, Know-how or Materials and in selling Licensed Products, it and its Affiliates, employees, sub-contractors and Sub-licensees comply
fully with any EU or UK legislation or regulation, from time to time in force, which impose arms embargoes or control the export of goods, technology or software, including weapons of mass destruction and arms, military, paramilitary and security
equipment and dual-use items (items designed for civil use but which can be used for military purposes) and certain drugs and chemicals. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

21 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	8.	INTELLECTUAL PROPERTY 

  

	8.1	Obtain and Maintain the Patents 

  

	 	8.1.1	The Licensee shall be responsible for the drafting, filing, prosecution and maintenance of all of the Patents at the Licensee’s cost and expense. Subject to resource availability, UCLB shall use commercially
reasonable efforts to provide such assistance as the Licensee may request to prosecute and maintain the Patents[***] that may be incurred in providing such assistance. 

 

	 	8.1.2	The Patents will be filed, prosecuted and maintained in the countries and territories where Licensee normally files its patent applications and patents for other gene therapy products. The Licensee shall notify UCLB of
any decisions as to which (if any) additional countries to file and maintain Patents in. 

  

	 	8.1.3	The Licensee shall consult with UCLB in relation to all material changes to the patent claims or specifications that would have the effect of reducing or limiting the scope of the Patents, and not make any such changes
without the prior written consent of UCLB. Such consent shall not be unreasonably withheld or delayed provided that UCLB has been given as much notice as is practicable, and in any event no less than [***] days’ notice (or such shorter period
for response dictated by the relevant patent office) of such proposed changes, and has been given an opportunity to file divisionals, continuations and/or such other types of protection to cover any claims or subject matter that the Licensee intends
to remove from the scope of the Patents. If UCLB fails to respond before the end of the [***] day period (or such shorter period for response dictated by the relevant patent office), the Licensee may proceed with the proposed changes to the patent
claims or specifications. The Licensee will ensure that UCLB receives copies of all correspondence to and from Patent Offices in respect of the Patents, including copies of all documents generated in or with such correspondence, and shall be given
reasonable notice (or such shorter period for response dictated by the relevant patent office) of and the opportunity to participate in any conference calls or meetings with the Licensee’s patent attorneys in relation to the drafting, filing,
prosecution and maintenance of the Patents, so that UCLB may be continuously informed of progress with the drafting, filing, prosecution and maintenance of the Patents. Such involvement of UCLB under this Clause 8.1.3 shall be at UCLB’s cost
and expense. 

  

	 	8.1.4	If the Licensee wishes to abandon any application contained with the Patents or not to maintain any such Patent, it shall give [***] ([***]) months’ prior written notice to UCLB and on the expiry of such notice
period the licences of the relevant Patents granted to the Licensee under this Agreement shall cease. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

22 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	8.1.5	In the event that any of rights granted hereunder become non-exclusive, responsibility for the drafting, filing, prosecution and maintenance of all of the Patents shall revert to
UCLB. 

  

	8.2	Infringement of the Patents, the Know-how and/or the Materials 

  

	 	8.2.1	The Licensee and UCLB shall promptly give to each other written notice if it becomes aware of any infringement or potential infringement of any of the Patents or any unauthorised use of the Know-how or the Materials or any challenge to the validity or ownership of the Patents, the Know-how or the Materials and the Licensee and UCLB shall consult with each other
to decide the best way to respond to such infringement, unauthorised use or challenge. 

  

	 	8.2.2	The Licensee shall have the primary obligation and right to take action against any third party alleged to be infringing the Patents or making unauthorised use of the Know-how or
the Materials and to defend the Patents against challenges to validity or ownership at its sole expense, provided that: 

  

	 	(a)	the Licensee and UCLB shall use their commercially reasonable efforts to eliminate the infringement without litigation. If the efforts of the Licensee, and UCLB are not successful in eliminating the infringement within
[***] ([***]) days after the infringer has been formally notified of the infringement by the Licensee, the Licensee shall have the right after consulting with UCLB, to commence suit on its own account; 

 

	 	(b)	UCLB shall on the Licensee’s request cooperate with the Licensee in such action [***]; and 

  

	 	(c)	the Licensee shall be solely responsible for the conduct of the action or for settlement thereof and shall be entitled to all damages received from such action, subject to Clause 8.2.4. 

 

	 	8.2.3	Before starting or defending or settling any legal action under Clause 8.2.2, the Licensee shall consult with UCLB as to the advisability of the action or defence or settlement, its effect on the good name of UCLB, the
public interest, and how the action or defence should be conducted. 

  

	 	8.2.4	The Licensee shall [***]. 

  

	 	8.2.5	UCLB shall if reasonably requested by the Licensee agree to be joined in any suit to enforce such rights or will take such action in its own name [***] and shall have the right to be separately represented by its own
counsel [***]. Notwithstanding the foregoing, [***]. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

23 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	8.3	Infringement of Third Party Rights 

  

	 	8.3.1	If any warning letter or other notice of infringement is received by the Licensee or UCLB, or legal suit or other action is brought against the Licensee or UCLB, alleging infringement of third party rights in the
manufacture, use or sale of any Licensed Product or use of any Patents, Know-how or Materials, that Party shall (in the case of UCLB) promptly provide full details to the Licensee and (in the case of the
Licensee) promptly provide full details to UCLB, and the Licensee and UCLB shall discuss the best way to respond. 

  

	 	8.3.2	The Licensee shall have the right but not the obligation to defend such suit to the extent it relates to Licensee’s or its Affiliates’ or Sub-licensee’s activities
and shall have the right to settle with such third party, provided that [***]. In the event that the Licensee, Affiliates or Sub-licensees do not take forward an action, UCLB shall have the right, at its sole
discretion, to defend such suit under its sole control and [***]. 

  

	9.	WARRANTIES AND LIABILITY 

  

	9.1	Warranties by UCLB 

 UCLB warrants and undertakes as follows to its reasonable knowledge
and without having undertaken any due and careful enquires whether specific or general in nature: 
  

	 	9.1.1	It is the owner of the Patents; 

  

	 	9.1.2	it has the authority to grant the licences under this Agreement; and. 

  

	 	9.1.3	so far as it is aware (having made no enquiry of any third parties or conducted any freedom to operate searches), use and exploitation of the Patents will not infringe the intellectual property rights of any third
party. 

 UCLB warrants and undertakes: 
  

	 	9.1.4	it has full power and authority to enter into and perform this Agreement which, when executed, will constitute valid and legally binding obligations on UCLB;
and 

  

	 	9.1.5	entry into this Agreement and subscription for the Consideration Shares will not result in any breach of, or violation of the terms or provisions of, the
constitutional documents of UCLB or any other agreement or instrument by which it is bound. 

  

	9.2	Warranties by the Licensee 

 The Licensee warrants and undertakes that: 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

24 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	9.2.1	full power and authority to enter into and perform this Agreement, which, when executed, will constitute valid and legally binding obligations on the Licensee;

  

	 	9.2.2	entry into this Agreement will not result in any breach of, or violation of the terms or provisions of, the constitutional documents of the Licensee or any other
agreement or instrument by which it is bound; 

  

	 	9.2.3	so far as it is aware (having made no enquiry of any third parties), use and exploitation of the Patents will not infringe the intellectual property rights of any third party; 

 

	 	9.2.4	neither it nor any of its Affiliates is currently researching, developing, marketing, selling or otherwise commercialising any Competing Product (“Competing Activities”), nor has any of them entered into an
agreement with any other person with respect to any Competing Activities; and 

  

	 	9.2.5	it shall notify UCLB if it or any of its Affiliates or its Sub-licensees commences any Competing Activities or enters into an agreement with any other person with respect to any
Competing Activities. 

  

	9.3	Warranties by Meira 

 Meira warrants and undertakes that: 

 

	 	9.3.1	full power and authority to enter into and perform this Agreement which, when executed, will constitute valid and legally binding obligations on Meira;

  

	 	9.3.2	entry into this Agreement and the issue and allotment of the Consideration Shares will not result in any breach of, or violation of the terms or provisions of, the
constitutional document of Meira or any other agreement or instrument by which it is bound;  

  

	 	9.3.3	it has all necessary authority and approvals to allot and issue the Consideration Shares (including a resolution passed by its shareholders giving its directors authority to allot pursuant to section 551 of the
Companies Act 2006); and 

  

	 	9.3.4	any and all pre-emption rights have been disapplied or waived by all relevant shareholders in relation to the allotment and issue of the Consideration Shares; and

  

	 	9.3.5	The Consideration Shares, when issued in accordance with this Agreement, will be validly allotted and issued, fully paid and free of liens, charges, encumbrances and other third party rights. 

 

	9.4	Acknowledgements 

 The Licensee acknowledges that: 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

25 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	9.4.1	the inventions claimed in the Patents, and the Know-how and the Materials are at an early stage of development. Accordingly, specific results cannot be guaranteed and any results,
materials, information or other items (together “Delivered Items”) provided under this Agreement are provided “as is” and without any express or implied warranties, representations or undertakings. As examples, but without
limiting the foregoing, UCLB does not give any warranty that Delivered Items are of merchantable or satisfactory quality, are fit for any particular purpose, comply with any sample or description, or are viable, uncontaminated, safe or non-toxic. 

  

	 	9.4.2	UCLB has not performed any searches or investigations into the existence of any third party rights that may affect any of the Patents, Know-how or Materials or the use and
exploitation of any of the Patents, Know-how or Materials. 

  

	9.5	No Other Warranties 

  

	 	9.5.1	Each of the Parties acknowledges that, in entering into this Agreement, it does not do so in reliance on any representation, warranty or other provision except as expressly provided in this Agreement, and any
conditions, warranties or other terms implied by statute or common law are excluded from this Agreement to the fullest extent permitted by law. 

  

	 	9.5.2	Without limiting the scope of Clause 9.5.1, UCLB does not make any representation nor give any warranty or undertaking: 

  

	 	(a)	express or implied, including, without limitation, any implied warranties of merchantability or of fitness for a particular purpose with respect to any Patent, trademark, software,
non-public or other information, or tangible research property, licensed or otherwise provided to the Licensee hereunder and hereby disclaims the same; 

 

	 	(b)	as to the efficacy or usefulness of the Patents, Know-how or Materials; or 

  

	 	(c)	whatsoever with regard to the scope of any of the Patents or that any of the Patents is or will be valid or (in the case of an application) will proceed to grantor that such Patents may be exploited by the Licensee,
Affiliate or Sub-licensee without infringing other patents; or 

  

	 	(d)	that the use of any of the Patents, Know-how or Materials, Licensed Technology, the manufacture, sale or use of the Licensed Products, or the exercise of any of the rights granted
under this Agreement will not infringe any intellectual property or other rights of any other person; or 

  

	 	(e)	that the Know-how or any other information communicated by UCLB to the Licensee under or in connection with this Agreement will produce Licensed Products of satisfactory quality
or fit for the purpose for which the Licensee intended or that any product will not have any defect, latent or otherwise, and whether or not discoverable by inspection; or 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

26 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	(f)	as imposing any obligation on UCLB to bring or prosecute actions or proceedings against third parties for infringement or to defend any action or proceedings for revocation of any of the Patents; or 

 

	 	(g)	as imposing any liability on UCLB in the event that any third party supplies Licensed Products to customers located in the Territory; or 

 

	 	(h)	that there will be no similar or competitive products or services manufactured, used, sold or supplied by any third party in the Territory. 

 

	9.6	Responsibility for Development of Licensed Products 

 The Licensee shall be exclusively
responsible for its and its Affiliates’ and Sub-licensees’ use of the Patents, Know-how and Materials, the technical and commercial development and manufacture
of Licensed Products and for incorporating any modifications or developments thereto that may be necessary or desirable, for all Licensed Products sold or supplied, notwithstanding any consultancy services or other contributions that UCLB and/or UCL
may provide in connection with such activities. 
  

	9.7	Indemnity 

 The Licensee shall indemnify each of UCLB and UCL, and each of their
respective officers, directors, Council members, employees and representatives (together, the “Indemnitees”) against all third party Claims that may be asserted against or suffered by any of the Indemnitees and which relate to: 

 

	 	9.7.1	the use by the Licensee or any of its Affiliates or Sub-licensees of any of the Patents, Know-how or Materials; or 

 

	 	9.7.2	the development, manufacture, use, marketing or sale of, or any other dealing in, any of the Licensed Products, by or on behalf of the Licensee or any of its Affiliates or
Sub-licensees, or subsequently by any customer or any other person, including claims based on product liability laws. 

The indemnity given by the Licensee to each Indemnitee under this Clause 9.7 will not apply to any third party Claim to the extent that it is
attributable to the negligence, gross negligence, reckless misconduct or intentional misconduct of any Indemnitee. 
  

	9.8	Limitations of Liability 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

27 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	9.8.1	To the extent that UCLB or any of its Affiliates has any liability in contract, tort, or otherwise under or in connection with this Agreement, including any liability for breach of warranty, their liability shall be
limited in accordance with the following provisions of this Clause 9.8. 

  

	 	9.8.2	The aggregate liability of UCLB and any of its Affiliates shall be limited to the total income that UCLB has received from the Licensee pursuant to this Agreement (but excluding any other costs or expenses associated
with drafting, filing, prosecuting, maintaining or defending any Patents or providing any assistance to the Licensee) during the period of [***] ([***]) years preceding the date on which the liability arises, or [***] pounds (£[***]) sterling,
whichever is the higher. 

  

	 	9.8.3	The liability of the Licensee to UCLB shall be limited to the limit of its insurance as set out in Clause 9.9.1, except that in the case of product liability, the liability of the Licensee under this Agreement shall be
unlimited. 

  

	 	9.8.4	In no circumstances shall any Party or any Indemnitee be liable for any loss, damage, costs or expenses of any nature that is (a) of an indirect, special or consequential nature or (b) any loss of profits
(whether direct or indirect), revenue, business opportunity or goodwill, which arises directly or indirectly from that Party’s breach or non performance of this Agreement, or negligence in the performance of this Agreement or from any liability
arising in any other way out of the subject matter of this Agreement even if the Party bringing the claim has advised any other Party or the relevant Indemnitee of the possibility of those losses arising, or if such losses were within the
contemplation of the Parties or the Indemnitee. 

  

	 	9.8.5	Nothing in this Agreement excludes any Party’s liability to the extent that it may not be so excluded under applicable law, including any such liability for death or personal injury caused by that Party’s
negligence, or liability for fraud or fraudulent misrepresentation. 

  

	9.9	Insurance 

  

	 	9.9.1	The Licensee shall take out with a reputable insurance company and maintain at all times during the term of this Agreement public and product liability and professional indemnity insurance including against all loss of
and damage to property (whether real, personal or intellectual) and injury to persons including death arising out of or in connection with this Agreement and the Licensee’s and its Affiliates’ and
Sub-licensees’ use of the Patents, Know-how or Materials and use, sale of or any other dealing in any of the Licensed Products. Such insurances may be limited in
respect of one claim provided that such limit must be at least [***] pounds (£[***]) sterling, unless the Licensee commences any business in manufacturing, distribution, supply or otherwise make available to the public any products, in which
case such limit must be at least [***] pounds (£[***]) sterling. Such insurance shall continue to be maintained for a further [***] years from the end of this Agreement. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

28 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	9.9.2	The Licensee will produce to UCLB at all times upon demand proof that the insurance cover required pursuant to Clause 9.9.1 is in force and evidence that all premiums have been paid up to date. If UCLB becomes aware
that the Licensee has failed to maintain the insurance required pursuant to Clause 9.9.1, UCLB may effect such insurance and the Licensee will reimburse UCLB for the reasonable cost of effecting and maintaining such insurance on demand.

  

	10.	DURATION AND TERMINATION 

  

	10.1	Commencement and Expiry 

 This Agreement and the licences granted hereunder, shall come
into effect on the Commencement Date and, unless terminated earlier in accordance with this Clause 10, the licences granted hereunder shall continue in force on a country by country basis until the later of the last payment obligation of Licensee
expires under this Agreement. Upon such expiry, Licensee’s licenses under this Agreement shall become full-paid, perpetual and irrevocable. 
  

	10.2	Early Termination 

 Each Party (the “Terminating Party”) may terminate this
Agreement at any time by notice in writing to the other Parties (“Other Parties”), such notice to take effect as specified in the notice: 
  

	 	10.2.1	If, in the case of UCLB, either of the Other Parties, or in the case of the Licensee or Meira, UCLB, is in material breach of this Agreement and, in the case of a breach capable of remedy within thirty (30) days,
the breach is not remedied within thirty (30) days of the Other Parties receiving notice specifying the breach and requiring its remedy; or 

  

	 	10.2.2	if: 

  

	 	(a)	in the case of UCLB, either of the Other Parties, or in the case of the Licensee or Meira, UCLB, becomes insolvent or unable to pay its debts as and when they become due; 

 

	 	(b)	an order is made or a resolution is passed for the winding up of in the case of UCLB, either of the Other Parties, or in the case of the Licensee or Meira, UCLB (other than voluntarily for the purpose of solvent
amalgamation or reconstruction); 

  

	 	(c)	a liquidator, administrator, administrative receiver, receiver or trustee is appointed in respect of the whole or any part of, in the case of UCLB, either of the Other Parties’, or in the case of the Licensee or
Meira, UCLB’s, assets or business; 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

29 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	(d)	in the case of UCLB, either of the Other Parties, or in the case of the Licensee or Meira, UCLB, makes any composition with its creditors; 

 

	 	(e)	in the case of UCLB, either of the Other Parties, or in the case of the Licensee or Meira, UCLB, ceases to continue its business; or 

 

	 	(f)	any event analogous to the events referred to in paragraphs (a) to (e) above occurs in any other jurisdiction. 

  

	10.3	UCLB may terminate this Agreement by giving written notice to the Licensee and Meira, such termination to take effect forthwith or as otherwise stated in the notice: 

 

	 	10.3.1	if there is any change of Control of the Licensee involving the categories of persons or Affiliates of persons prohibited by Clause 2.3; 

 

	 	10.3.2	if Meira fails to comply with its obligations under Clause 4.1.2; or 

  

	 	10.3.3	the Licensee is in persistent breach of the Agreement and where the Licensee and UCLB have failed to agree a mechanism to remedy the persistent nature of such breaches within a reasonable period following UCLB notifying
the Licensee of the persistent breach and requesting that the Licensee enters into discussions with UCLB as to mechanisms for remedying the persistent breaches or if the Licensee and UCLB have agreed a mechanism to remedy the persistent breach but
that mechanism if not fully complied with by the Licensee; or 

  

	 	10.3.4	if the Licensee shall enter into any sub-licence with any of the categories of persons or Affiliates of persons prohibited by Clause 2.3 which may, adversely affect UCL’s and/or UCLB’s reputation.

  

	10.4	A Party’s right of termination under this Agreement, and the exercise of any such right, shall be without prejudice to any other right or remedy (including any right to claim damages) that such Party may have in
the event of a breach of contract or other default by any other Party. 

  

	10.5	Consequences of Termination 

  

	 	10.5.1	Upon expiry of the period of this Agreement, and subject to all royalties and any other sums due to UCLB under this Agreement having been duly paid, the Licensee shall have a fully paid up licence to the Patents, the Know-how and the Materials of the same scope as set forth in Clauses 2.1.1 and 2.1.2 without any further obligation to pay any further sums to UCLB under Clause 4. Notwithstanding the foregoing the Licensee
acknowledges that once each Patent expires or is abandoned or withdrawn or allowed to lapse in any country or territory, third parties in that country or territory will be entitled to use the inventions claimed in the Patent and that accordingly the
licence granted to the Licensee under Clause 2.1.1 will no longer be exclusive in that country or territory. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

30 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	10.5.2	Upon termination of this Agreement by UCLB under Clause 10.2.1 (for Licensee’s uncured material breach) or under Clause 10.3: 

  

	 	(a)	the Licensee and its Affiliates and Sub-licensees shall be entitled to sell, use or otherwise dispose of (subject to payment of royalties under Clause 4) any unsold or unused
stocks of the Licensed Products for a period of six (6) months following the date of termination; 

  

	 	(b)	subject to paragraph (a) above, any license that has not become fully paid-up in accordance with Clause 10.1 shall terminate and the Licensee and its Affiliates (and subject
to Clause 2.3, its Sub-licensees) shall no longer be licensed to use or otherwise exploit the Patents and/or the Know-how and/or the Materials, in so far and for as long
as any of the Patents remains in force and the Know-how remains confidential; 

  

	 	(c)	the Licensee shall consent to the cancellation of any formal licence granted to it, or of any registration of it in any register, in relation to any of the Patents; 

 

	 	(d)	the Licensee will, promptly on UCLB’s request, provide (and will ensure that its patent agents provide) to UCLB all information, documentation and assistance (including executing documents) which UCLB may
reasonably require to enable it to continue with the drafting, filing, prosecution and maintenance of the Patents; 

  

	 	(e)	except as set out in Clause 2.3, all sub-licences of the Patents and/or the Know-how and/or the Materials granted by the Licensee pursuant to this Agreement will automatically
terminate; 

  

	 	(f)	UCLB shall, upon the written request of either of the other Parties, and each of the Licensee and Meira shall, upon the written request of UCLB, return or destroy any documents or other materials that are in its or its
Affiliates possession or under its or their control and that contain the requesting Party’s Confidential Information. 

  

	10.6	If Licensee may terminate this Agreement under Clause 10.2.1 (for UCLB or its Affiliates uncured material breach), then Licensee may elect, in lieu of terminating the entire Agreement, to have all licenses granted under
this Agreement survive, subject to Licensee’s fulfilment of [***] percent ([***]%) of its payment obligations under Clause 4 after what would have been the effective date of such termination. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

31 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	10.7	Upon termination of this Agreement for any reason, the provisions of Clauses 1, 2.3, 2.5, 3.2 to 3.6, 4 (in respect of amounts paid and payable to UCLB in respect of the period up to and including the date of
termination) 5.6, 7, 9, 10.5, 10.6, 10.7 and 11 of this Agreement shall remain in force. 

  

	11.	GENERAL 

  

	11.1	Force Majeure 

  

	 	11.1.1	Any delays in or failure of performance by a Party under this Agreement will not be considered a breach of this Agreement and if and to the extent that such delay or failure is caused by occurrences beyond the
reasonable control of that Party including acts of God; acts, regulations and laws of any government; strikes or other concerted acts of workers; fire; floods; explosions; riots; wars; rebellion; and sabotage; and any time for performance hereunder
will be extended by the actual time of delay caused by any such occurrence. 

  

	 	11.1.2	If (a) UCLB or (b) the Licensee or Meira is prevented from carrying out its obligations: 

  

	 	(a)	under this Agreement for a continuous period of [***] ([***]) months, the Licensee (in the case of (a) or UCLB (in the case of (b), may terminate this Agreement on giving [***] ([***]) days prior written notice
provided always that at the date upon which termination becomes effective the Party which was prevented from carrying out its obligations under this Agreement remains so prevented. 

 

	11.2	Amendment 

 This Agreement may only be amended in writing signed by duly authorised
representatives of the Parties. 
  

	11.3	Assignment and Third Party Rights 

  

	 	11.3.1	Subject to Clause 11.3.3, the Licensee shall not assign, mortgage, charge or otherwise transfer any rights or obligations under this Agreement, nor any of the Patents, Know-how or
Materials, without the prior written consent of UCLB. 

  

	 	11.3.2	UCLB may assign all its rights and obligations under this Agreement together with its rights in the Patents, Know-how and Materials to any third party. 

 

	 	11.3.3	The Licensee, subject to obtaining the consent of UCLB which shall not be unreasonably withheld or delayed (except in relation to those categories of persons or Affiliates of persons prohibited by Clause 2.3), may
assign all its rights and obligations under this Agreement together with its rights in the Patents, Know-how and Materials to any third party to which it transfers all or substantially all of its assets or
business, provided that the assignee undertakes to UCLB to be bound by and perform the obligations of the assignor under this Agreement. However, the Licensee shall not have such a right to assign this Agreement if it is insolvent.

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

32 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	11.3.4	Meira shall not assign, mortgage, charge or otherwise transfer any rights or obligations under this Agreement without the prior written consent of UCLB. 

 

	11.4	Waiver 

 Any waiver given under or in relation to this Agreement shall be in writing and
signed by or on behalf of the relevant Party. No failure or delay on the part of a Party to exercise any right or remedy under this Agreement shall be construed or operate as a waiver thereof, nor shall any single or partial exercise of any right or
remedy preclude the further exercise of such right or remedy. 
  

	11.5	Invalid Clauses 

 If any provision or part of this Agreement is held to be invalid,
amendments to this Agreement may be made by the addition or deletion of wording as appropriate to remove the invalid part or provision but otherwise retain the provision and the other provisions of this Agreement to the maximum extent permissible
under applicable law. 
  

	11.6	No Agency 

 No Party shall act or describe itself as the agent of the other, nor shall it
make or represent that it has authority to make any commitments on the other’s behalf. 
  

	11.7	Interpretation 

 In this Agreement: 

 

	 	11.7.1	the headings are used for convenience only and shall not affect its interpretation; references to persons shall include incorporated and unincorporated persons; references to the singular include the plural and vice
versa; and references to the masculine include the feminine; 

  

	 	11.7.2	references to Clauses and Schedules mean clauses of, and schedules to, this Agreement; 

  

	 	11.7.3	references in this Agreement to termination shall include termination by expiry; 

  

	 	11.7.4	where the word “including” is used it shall be understood as meaning “including without limitation”; 

  

	 	11.7.5	any reference to any English law term for any action, remedy, method or judicial proceeding, legal document, legal status, court, official or any legal concept or thing shall in respect of any jurisdiction other than
England be deemed to include what most nearly approximates in that jurisdiction to the English law term; 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

33 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	 	11.7.6	where there is any conflict or inconsistency between the main body of this Agreement and any of the schedules, then the main body of the Agreement shall prevail; 

 

	 	11.7.7	time shall be of the essence in relation to the performance of Meira’s and the Licensee’s obligations under this Agreement; and 

 

	 	11.7.8	any reference to the sale of a Licensed Product by the Licensee or its Affiliates or Sub-licensees will be taken to include any supply or other disposal of Licensed Products, and
the term sold shall be construed accordingly. 

  

	11.8	Notices. Addresses for Service 

  

	 	11.8.1	Any notice to be given under this Agreement shall be in English, in writing and shall be delivered by first class recorded delivery mail (if sent to an inland address) or by international courier (if sent to an address
outside of the United Kingdom), to the address of the relevant Party set out at the head of this Agreement, or such other address as that Party may from time to time notify to the other Parties in accordance with this Clause 11.8. 

 

	 	11.8.2	Notices sent as above shall be deemed to have been received [***] ([***]) working day after the day of posting in the case of delivery inland first class recorded delivery mail, or [***] ([***]) working days after the
date of collection by the international courier. 

  

	11.9	Law and Jurisdiction 

 The validity, construction and performance of this Agreement, and
any contractual and non-contractual claims arising hereunder, shall be governed by English law and shall be subject to the exclusive jurisdiction of the English courts to which the Parties hereby submit,
except that a Party may seek an interim injunction (or an equivalent remedy) in any court of competent jurisdiction. 
  

	11.10	Entire Agreement 

 This Agreement, including its Schedules, sets out the entire agreement
between the Parties relating to its subject matter and supersedes all prior oral or written agreements, arrangements or understandings between them relating to such subject matter (including Licence Addendum Number 2 entered into by UCLB and
Licensee pursuant to a Licence Agreement dated 4 February 2015 (“Licence Agreement”), which, to the extent of subject matter of this Agreement, stands modified by this Agreement), and Licensee will not owe UCLB any payments for
Licensed Products under such prior agreements. For clarity, the said Addendum Number 2 shall be deemed to be terminated and, as such, excluded from the scope of the Licence Agreement as of the Commencement Date. Subject to Clause 9.8.5, the Parties
acknowledge that they are not relying on any representation, agreement, term or condition which is not set out in this Agreement. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

34 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

	11.11	Third Parties 

 Except for the rights of UCL as provided in Clause 2.4, the rights of the
Indemnitees as provided in Clause 9.7, the limitations of liability afforded to the Indemnitees pursuant to Clause 9.8, who may in their own right enforce and rely on the provisions of those Clauses, this Agreement does not create any right
enforceable by any person who is not a party to it (“Third Party”) under the Contracts (Rights of Third Parties) Act 1999, but this Clause 11.11 does not affect any right or remedy of a Third Party which exists or is available apart from
that Act. 
  

	11.12	Non-use of Names; Announcements 

  

	 	11.12.1	The Licensee shall not use, and shall ensure that its Affiliates and Sub-licensees do not use, the name, any adaptation of the name, any logo, trademark or other device of UCLB,
nor of the inventors named on the Patents nor the Principal Investigators in any advertising, promotional or sales materials without prior written consent obtained from UCLB in each case, except that the Licensee may state that it is licensed by
UCLB under the Patents. 

  

	 	11.12.2	Except as permitted under Clauses 3.4.1 and 5.6, no Party shall make any press or other public announcement concerning any aspect of this Agreement, or make any use of the name or trademarks of any other Party in
connection with or in consequence of this Agreement, without the prior written consent of the relevant other Party. 

  

	11.13	Escalation 

 If the Licensee or Meira on the one hand, and UCLB on the other, are unable
to reach agreement on any issue concerning this Agreement or the Project within [***] days after one either has notified the other of that issue, they will refer the matter to the [***] in the case of UCLB, and to the [***] in the case of the
Licensee and Meira in an attempt to resolve the issue within the time specified elsewhere in this Agreement in the case of other disputes. Any Party may bring proceedings in a court of competent jurisdiction if the matter has not been resolved
within that prescribed period, and any Party may apply to the court for an injunction, whether or not any issue has been escalated under this Clause 11.13. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

35 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 EXECUTED on the date set out at the head of this Agreement. 

 

			
	For and on behalf of	  	 For and on behalf of
		
	UCL Business PLC	  	 MEIRAGTX UK II LIMITED

  

					
	 /s/ Anne Lane
	 		  	 /s/ Richard Giroux

	Signed	 		  	Signed
			
	 Dr. Anne Lane
	 		  	 Rich Giroux

	Print name	 		  	Print name
			
	 Executive Director UCL Business PLC
	 		  	 Director

	Title	 		  	Title
			
	 14 March 2018
	 		  	 3.14.18

	Date	 		  	Date

  

	
	 For and on behalf of
  

MEIRAGTX LIMITED
  

	 /s/ Alexandria Forbes

	Signed
	
	 Alexandria Forbes

	Print name
	
	 President & CEO

	Title
	
	 3.15.18

	Date

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

36 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 SCHEDULE 1 

LICENSED TECHNOLOGY 
  

	Part	A: The Patents 

 [***] 
  

	Part	B: The Know-how 

 a. [***] 

The Know-how Data: 

1. [***] 
  

	Part	C: The Materials 

 1. [***] 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

37 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 SCHEDULE 2 

APPOINTMENT OF EXPERT 
 For the purposes
of this Schedule 2 only, the “Parties” shall mean the Licensee and UCLB. If either Party wishes to appoint an independent expert (the “Expert”) to determine any matter pursuant to any Clause of this Agreement, the following
procedures will apply: 
  

	1.	The Party wishing to appoint the Expert (“the Appointing Party”) will serve a written notice on the other Party (“the Responding Party”). The written notice will specify the Clause pursuant to which
the appointment is to be made and will contain reasonable details of the matter(s) which the Appointing Party wishes to refer to the Expert for determination 

  

	2.	The Parties shall within [***] ([***]) days following the date of the Appointing Party’s written notice use all reasonable efforts to agree who is to be appointed as the Expert to determine the relevant matter(s).
If the Parties are unable to agree upon the identity of the Expert within that timescale, the Expert shall be appointed by the President (for the time being) of the Licensing Executives Society Britain and Ireland upon written request of either
Party. 

  

	3.	Each Party will within [***] ([***]) days following appointment of the Expert, prepare and submit to the Expert and the other Party a detailed written statement setting out its position on the matter(s) in question and
including any proposals which it may wish to make for settlement or resolution of the relevant matter. 

  

	4.	Each Party will have [***] ([***]) days following receipt of the other Party’s written statement to respond in writing thereto. Any such response will be submitted to the other Party and the Expert.

  

	5.	The Expert will if he/ she deems appropriate be entitled to seek clarification from the Parties as to any of the statements or proposals made by either Party in their written statement or responses. Each Party will on
request make available all information in its possession and shall give such assistance to the Expert as may be reasonably necessary to permit the Expert to make his/ her determination. 

 

	6.	The Expert will issue his/ her decision on the matter(s) referred to him/ her in writing as soon as reasonably possible, but at latest within [***] ([***]) months following the date of his/ her appointment. The
Expert’s decision shall (except in the case of manifest error) be final and binding on the Parties. 

  

	7.	The Expert will at all times act as an independent and impartial expert and not as an arbitrator. 

  

	8.	The Expert’s charges will be borne as he/ she determines in his written decision. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

38 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 SCHEDULE 3 

DEFINITION OF TOBACCO INDUSTRY FUNDING (REVISED 2009) 

FROM THE CANCER RESEARCH UK CODE OF PRACTICE ON TOBACCO INDUSTRY FUNDING TO UNIVERSITIES.

http://www.cancerresearchuk.org/science/funding/terms-conditions/funding-policies/policy-tobacco/ 

A tobacco company is defined for the purposes of this policy as one that: 
  

	 	•	 	Derives over 5% of revenues from manufacturing tobacco products; 

  

	 	•	 	Derives 15%+ of revenues from the manufacture of products necessary for the production of tobacco products; 

  

	 	•	 	Derives 15% of revenues from the sale of tobacco products (and has 30 or more staff); 

  

	 	•	 	Owns a tobacco company (the company owns 50% or more of a tobacco company); 

  

	 	•	 	Is more than 50% owned by a company with tobacco involvement. 

 The following do not constitute tobacco
industry funding for the purposes of this Code: 
  

	 	•	 	legacies from tobacco industry investments (provided these are sold on immediately) 

  

	 	•	 	funding from a trust or foundation no longer having any connection with the tobacco industry even though it may bear a name that (for historical reasons) has tobacco industry associations.

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

39 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 SCHEUDLE 4 

INITIAL DEVELOPMENT PLAN 
 The Initial
Development Plan for the Licensed Technology is shown below 
  

					
	 Activity
	  	Timeline	 
		
	 Phase I/II Start
	  	 	[	***] 
		
	 Phase I/II Finish
	  	 	[	***] 
		
	 Phase III /pivotal confirmatory study Start
	  	 	[	***] 
		
	 Phase III /pivotal confirmatory study Finish
	  	 	[	***] 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

40EX-10.14

 Exhibit 10.14 

Confidential Treatment Requested by MeiraGTx Holdings plc 

EXECUTION COPY 
 AGREEMENT AND
PLAN OF MERGER 
 This AGREEMENT AND PLAN OF MERGER (this “Agreement”) is entered into on this 31st day of December, 2015 (the “Effective Date”) by and between MeiraGTx Acquisition Corporation, a Delaware corporation (“Merger Sub”), BRI-Alzan Inc., a Delaware
corporation (the “Company”), F-Prime Inc. (f/k/a Fidelity Biosciences Corp.), a Delaware corporation with the address of its principal office set forth on the signature page hereto
(“Fidelity”), Gregory Petsko, an individual resident at the address set forth on the signature page hereto (“Petsko”), Dagmar Ringe, an individual resident at the address set forth on the signature page hereto
(“Ringe”), and Brandeis University, a not-for-profit corporation duly incorporated and existing under the laws of the Commonwealth of Massachusetts with
the address of its principal office set forth on the signature page hereto (“Brandeis” and together with Fidelity, Petsko and Ringe, each, a “Seller” and, collectively, the “Sellers”), Fidelity,
solely in its capacity as agent for the Sellers (the “Sellers’ Representative”), and MeiraGTx Limited, a private limited company duly formed and existing under the laws of England and Wales (Company No. 9501998) and the
sole shareholder of Merger Sub (“Parent”). Merger Sub, the Company, the Sellers and Parent may each be referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized
terms used in this Agreement shall have the meanings ascribed to them in Section 1 herein. 
 RECITALS

 WHEREAS, the Sellers own all of the issued and outstanding shares of common stock, par value $0.01 per share (the
“Company Shares”), of the Company; 
 WHEREAS, the Company is party to that certain License Agreement, dated as of
May 1, 2013 (the “License Agreement”), by and between the Company and Brandeis, for the commercial development, manufacture and distribution of products derived from the technology licensed under the License Agreement, a true
and complete copy of which is attached hereto as Exhibit A; and 
 WHEREAS, Merger Sub and the Company believe it is in the best
interests of their respective companies and the stockholders of their respective companies that the Company and Merger Sub combine into a single company through the statutory merger of Merger Sub with and into the Company (the
“Merger”), with the Company surviving the Merger and Merger Sub ceasing to exist, such that the Company becomes a wholly-owned subsidiary of Parent and Parent thereby indirectly acquires the License Agreement and the Company’s
rights and obligations thereunder, in each case, upon the terms and subject to the conditions set forth herein. 
 AGREEMENT

 NOW, THEREFORE, in consideration of the promises and mutual agreements and covenants contained herein, the receipt and
sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 1. DEFINITIONS. 

1.1 “409A Valuation” has the meaning set forth in Section 6.4.5(b)(ii)(A). 

1.2 “Accounting Firm” has the meaning set forth in Section 2.3.3(b). 

1.3 “Action” has the meaning set forth in Section 7.2.2. 

1.4 “Affiliate(s)” means, with respect to a Party, any Person that, directly or indirectly, through one or more
intermediaries, controls, is controlled by or is under common control with such Party. For purposes of this definition, “control” and, with correlative meanings, the terms “controlled by” and “under common control with”
means (i) the possession, directly or indirectly, of the power to direct the management or policies of a Person, whether through the ownership of voting securities or by contract relating to voting rights or corporate governance; or
(ii) the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of a Person (or, with respect to a limited partnership or other similar entity, its general partner or controlling
entity). For the avoidance of doubt, for purposes of this Agreement and the Ancillary Agreements, (a) the Company shall be an Affiliate of Parent from and after the Effective Time, (b) no Seller shall be an Affiliate of the Company or
Parent from and after the Effective Time, and (c) the Company shall not be an Affiliate of Brandeis or any of Brandeis’s Affiliates at any time. 

1.5 “Agreement” has the meaning set forth in the preamble. 

1.6 “Ancillary Agreements” means, other than this Agreement, the agreements and instruments executed and delivered in
connection with the transactions contemplated by this Agreement. 
 1.7 “Applicable Laws” means all federal, state, local or
foreign laws, codes, statutes, ordinances, regulations, rules, requirements, guidance, or orders of any kind whatsoever pertaining to any Party, the Company Shares, the Parent Shares or any of the activities contemplated by this Agreement,
including, without limitation, the FDCA, the Anti-Kickback Statute (42 U.S.C. § 1320a-7b et seq.), data security, confidentiality, and privacy laws, rules, regulations and standards, including, without
limitation, the Fair Credit Reporting Act, 15 U.S.C. 1681 et seq. (including the Fair and Accurate Credit Transactions Act of 2003) and the PCI Security Standards Council’s Payment Card Industry Data Security Standard, including, without
limitation, the Payment Application Data Security Standards and all audit and filing requirements, and Tax laws, and any other regulations promulgated by any Governmental Authority, all as amended from time to time in the relevant territory. 

1.8 “BLA” means a Biologics License Application as defined in the FDCA and any equivalent foreign application, registration or
certification. 
 1.9 “BLA Acceptance” means the written notification by the FDA or equivalent Governmental Authority for a
country in the Territory that the BLA has met all the criteria for filing acceptance pursuant to 21 C.F.R. §314.101 or its foreign equivalent if such filing is outside the US. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

2 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 1.10 “Brandeis” has the meaning set forth in the Recitals. 

1.11 “Business Day” means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United
States, or any day on which banking institutions in New York City are authorized or required by law or other governmental action to close. 

1.12 “Certificate of Merger” has the meaning set forth in Section 2.1.1. 

1.13 “Closing” has the meaning set forth in Section 2.4. 

1.14 “Closing Date” has the meaning set forth in Section 2.4. 

1.15 “Code” means the U.S. Internal Revenue Code of 1986, as amended, and the rules and regulations thereunder. 

1.16 “Combination Product” means a product which comprises (a) a Product and (b) at least one other active
ingredient (including a biologic product) or medical device. 
 1.17 “Commercially Reasonable Efforts” means with respect to
the efforts to be expended by a Party with respect to any objective, reasonable, good faith efforts to accomplish such objective as a Person in the life sciences industry would normally use to accomplish a similar objective under similar
circumstances, taking into consideration the stage of development or product life, present and future market potential, efficacy, safety, approved labeling or anticipated labeling, competitiveness of alternative products sold by Third Parties in the
marketplace, patent and other proprietary positions, present and future regulatory environment, profitability (including royalties payable to licensors of patent or other intellectual property rights other than any royalty, milestone or other
payment to be made under this Agreement) and past performance of a Product developed by such Party. 
 1.18
“Commercialization” and “Commercialize” means the activities carried out by or on behalf of a Party in distributing (including importing, transporting, warehousing, invoicing, handling and delivering Product to
customers), promoting, marketing and selling Product, but does not include selling the Product for clinical trial purposes. 
 1.19
“Company” has the meaning set forth in the preamble. 
 1.20 “Company Assets” has the meaning set forth in
Section 3.3.6. 
 1.21 “Company Confidential Information” has the meaning set forth in
Section 5.1.3. 
 1.22 1.22 “Company Intellectual Property Rights” has the meaning set forth in
Section 3.3.7. 
 1.23 “Company Shares” has the meaning set forth in the Recitals. 

1.24 “Competing Technology” means any materials, technology, technical and scientific information, improvements, methods, data
(whether in vitro, in vivo, and whether in animals or humans), know-how, and expertise, for the treatment, prevention, or delay in onset of 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

3 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
amyotrophic lateral sclerosis (ALS) by providing one or more nonsense-mediated mRNA decay polypeptides to neuronal or glial cells to reduce FUS/TLS and/or
TDP-43 toxicity as described in the claims in the Patent Rights pending or issued as of the Effective Date. For the avoidance of doubt, actions taken by Fidelity or any of its Affiliates (excluding any Seller
other than Fidelity) related to proposed or actual investments, or actions taken by any of their or their Affiliates’ partners, officers or representatives (in each case, excluding any Seller other than Fidelity) related to such proposed or
actual investments, shall not be considered “consulting] with, render[ing] services for or otherwise engag[ing] in any business, endeavor or activity anywhere in the Territory for the development, manufacture, use or Commercialization of any
Competing Technology” for purposes of Section 5.2(a) of this Agreement. 
 1.25 “Confidential Information” means
technical, financial, manufacturing or marketing information, ideas, methods, developments, improvements, business plans, know-how, trade secrets or other proprietary information relating thereto, together with analyses, compilations, studies or
other documents, records or data of a Party or its Affiliates, which contain or otherwise reflect or are generated from such information. 

1.26 “Confidentiality Agreements” means (a) the Confidentiality Agreement dated as of June 15, 2015 by and between
Kadmon Corporation, LLC, MeiraGTx, LLC and Fidelity, and (b) the Confidentiality Agreement dated as of November 2, 2015 by and between Parent and Brandeis. 

1.27 “Contracts” means any and all contracts, agreements, leases, licenses, franchises, warranties, guaranties, mortgages,
notes, bonds, options, warrants, rights, purchase orders, letter agreements, subscriptions, commitments, understandings and other obligations in each case, whether written or oral, proposed, contingent or otherwise, and includes any amendment,
modification or supplement thereto. 
 1.28 “Control” means, with respect to any item of Company Intellectual Property
Rights or Company Confidential Information, ownership of or possession of the right, whether by ownership or by license, to enforce, use, assign or practice such item of Company Intellectual Property Rights or Company Confidential Information. 

1.29 “Covered Person” has the meaning set forth in Section 3.3.9(m). 

1.30 “Delaware Law” has the meaning set forth in Section 2.1. 

1.31 “Direct Claims” has the meaning set forth in Section 6.6. 

1.32 “Disqualification Event” has the meaning set forth in Section 3.3.9(m). 

1.33 “DFAR” has the meaning set forth in Section 3.3.9(l). 

1.34 “Effective Date” has the meaning set forth in the preamble. 

1.35 “Effective Time” has the meaning set forth in Section 2.1.1. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

4 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 1.36 “Employee Benefit Plan” means each “employee benefit plan”
(as such term is defined in Section 3(3) of ERISA) and each other employee benefit plan, program or arrangement, company or payroll practice, including without limitation severance pay, redundancy programs or practices, sick leave, vacation
pay, salary continuation for disability, employment, consulting or other compensation agreements, retirement, pension, deferred compensation, bonus, stock purchase, stock appreciation rights, hospitalization, medical insurance, voluntary or other
health insurance, life insurance, disability, death or sickness insurance and scholarship programs maintained, sponsored or contributed to by or on behalf of the Company or with respect to which the Company has or may have any Liability, including
any Multiemployer Plan. 
 1.37 “Encumbrance” means any lien, mortgage, security interest, pledge, restriction on
transferability or use, right of first refusal, defect of title, or other claim, charge or encumbrance of any nature whatsoever on any asset, property or property interest. 

1.38 “Environmental Laws” has the meaning set forth in Section 3.3.18. 

1.39 “Environmental Liabilities” has the meaning set forth in Section 3.3.18. 

1.40 “ERISA” means the Employee Retirement Income Security Act of 1974, as amended. 

1.41 “ERISA Affiliate” means any entity that, together with the Company, would be deemed a “single employer” within
the meaning of Section 4001(b) of ERISA or Sections 414(b), (c), (m), or (o) of the Code and the regulations thereunder. 
 1.42
“Exchange Rate” has the meaning set forth in Section 7.12.1. 
 1.43 “Expiration
Date” has the meaning set forth in Section 6.1. 
 1.44 “FAR” has the meaning set forth
in Section 3.3.9(l). 
 1.45 “FDA” means the United States Food and Drug Administration, and any
successor agency(ies) or authority having substantially the same function. 
 1.46 “FDCA” means the U.S. Federal Food, Drug
and Cosmetic Act, as amended, 21 U.S.C. § 321, et seq. 
 1.47 “Fidelity” has the meaning set forth in the preamble.

 1.48 “Fidelity Subscription Agreement” has the meaning set forth in Schedule 1.59. 

1.49 “First Commercial Sale” means the first bona fide, arm’s length sale by, on behalf of or under the authority of the
Company, its Affiliates or sublicensees to a Third Party for end use or consumption in the Territory after the required marketing and pricing approval has been granted by the Pharmaceutical Product Regulatory Authority of such country. Sale of a
Product to an Affiliate or sublicensee, unless the Affiliate or sublicensee is the end user of the Product, transfers or dispositions as samples or for charitable purposes (including, without limitation, pursuant to an early access, compassionate
use, named patient, indigent access or patient assistance program), or transfers or dispositions for preclinical, clinical or regulatory purposes in furtherance of obtaining regulatory approval of the Product shall not constitute a First Commercial
Sale. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

5 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 1.50 “Governmental Authority” means any nation or government, any
provincial, state, regional, local or other political subdivision thereof, any supranational organization of sovereign states, and any entity, department, commission, bureau, agency, authority, board, court, official or officer, domestic or foreign,
exercising executive, judicial, regulatory or administrative functions of or pertaining to government, including the FDA. 
 1.51
“Government Contract” means any Contract entered into by the Company with any Governmental Authority or with any prime contractor or subcontractor (at any tier) relating to a Contract where any Governmental Authority is a party
thereto. A task, purchase or delivery order under a Government Contract or any amendment, supplement or modification to a Government Contract shall not constitute a separate Government Contract for purposes of this definition, but shall be part of
the Government Contract to which it relates. 
 1.52 “Hazardous Materials” has the meaning set forth in
Section 3.3.18. 
 1.53 “Indemnified Party” has the meanings set forth in each of
Section 6.4 and Section 6.5.1. 
 1.54 “Indemnifying Party” has the
meaning set forth in Section 6.5.1. 
 1.55 “Institutional Review Board” means any domestic or
foreign institutional review board or ethics committee overseeing any clinical trial involving the Product. 
 1.56 “Intellectual
Property Rights” means all intellectual property rights, including (i) Patent Rights, (ii) trademarks, trademark registrations, trademark applications, service marks, service mark registrations, service mark applications and
domain names, (iii) copyrights, copyright registrations and copyright applications, (iv) know-how, inventions (whether or not patentable), non-clinical data, pre-clinical data, in-vitro data, formulae, processes, methodologies, and trade secrets, and (v) all rights in all of the foregoing provided by Applicable Law. 

1.57 “Interested Parties” has the meaning set forth in Section 3.3.17. 

1.58 “Inventors” has the meaning set forth in Section 3.5.2. 

1.59 “Investment Agreements” means the Contracts listed on Schedule 1.59. 

1.60 “Know How” has the meaning given to such term in the License Agreement (as amended by the License Agreement Amendment).

 1.61 “Knowledge” means all facts actually known, or which should have been reasonably known, by the relevant personnel
with primary responsibility for the matter in question on a day to day basis, following reasonable investigation and inquiry by such personnel. 

1.62 “Liability” means, collectively, any indebtedness, guaranty, endorsement, claim, loss, damage, deficiency, cost, expense,
obligation or responsibility, fixed or unfixed, known or unknown, choate or inchoate, liquidated or unliquidated, secured or unsecured, direct or indirect, matured or unmatured, due or to become due, absolute or contingent, accrued or not accrued,
and whether or not required to be reflected in the financial statements in accordance with U.S. or U.K., as applicable, generally accepted accounting principles. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

6 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 1.63 “License Agreement” has the meaning set forth in the Recitals. 

1.64 “License Agreement Amendment” has the meaning set forth in Section 4.1.5. 

1.65 “Licensed Know How” means the Know How licensed to the Company under the License Agreement (as amended by the License
Agreement Amendment). 
 1.66 “Licensed Patent Rights” means the Patent Rights licensed to the Company under the License
Agreement (as amended by the License Agreement Amendment). 
 1.67 “Losses” means any and all losses, Liabilities, damages,
claims, awards, judgments, Taxes, interest, penalties, costs and expenses (including, without limitation, attorneys’ fees, experts’ fees and other similar
out-of-pocket expenses) actually suffered or incurred. 

1.68 “Material Adverse Effect” means any change, circumstance or event that, individually or in the aggregate, has a material
adverse effect on the Company, the Company Shares, or the Licensed Patent Rights; provided, however, that Material Adverse Effect shall exclude any adverse changes or conditions as and to the extent such changes or conditions relate to or
result from: (a) the announcement of this Agreement or the pendency of the transactions contemplated hereby; (b) the execution, delivery or performance of this Agreement and the Ancillary Agreements; (c) general economic conditions or
other conditions generally affecting the pharmaceutical industry which do not have a disproportionate impact on the Company, the Company Shares or the Licensed Patent Rights; (d) any change in Applicable Laws or the interpretation thereof by
any Governmental Authority; or (e) any natural disaster, force majeure events or any acts of terrorism, sabotage, military action or war (whether or not declared) or any escalation or worsening thereof, except, in the case of the foregoing
clauses (c) through (f), to the extent such event, change, development, circumstance, occurrence, effect or state of facts has had (or would reasonably be expected to have) a materially disproportionate adverse impact on the Company, taken as a
whole, the Company, the Company Shares, or the Licensed Patent Rights, individually or in the agreement, as compared to other Persons in the industry in which the Company conducts its business. 

1.69 “Merger” has the meaning set forth in the Recitals. 

1.70 “Merger Sub” has the meaning set forth in the preamble. 

1.71 “Merger Sub Share” has the meaning set forth in Section 2.1.5(c). 

1.72 “Milestone Payment” has the meaning set forth in Section 2.3.1. 

1.73 “Multiemployer Plan” has the meaning provided in Section 3(37) of ERISA. 

1.74 “NDA” means any New Drug Application under the FDCA (together with all subsequent submissions, supplements and amendments
thereto, and any materials, documents or information referred to or relied upon thereby) seeking approval to market, sell or otherwise distribute a Product, in any formulation or dosage form, in the United States, and similar applications or filings
in the countries within the Territory. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

7 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 1.75 “Net Sales” means, with respect to a Product for any period, the
aggregate gross amount billed or invoiced on sales of such Product during such period by the Company or its sublicensees in a particular country in the Territory to Third Parties (including wholesalers or distributors) in bona fide arm’s-length transactions, less the following deductions, in each case related specifically to the Product and actually allowed and taken by or credited to such Third Parties: 

(a) normal trade, cash or quantity discounts actually given; 

(b) chargeback payments, price reductions or rebates, retroactive or otherwise, imposed by, negotiated with or otherwise paid to governmental
authorities or other payees; 
 (c) Taxes, tariffs on sales (such as sales, value added, or use taxes), duties or other governmental charges
levied on or measured by the sale of Products, whether absorbed by the Company or its Affiliates or paid by the payee to the extent added to the sale price and set forth separately as such in the total amount invoiced (provided that, in no event,
will the deductions in this subsection (c) include franchise taxes or income taxes of any kind); 
 (d) amounts repaid, credited or
allowed or price adjustments by reason of rejections, defects, damaged Product or for the rejection or return of Product previously sold; 

(e) any consideration actually paid or payable for any delivery system related to a billed or invoiced sale of such Product, where, for
purposes of this Net Sales definition, a “delivery system” means any delivery system comprising equipment, instrumentation, one or more devices, or other components designed to assist in the administration of such Product; 

(f) freight, insurance, shipping and handling or other transportation charges to the extent set forth separately as such in the total amount
invoiced, as well as any fees for services provided by wholesalers and warehousing chains related to the distribution of such Product; 

(g) any royalties owed to Brandies under the License Agreement for sales of Product to any governmental authority for which such governmental
authority is entitled to a royalty-free right pursuant 35 USC 202(c)(paragraph 4); and 
 (h) any other similar and customary deductions to
the extent set forth separately as such in the total amount invoiced. 
 Net Sales shall not include transfers or dispositions for
charitable, compassionate, promotional, pre-clinical, clinical, regulatory, or governmental purposes. Net Sales shall not include sales between or among the Parent and its Subsidiaries (including, after the
Closing, the Company) or their sublicensees. Subject to the above, Net Sales shall be calculated in accordance with U.K. GAAP, consistently applied with the past practice of the Parent and its Subsidiaries. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

8 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 For Net Sales of a Product sold or supplied as a Combination Product, the Net Sales of such a
Combination Product will be determined, subject to the provisions set forth below in this Section 1.74, by multiplying the actual Net Sales of such Combination Product in a particular country in the Territory by the
fraction of A/(A+B), where A is the average gross amount billed or invoiced per unit of such Product in such country in the Territory during the period in respect of which Net Sales are being calculated of the Product sold separately and B is the
total average gross amount billed or invoiced per unit in such country in the Territory of the other active ingredient (including a biologic product) or device included in the Combination Product during the period in respect of which Net Sales are
being calculated, when sold separately. If neither the Product nor the other active ingredient (including a biologic product) or device included in the Combination Product are sold separately as a monotherapy in such country in the Territory during
the period in respect of which Net Sales are being calculated, then the Company or the Parent, on the one hand, and the Sellers’ Representative on the other, shall agree in writing on the fair market value of the other active ingredient
(including a biologic product) or device included in the Combination Product that is to be deducted from the Net Sales of the Combination Product in determining the Net Sales of the Product contained in the Combination Product; provided, however, if
such Parties shall be unable to agree in writing on the fair market value of such other active ingredient (including a biologic product) or device within thirty (30) days from the date of First Commercial Sale of such Combination Product, then
the parties shall request that the Accounting Firm resolve such disagreement in accordance with the procedures set forth in Section 2.3.3 of this Agreement, which determination by the Accounting Firm shall be final, binding
and conclusive on the Company, the Sellers’ Representative and the Sellers and shall not be appealable. 
 1.76 “Objection
Notice” has the meaning set forth in Section 2.3.3(b). 
 1.77 “Parent” has the meaning
set forth in the preamble. 
 1.78 “Parent’s Accounting Principles” has the meaning set forth in
Section 2.3.2(c). 
 1.79 “Parent Indemnified Party” has the meaning set forth in
Section 6.3.1. 
 1.80 “Parent Shares” has the meaning set forth in
Section 2.1.5(a). 
 1.81 “Parent Shareholder Agreement” has the meaning set forth in Schedule
4.1.1. 
 1.82 “Patent Files” mean copies (or originals, where available to the Company or its agents or Affiliates) of
the following to the extent comprising or relating to Licensed Patent Rights: (a) all patents, patent applications, assignments and correspondence to and from any country in the Territory (whether or not to or from the Company); and (b) to
the extent that the same are in existence and related to the items in clause (a), all files, records, workbooks (including, without limitation, laboratory notebooks), correspondence, data, notes and information in the possession or Control of the
Company or its agents. 
 1.83 “Patent Rights” has the meaning given to such term in the License Agreement (as amended by
the License Agreement Amendment). 
 1.84 “Person” means any individual, corporation, partnership, joint venture, limited
liability company, joint stock company, trust or unincorporated organization or Governmental Authority. 
 1.85 “Petsko” has
the meaning set forth in the preamble. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

9 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 1.86 “Pharmaceutical Product Regulatory Authority” means any Governmental
Authority that is concerned with the safety, efficacy, reliability, manufacture, investigation, sale or marketing of pharmaceuticals or medical products, and from which permission is needed to market any such products, including the FDA. 

1.87 “Phase III Study” means any controlled study in humans of the efficacy and safety of a product which is conducted after
Phase II Study has been completed and which is prospectively designed to demonstrate statistically whether the product is safe and effective for use in a particular indication and is usually intended to be sufficient to support registration of the
Product. 
 1.88 “Preclinical Stud(y/ies)” means all studies and other testing, including any animal or other non-clinical studies and testing, not conducted on humans. 
 1.89
“Pre-Closing Tax Period” means any Tax period ending on or before the Closing Date; and, with respect to a Straddle Period, the portion of such Tax period ending at the end of the Closing
Date. 
 1.90 “Privacy Practices” has the meaning set forth in Section 3.3.9(h). 

1.91 “Product” means a product for the therapeutic or prophylactic treatment of amyotrophic lateral sclerosis (ALS) that is
covered by a Valid Claim of the Licensed Patent Rights. 
 1.92 “Post-Closing Tax Period” means any taxable period beginning
after the Closing Date and, with respect to any taxable period beginning before and ending after the Closing Date, the portion of such taxable period beginning after the Closing Date. 

1.93 “Post-Closing Taxes” means Taxes of the Company for any Post-Closing Tax Period. 

1.94 “Qualified Financing” shall mean an equity financing of the Parent in which the Parent issues ordinary or preferred
shares in a transaction or series of transactions, excluding pursuant to an employee benefit plan of Parent. 
 1.95
“Registrations” means, with respect to any jurisdiction, any and all of the regulatory approvals, licenses, registrations, agreements, permits, exemptions, clearances, certificates, consents, authorizations, other permissions, and
requests for approval for, and supplements or amendments to, the foregoing Controlled by the Company or its Affiliates relating to the Product issued by any Governmental Authority, necessary or useful to study, manufacture, or Commercialize a
Product in a country in the Territory, including where applicable, applications for pricing and reimbursement approval. 
 1.96
“Regulatory Documentation” means any and all applications to or from the FDA or any other Governmental Authority for approvals (including all drug approval applications, NDAs, NDA amendments, supplemental NDAs, BLAs, BLA amendments,
supplemental BLAs, CTAs and CTA amendments), registrations, licenses, authorizations and approvals (including all Registrations), submissions, notifications, and Preclinical Study and clinical study authorization applications or notifications
(including all supporting files, writings, data, studies and reports) 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

10 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
prepared for submission to a Governmental Authority or research Institutional Review Board with a view to the granting of any Registration (investigational new drug application or clinical trial
application), approvals granted by or received from the FDA or any other Governmental Authority (including marketing approvals, variations and pricing applications) or other marketing authorization or approval, and any correspondence to or with the
FDA or any other Governmental Authority with respect to Product as it relates to the Territory (including minutes, tracking logs, internal meeting minutes and contact reports, and official contact reports relating to any communications, written or
verbal, with any Governmental Authority), and all data contained in any of the foregoing, including all regulatory drug lists, advertising and promotion documents, adverse event files and complaint files relating to the Product. 

1.97 “Report” has the meaning set forth in Section 2.3.2(a). 

1.98 “Representatives” means, with respect to any Party, such Party’s counsel, accountants, financial advisors, lenders
and other agents and representatives. 
 1.99 “Restricted Party” means each of Fidelity, Petsko and Ringe who are subject to
the restrictions contained in Section 5.2 of this Agreement. 
 1.100 “Return Date” has the
meaning set forth in Section 6.4.5(b). 
 1.101 “Ringe” has the meaning set forth in the preamble.

 1.102 “Royalty Payment” has the meaning set forth in Section 2.3.2(a). 

1.103 “Royalty Period” has the meaning set forth in Section 2.3.2(a). 

1.104 “Securities Act” mean the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.105 “Sellers” has the meaning set forth in the preamble. 

1.106 “Seller Indemnified Party” has the meaning set forth in Section 6.2. 

1.107 “Sellers’ Representative” has the meaning set forth in the preamble. 

1.108 “Special Representations” has the meaning set forth in Section 6.1. 

1.109 “Straddle Period” has the meaning set forth in Section 5.4.2. 

1.110 “Subsidiary” means any corporation, partnership, limited liability company or other legal entity of which the Company
(either alone or together with any other Subsidiary) owns any stock or other equity or partnership interests the holders of which are generally entitled to vote for the election of the board of directors or other governing body of such corporation
or other legal entity or of which such corporation or other legal entity controls the management. 
 1.111 “Surviving
Corporation” has the meaning set forth in Section 2.1. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

11 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 1.112 “Tax” or “Taxes” means (a) any and all federal,
state, local, or non-U.S. income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise,
profits, withholding, social security (or similar), unemployment, disability, real property, gross margins, personal property, sales, use, transfer, registration, alternative or add-on minimum, estimated, or
other tax of any kind whatsoever, including any interest, fine, penalty, or addition thereto, (b) any liability for the payment of any amounts of the type described in clause (a) as a result of being a member of an affiliated,
consolidated, combined, unitary, or aggregate group for any taxable period, and (c) any liability for the payment of any amounts of the type described in clause (a) or (b) as a result of being a transferee of or successor to any Person or
as a result of an obligation to indemnify any Person. 
 1.113 “Tax Claim” has the meaning set forth in
Section 5.4.3. 
 1.114 “Tax Return” means any report, return, declaration or other information or
filing, including any amendments thereto, supplied or required to be supplied to any Taxing Authority with respect to Taxes, including information returns, claims for refund and any documents with respect to or accompanying payments of estimated
Taxes. 
 1.115 “Taxing Authority” means any federal, state, or local Governmental Authority responsible for the assessment,
collection, imposition or administration of any Tax. 
 1.116 “Technical Information” means any and all technical and/or
scientific data and information, including any chemical, formulation, structural, functional biological, chemical, pharmacological, toxicological, pharmaceutical, physical, analytical, process, pre-clinical,
clinical, assay, control, safety, manufacturing and quality control data and information, and all copyrights, trade secret rights and other Intellectual Property Rights relating to any of the foregoing. 

1.117 “Territory” means the US, Australia, Canada and Europe and any other jurisdiction in which the Company is granted orphan
drug or other regulatory exclusivity. 
 1.118 “Third Part(y/ies)” means any Person(s) other than Company and its Affiliates
and Merger Sub, the Parent and their respective Affiliates. 
 1.119 “Third Party Claim” has the meaning set forth in
Section 6.5.1. 
 1.120 “Transaction Documents” means this Agreement and the Ancillary Agreements.

 1.121 “United Kingdom” or “U.K.” means the United Kingdom of Great Britain and Northern Ireland. 

1.122 “U.K. GAAP” means United Kingdom generally accepted accounting principles. 

1.123 “United States” or “U.S.” means the United States of America, its territories, protectorates and
possessions. 
 1.124 “U.S. GAAP” means United States generally accepted accounting principles. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

12 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 1.125 “Valid Claim” means any claim in any (a) issued and unexpired
patent of the Licensed Patent Rights that has not been abandoned in accordance with the terms of the License Agreement, has not been rejected, revoked, held unenforceable, unpatentable or invalid in a final decision of a court or other Governmental
Authority of competent jurisdiction from which no appeal has been or can be taken or (b) pending patent application among the Licensed Patent Rights that have been pending for no more than four (4) years from the first priority date
claimed in such patent application. 
 2. THE MERGER. 

2.1 The Merger. At the Effective Time, subject to the terms and conditions set forth in this Agreement and the applicable provisions of
the Delaware General Corporation Law (“Delaware Law”), Merger Sub shall be merged with and into the Company, the separate corporate existence of Merger Sub shall cease and the Company shall continue as the surviving corporation. The
Company as the surviving corporation after the Merger is hereinafter sometimes referred to as the “Surviving Corporation.” 

2.1.1 Effective Time. At the Closing, the Parties shall file a certificate of merger in substantially the form attached hereto as
Exhibit B (the “Certificate of Merger”) and executed in accordance with the relevant provisions of Delaware Law and make such other filings and recordings as required under Delaware Law. The Merger shall become effective at
such time as is specified in the Certificate of Merger as is duly filed with the Delaware Secretary of State (the “Effective Time”). 

2.1.2 Effect of Merger. At the Effective Time, the effect of the Merger shall be as provided in this Agreement, the Certificate of
Merger and the applicable provisions of Delaware Law. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, all the property, rights, privileges, powers and franchises of the Company and Merger Sub shall vest
in the Surviving Corporation, and all debts, Liabilities and duties of the Company and Merger Sub shall become the debts, Liabilities and duties of the Surviving Corporation. 

2.1.3 Charter; Bylaws. At the Effective Time, the Certificate of Incorporation of the Surviving Corporation shall be amended as provided
in the Certificate of Merger. The Bylaws of Merger Sub, as in effect immediately prior to the Effective Time, shall be the Bylaws of the Surviving Corporation until thereafter amended. 

2.1.4 Directors; Officers. At the Effective Time, the directors of Merger Sub immediately prior to the Effective Time shall be the
directors of the Surviving Corporation, to hold office until such time as such directors resign, are removed or their respective successors are duly elected or appointed and qualified. The officers of Merger Sub immediately prior to the Effective
Time shall be the officers of the Surviving Corporation, to hold office until such time as such officers resign, are removed or their respective successors are duly elected or appointed and qualified. 

2.1.5 Effect of Merger on the Capital Stock of the Constituent Corporations. 

(a) At the Effective Time, by virtue of the Merger and without any action on the part of Merger Sub, the Company or the Sellers, upon the
terms and subject to the conditions set forth in this Agreement, each Company Share issued and outstanding immediately prior to the Effective Time will be cancelled and extinguished and be converted automatically into

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

13 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
the right to receive, credited as fully paid, 15 A ordinary shares of £0.0001 each in the capital of the Parent (the “Parent Shares”), which Parent Shares, for the
avoidance of doubt, the Parent is issuing to the Sellers in consideration for the Merger. At the Effective Time, upon the terms and subject to the conditions set forth in this Agreement, Parent will, and Merger Sub hereby procures that Parent will,
allot and issue the Parent Shares to the Sellers as set forth on Schedule 2.1.5. In no event, shall the Parent Shares to be issued to the Sellers under this Agreement in respect of the Merger exceed, credited as fully paid, in aggregate
30,000 A ordinary shares of £0.0001 each in the capital of the Parent. The Parent Shares shall be distributed amongst the Sellers as set forth on Schedule 2.1.5. 

(b) Each outstanding Company Share owned by the Company as treasury stock or authorized but currently unissued Company Shares immediately
prior to the Effective Time will, by virtue of the Merger, and without any action on the part of the holder thereof, no longer be outstanding, be cancelled and extinguished without payment of any Merger Consideration therefor and will cease to
exist. 
 (c) At the Effective Time, by virtue of the Merger and without any action on the part of the Parent, Merger Sub, the Company, the
Sellers, or any other Person, upon the terms and subject to the conditions set forth in this Agreement, each share of common stock, par value $0.01 per share, of Merger Sub (each, a “Merger Sub Share”) that is outstanding
immediately prior to the Effective Time shall be cancelled and extinguished and be converted automatically into, and shall thereupon represent, one fully paid and non-assessable share of common stock, par
value $0.01 per share, of the Surviving Corporation, with the same rights, powers and privileges as the Merger Sub Shares so converted and shall thereupon constitute the only outstanding shares of capital stock of the Surviving Corporation, to be
held exclusively by the Parent. 
 2.1.6 Stock Certificates Evidencing Company Shares. 

(a) At the Effective Time, (i) no holder of record of a stock certificate that immediately prior to the Effective Time represented
outstanding Company Shares shall have any rights as a stockholder of the Company other than the right to receive the applicable portion of the Parent Shares as set forth above in Section 2.1.5(a) in this Agreement, and
(ii) each stock certificate representing any outstanding Company Shares shall thereafter represent only the right to receive the applicable portion of the Parent Shares as set forth above in Section 2.1.5(a) in this
Agreement. 
 (b) In the event any stock certificate representing any Company Shares shall have been lost, stolen or destroyed, upon the
making of an affidavit of that fact by such Seller, the Parent shall issue to the Seller who is the record holder of such stock certificate representing any Company Shares a certificate evidencing such Seller’s applicable portion of the Parent
Shares; provided, however, that the Parent or the Surviving Corporation may, in its discretion and as a condition precedent to the payment of such consideration, require such Seller to indemnify the Parent and the Surviving Corporation
against any claim that may be made against Merger Sub or the Surviving Corporation with respect to such stock certificate representing any Company Shares. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

14 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 (c) At the Effective Time, the stock transfer books of the Company shall be closed, and
there shall thereafter be no further registration of transfers of shares of Company Shares outstanding immediately prior to the Effective Time on the records of the Company. After the Effective Time, no transfer of such Company Shares shall
thereafter be made on the stock transfer books of the Surviving Corporation. 
 2.2 Issuance of Merger Sub Share; Procurement of Parent
Shares. 
 2.2.1 Issuance of Merger Sub Share. At the Closing and immediately prior to the Effective Time, Merger Sub shall, in
consideration for the Parent issuing the Parent Shares in accordance with the provisions Section 2.1.5(a) (which Parent Shares, for the avoidance of doubt, the Parent is issuing to the Sellers in consideration for the
Merger), issue to the Parent, one Merger Sub Share, which Merger Sub Share shall be duly authorized, validly issued, fully paid and non-assessable upon issuance. 

2.2.2 Procurement of the Issue of Parent Shares. At the Effective Time, Merger Sub shall, in consideration for the Merger and in
exchange for the issuance of a Merger Sub Share, procure that the Parent issues to the Sellers, credited as fully paid, the Parent Shares in accordance with the provisions of Section 2.1.5(a) of this Agreement (which Parent
Shares, for the avoidance of doubt, the Parent is issuing to the Sellers in consideration for the Merger). In addition, Merger Sub shall procure that the Sellers are entered into the register of members of the Parent in respect of the number of
Parent Shares to be issued to each such Seller pursuant to Section 2.1.5(a). 
 2.3 Contingent Payments. In
addition to the issuance of the Parent Shares, the Parent shall make, or cause the Company to make, to the Sellers or the Sellers’ Representative, as herein set forth in this Section 2.3, the payments described in this
Section 2.3 as additional consideration for the Merger (the “Contingent Payments” and together with the Parent Shares, the “Merger Consideration”) if, and at such times as, herein provided.

 2.3.1 Milestone Payments. The following cash payments (each, a “Milestone Payment”) to the Sellers in accordance
with the payment instructions set forth on Schedule 2.3.1, each of which Milestone Payments shall be allocated amongst the Sellers in accordance with the proportions set forth on such Schedule 2.3.1: 

(a) [***] dollars (US$[***]) to be paid, if at all, by wire transfer of immediately available funds within [***] ([***]) Business Days
following [***]; and 
 (b) [***] dollars (US$[***]) to be paid, if at all, by wire transfer of immediately available funds within [***]
([***]) Business Days following [***]. 
 Under no circumstances shall Parent or the Company be obligated under this
Section 2.3.1 to make Milestone Payments to the Sellers in excess of [***] dollars (US$[***]) in the aggregate. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

15 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 2.3.2 Royalty Payments. 

(a) For so long as there is at least one Valid Claim or orphan drug or other regulatory exclusivity in effect following the First Commercial
Sale of any Product (the “Royalty Period”) in any country within the Territory, an annual royalty payment (the “Royalty Payment”) equal to [***] percent ([***]%) of annual Net Sales of such Product in such country
within the Territory. Within [***] ([***]) days after the end of each calendar quarter during the Royalty Period, the Parent or its designee shall deliver a report (each a “Report”) to the Sellers’ Representative specifying the
Net Sales by Product and by country in the Territory during the just completed calendar quarter for the applicable Royalty Period, and the actual aggregate amount payable to the Sellers’ Representative on behalf of the Sellers on account of
sales of any Product during such calendar quarter in the Royalty Period, which Report will provide the Sellers’ Representative with calculations of the amount of the Royalty Payment in sufficient detail to enable the Sellers’
Representative to review Net Sales of each Product for the period and the amount of the Royalty Payment paid. Subject to Section 2.3.3(b), any amounts payable by or on behalf of the Parent under this
Section 2.3.2 shall be due and payable within [***] ([***]) days after the end of each calendar quarter during the applicable Royalty Period. Following the Royalty Period in respect of a Product, no additional Royalty
Payment shall be due and owing in respect of such Product except for any Royalty Payment in respect of such Product that was accrued but unpaid during the Royalty Period. 

(b) All cash payments to be made by the Parent, the Company or one of their respective Affiliates under this
Section 2.3.2 will be made to the Sellers’ Representative, as agent for the Sellers, in U.S. dollars by wire transfer to a single bank account specified on Schedule 2.3.2 attached hereto or to such bank account
as the Sellers’ Representative may subsequently designate in writing to the Parent or the Company. 
 (c) From and after the Closing
Date, the Parent and the Company shall, and shall cause their Affiliates and their and their Affiliates’ respective successors and assigns to determine Net Sales as follows: 

(i) The Parent, the Company and their Affiliates shall use accounting principles, methods and practices (including the application of U.K.
GAAP) that it determines, in consultation with its advisors, to be consistent with U.K. GAAP (the “Parent’s Accounting Principles”) and shall not be required under this Agreement or otherwise to prepare the Report consistent
with the historical accounting principles, methods and practices (including the application of U.S. GAAP) used by the Sellers or the Company prior to the Closing Date. 

(ii) The Company and its Affiliates (to the extent licensees or sublicensees of any Licensed Patent Rights) shall use Commercially Reasonable
Efforts to operate and conduct the development, manufacture and/or Commercialization of the Licensed Patent Rights and any Product. 
 2.3.3
Records and Audits. 
 (a) The Company shall keep, and shall cause each of its Affiliates (to the extent licensees or sublicensees of
any Licensed Patent Rights) and licensees, to keep adequate books and records of accounting for the purpose of calculating all Royalty Payments payable to the Sellers under Section 2.3.2. For the seven (7) years next
following the end of the calendar year to which each shall pertain, such books and records of accounting (including those of the Company’s applicable Affiliates and licensees) shall be kept at each of their principal place of business and shall
be open for inspection at reasonable times and upon reasonable notice by the 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

16 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
Accounting Firm for the sole purpose of inspecting the Royalty Payments due to the Sellers under this Agreement. In no event shall such inspections be conducted hereunder more frequently than
once every twelve (12) months. The Accounting Firm must have executed and delivered to the Company and its Affiliates (to the extent licensees or sublicensees of any Licensed Patent Rights) or licensees, a confidentiality agreement as
reasonably requested by the Company, which shall include provisions limiting the Accounting Firm’s disclosure to the Sellers’ Representative and the Sellers to only the results and basis for such results of such inspection. The results of
such inspection, if any, shall be binding on all Parties. Any underpayments shall be paid by the Company within thirty (30) days of notification of the results of such inspection. Any overpayments shall be fully creditable against amounts
payable in subsequent payment periods. Sellers’ Representative shall pay for such inspections, except that in the event there is any upward adjustment in aggregate Royalty Payments payable for any calendar year shown by such inspection of more
than five percent (5%) of the amount paid, in which case, the Company shall reimburse Sellers’ Representative for any reasonable out-of-pocket costs of the Accounting Firm. 

(b) Each Report delivered pursuant to Section 2.3.2 shall be final, binding and conclusive, unless the Sellers’
Representative notifies the Company and the Parent in writing of any disagreement therewith (an “Objection Notice”) within thirty (30) days after its receipt thereof, specifying (a) those items as to which there is
disagreement and (b) a reasonably detailed description of the basis, nature, dollar amount and extent of the dispute or disagreement. If the Sellers’ Representatives delivers an Objection Notice within such 30 day- period, then for a period of ten (10) Business Days from the date of delivery of the Objection Notice, the Company shall afford the Sellers’ Representative and its Representatives with reasonable
access during normal business hours to the books and records of the Company or its Affiliates (to the extent licensees or sublicensees of any Licensed Patent Rights) and its licensees so as to enable its review of the applicable Report and the
information contained therein. The Company and the Sellers’ Representative shall attempt in good faith to resolve such dispute, and any resolution by them as to any disputed amounts shall be final, binding and conclusive. If the Company and the
Sellers’ Representative are unable to resolve all disputes reflected in the Objection Notice within ten (10) Business Days after the date of delivery of the Objection Notice (or such longer period as the Company and the Sellers’
Representative may mutually agree upon), then the Company shall request that Ernst & Young LLP or such other independent certified public accounting firm of national recognition as mutually agreed upon by the Company and the Sellers’
Representative (the “Accounting Firm”) to resolve any remaining disagreements. The Company and the Sellers’ Representative shall use their commercially reasonable efforts to cause the Accounting Firm to make its determination
within thirty (30) days of its engagement for such purpose. The determination by the Accounting Firm shall be final, binding and conclusive on the Company, the Sellers’ Representative and the Sellers and shall not be appealable. The
Company and the Sellers’ Representative shall deliver to the Accounting Firm all work papers and back-up materials relating to the unresolved disputes requested by the Accounting Firm to the extent
available to the Company and the Sellers’ Representative and their respective Representatives. The Company and the Sellers’ Representative shall be afforded the opportunity to present to the Accounting Firm any material related to the
unresolved disputes and to discuss the issues with the Accounting Firm; provided, however, that no such presentation or discussion shall occur without the presence of Representatives of the Company and the Sellers’ Representative. The
determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. Upon resolution by the Accounting Firm to its satisfaction of all such disputed matters, the Accounting 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

17 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
Firm shall cause to be prepared and shall deliver to the Company and the Sellers’ Representative a final Report setting forth the Net Sales for each Product by country in the Territory in
dispute as specified in the Objection Notice in respect of the calendar quarter at issue in the disputed Report, and the date of such delivery by the Accounting Firm shall be deemed the date on which the Report and the Net Sales for the applicable
Products in the Territory in respect of the calendar quarter at issue in the disputed Report shall become final, binding and conclusive. 

(c) The fees, costs and expenses of the Accounting Firm pursuant to Section 2.3.3(b) shall be allocated between the
Company or the Parent, on the one hand, and the Sellers’ Representative, on the other hand, in the same proportion that the aggregate amount of the disputed items that are unsuccessfully disputed by such Party (as finally determined by the
Accounting Firm) bears to the total amount of disputed items submitted. 
 (d) The Company, its Affiliates (to the extent licensees or
sublicensees of any Licensed Patent Rights) and licensees shall not be required under this Agreement to maintain books and records in respect of Royalty Payments or Net Sales of any Product for more than seven (7) years following the end of any
calendar year. 
 (e) All financial information subject to review under this Section 2.3 shall be held by each
Party in accordance with the confidentiality and non-use provisions of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with the Company and/or its
Affiliates obligating it to retain all such information in confidence pursuant to such confidentiality agreement. 
 (f) The resolution of
any claim or dispute in respect of Net Sales or any Royalty Payment shall be resolved as provided in this Section 2.3.3 and shall not be subject to any other dispute resolution provision (if any) provided for in this
Agreement. 
 2.3.4 No Implied Rights. The right of the Sellers (directly or through the Sellers’ Representative) to receive any
Milestone Payment or Royalty Payment (i) is solely a contractual right and is not a security for purposes of any federal or state securities laws (and shall confer upon the Sellers only the rights of a general unsecured creditor under
Applicable Law); (ii) will not be represented by any form of certificate or instrument; (iii) does not give the Sellers’ Representative or Sellers any dividend rights, voting rights, liquidation rights, preemptive rights or other rights
including, without limitation, any rights with respect to the operation or conduct of the business of the Company or the Company from and after the Closing; and (iv) may not be sold, assigned, pledged, gifted, conveyed, transferred or otherwise
disposed. 
 2.4 Closing. The closing of the Merger hereunder shall be conducted telephonically and/or via email, facsimile transfer
or other similar means of correspondence (the “Closing”) concurrently with the execution and delivery of this Agreement on the Effective Date (the date of Closing, the “Closing Date”), and shall be deemed to have
taken place at the offices of DLA Piper LLP (US) in New York City or at such other place as the Parties may mutually agree. Subject to the terms and conditions of this Agreement, at the Closing, (i) Merger Sub will issue one Merger Sub Share to
the Parent in consideration for the Parent issuing the Parent Shares in accordance with the provisions Section 2.1.5(a) (which Parent Shares, for the avoidance of doubt, the Parent is issuing to the Sellers in consideration
for the Merger), which Merger Sub Share shall be duly authorized, validly issued, fully-paid and non-assessable; (ii) the Parent will issue, subject to the 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

18 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
filing of the Certificate of Merger as provided in Section 2.1.1 of this Agreement, the Parent Shares to the Sellers (which Parent Shares, for the avoidance of doubt,
the Parent is issuing to the Sellers in consideration for the Merger), credited as fully paid, in accordance with Section 2.1.5(a) of this Agreement, which shall be allocated amongst the Sellers as set forth on Schedule
2.1.5, in exchange for the issue of one Merger Sub Share by Merger Sub; and (iii) the Parties will exchange (or cause to be exchanged) the certificates and/or other documents, or do, or cause to be done, all of the things respectively
required of each Party as specified in Article 4 herein. 
 2.5 Withholding. Notwithstanding any other provision of this
Agreement, Merger Sub, the Parent or, following the Effective Time, the Company, as the case may be, shall be entitled to withhold, or cause to be withheld, any and all amounts paid or deemed paid by it to any Person as a result of the transactions
contemplated by this Agreement, including from any Contingent Payments, that it reasonably believes are required to be withheld under Applicable Law. To the extent such amounts are so deducted and withheld and paid over to the applicable
Governmental Authority, such amounts shall be treated for all purposes of this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid and the payor Party shall secure and, from time to time (if and as
applicable), send to the payee Party evidence in its possession of such payment. 
 2.6 Allocation of Company Expenses. From and after
the Effective Time, all accounts payable or other expenses of the Company (the “Company Expenses”) in respect of the periods prior to and following the Effective Time shall be prorated and apportioned as follows: 

(a) to Fidelity for all Company Expenses incurred in respect of any period prior to the Effective Time (which shall include the Closing Date),
and 
 (b) to Parent and the Surviving Corporation for all Company Expenses incurred in respect of any period from and after the Effective
Time. 
 The payment of any Company Expenses subject to this Section 2.6 shall be the responsibility of the Party required to pay
such Company Expense pursuant to this Section 2.6; provided, however, that Parent or the Surviving Corporation shall be entitled to pay any Company Expense allocable to Fidelity pursuant to this
Section 2.6 and then, upon submission of an invoice or other reasonable documentation evidencing the applicable Company Expense, to be reimbursed for such Company Expense from Fidelity promptly (but within any event within
30 days) following submission of such invoice or other documentation evidencing such Company Expense. Each of Fidelity, on the one hand, and Parent and the Surviving Corporation, on the other, shall use Commercially Reasonable Efforts to make
payment of any Company Expenses submitted for payment by such Party pursuant to this Section 2.6 when the payment of such Company Expense is due. 

3. REPRESENTATIONS AND WARRANTIES. 
 3.1
Representations and Warranties of Merger Sub. Merger Sub hereby represents and warrants to the Sellers that as of the Closing Date: 

3.1.1 Authorization. The execution, delivery and performance of this Agreement and each of the Ancillary Agreements to which it is or
will be a party have been duly authorized by the Board of Directors and the sole stockholder of Merger Sub. No other action or approval on the part of Merger Sub or its Affiliates is required for the execution, delivery and performance of this
Agreement by Merger Sub other than those which shall have already been made or obtained. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

19 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 3.1.2 Organization. Merger Sub is a corporation duly organized, validly existing and
in good standing under the laws of the State of Delaware. Merger Sub has all requisite power and authority to own, lease and operate the properties and assets it currently owns, leases and operates and to carry on its business and is duly qualified
to transact business and is in good standing in each jurisdiction wherein the nature of the business conducted by Merger Sub as of the Closing Date or the ownership of its assets makes such qualification necessary. Merger Sub has previously made
available to the Sellers true, correct and complete copies of its certificate of incorporation and bylaws. 
 3.1.3 Power and
Authority. Merger Sub has the power and authority to execute and deliver this Agreement and the Ancillary Agreements to which it is or will be a party and to perform its obligations hereunder and thereunder. This Agreement and the Ancillary
Agreements to which it is or will be a party have been duly executed and delivered by Merger Sub, and constitute the legal, valid and binding obligations of Merger Sub, enforceable against it in accordance with their terms except as such
enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity. 

3.1.4 Non-Contravention. The execution, delivery and performance by Merger Sub of this Agreement
and the Ancillary Agreements to which it is or will be a party and the consummation of the transactions contemplated by this Agreement and the Ancillary Agreements to which it is or will be a party do not: (a) violate, conflict with, result in
any material breach of, or constitute a default (or an event that, with notice or lapse of time or both, would constitute a default) under (i) any Contract to which Merger Sub is a party, (ii) the provisions of its certificate of
incorporation or bylaws, or (iii) any order, writ, injunction or decree of any Governmental Authority entered against it or by which any of its property is bound that would adversely affect Merger Sub’s ability to consummate the
transactions contemplated by this Agreement and the Ancillary Agreements; or (b) violate any Applicable Laws. There is no consent, approval, order or authorization of or from, or registration, notification, declaration or filing to or with, any
Governmental Authority that is required by Merger Sub in connection with the execution, delivery or performance by Merger Sub of this Agreement and the Ancillary Agreements to which it is or will be a party or the consummation of the transactions
contemplated hereby and thereby. 
 3.1.5 Litigation. There is no litigation or proceeding (including, but not limited to
arbitration), in law or in equity, and there are no proceedings or governmental investigations before any commission or other administrative authority or Governmental Authority, pending, or, to Merger Sub’s Knowledge, threatened, against Merger
Sub or with respect to this Agreement or the consummation of the transactions contemplated hereby. 
 3.1.6 Brokers. No broker,
investment banker, agent, finder or other intermediary acting on behalf of Merger Sub or under the authority thereof, is or will be entitled to any broker’s or finder’s fee or any other commission or similar fee directly or indirectly in
connection with the transactions contemplated under this Agreement. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

20 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 3.1.7 Compliance with Applicable Laws. Merger Sub is, and has been since its
formation, in compliance with all Applicable Laws in all material respects. 
 3.2 Representations and Warranties of the Parent. The
Parent hereby represents and warrants to the Sellers that as of the Closing Date: 
 3.2.1 Authorization. The Parent has all necessary
consents and authorizations to enter into and perform its obligations under this Agreement and each of the Ancillary Agreements to which it is or will be a party. 

3.2.2 Organization. The Parent is a private company limited by shares duly incorporated in England and Wales. 

3.2.3 Parent Capitalization; Parent Shares. Schedule 3.2.3 sets forth the entire issued share capital of the Parent as of
immediately prior to the Closing. All the issued shares of the Parent as of immediately prior to the Closing set forth on Schedule 3.2.3 have been properly allotted and are fully paid up and were issued in conformity with all Applicable Laws,
including U.S. federal securities Applicable Laws. The issued shares of the Parent as of immediately prior to the Closing set forth on Schedule 3.2.3 were not issued in violation of any purchase option, call option, right of first refusal,
preemptive right, subscription right or any similar right under any Applicable Law, any provision of the articles of association, or any Contract to which Parent is a party or by which it is otherwise bound. No Person has any right (whether
contingent or otherwise) to require the Parent: (a) to allot or grant rights to subscribe for any shares; or (b) to convert any existing securities into shares or issue securities that have rights to convert into shares. Except for the
Parent Shareholder Agreement and articles of association, the Parent is not a party to any shareholder, member, investor or similar agreements or understandings with respect to the repurchase or transfer of any issued share capital of the Parent.
The Parent Shares shall, at the Effective Time, be validly authorized and allotted, free of Encumbrances (other than such Encumbrances incurred pursuant to the Parent Shareholder Agreement or the articles of association). 

3.2.4 Power and Authority. The Parent has the power and authority to execute and deliver this Agreement and the Ancillary Agreements to
which it is or will be a party and to perform its obligations hereunder and thereunder. This Agreement and the Ancillary Agreements to which it is or will be a party have been duly executed and delivered by the Parent, and constitute the legal,
valid and binding obligations of the Parent, enforceable against it in accordance with their terms except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights
generally and by general principles of equity. 
 3.2.5 Non-Contravention. The execution,
delivery and performance by the Parent of this Agreement and the Ancillary Agreements to which it is or will be a party and the consummation of the transactions contemplated by this Agreement and the Ancillary Agreements to which it is or will be a
party do not: (a) violate, conflict with, result in any material breach of, or constitute a default (or an event that, with notice or lapse of time or both, would constitute a default) under (i) any material Contract to which the Parent is
a party, other than such consents, approvals or notices which have already been obtained or given; (ii) result in the creation of any Encumbrance on any of the Parent Shares other than as set forth in the Parent Shareholder Agreement and
articles of association; (iii) the provisions of its articles of association or other 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

21 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
governing documents; or (iv) any order, writ, injunction or decree of any Governmental Authority entered against it or by which any of its property is bound that would adversely affect the
Parent’s ability to consummate the transactions contemplated by this Agreement and the Ancillary Agreements to which it is or will be a party; or (b) violate any Applicable Laws. Except for the filing of a Form SH01 in respect of the
Parent Shares with the U.K. Companies House, there is no consent, approval, order or authorization of or from, or registration, notification, declaration or filing to or with, any Governmental Authority that is required by the Parent in connection
with the execution, delivery or performance by the Parent of this Agreement and the Ancillary Agreements to which it is or will be a party or the consummation of the transactions contemplated hereby and thereby. 

3.2.6 Litigation. There is no litigation or proceeding (including, but not limited to arbitration), in law or in equity, and there are
no proceedings or governmental investigations before any commission or other administrative authority or Governmental Authority, pending, or, to the Parent’s Knowledge, threatened, against the Parent or with respect to this Agreement or the
consummation of the transactions contemplated hereby. 
 3.2.7 Brokers. No broker, investment banker, agent, finder or other
intermediary acting on behalf of the Parent or under the authority thereof, is or will be entitled to any broker’s or finder’s fee or any other commission or similar fee directly or indirectly in connection with the transactions
contemplated under this Agreement. 
 3.2.8 Compliance with Applicable Laws. Parent is, and has been since its formation, in
compliance with all Applicable Laws in all material respects. 
 3.2.9 Parent Financial Statements. Parent has delivered to Sellers an
unaudited balance sheet of Parent as at September 30, 2015 (the “Parent Unaudited Balance Sheet”) and related unaudited statements of operations and cash flows, as applicable, for the period from April 24, 2015 through
September 30, 2015 (the “Parent Unaudited Income Statement” and, together with the Parent Unaudited Balance Sheet, the “Parent Financial Statements”). A true copy of the Parent Financial Statements is attached
at Schedule 3.2.9. Except as described in Schedule 3.2.9, the Financial Statements (a) were prepared in accordance with U.K. GAAP, consistently applied with past practice (except for the absence of footnote disclosure and any year-end audit adjustments), and (b) fairly present, in all material respects, the financial position and results of operations, and cash flows of the Parent, on a consolidated basis, as of the date and for the
period indicated. 
 3.2.10 Absence of Undisclosed Liabilities. The Parent does not have any debt or liabilities required to be shown
on a balance sheet prepared in accordance with U.K. GAAP, applied in a manner consistent with the preparation of the Parent Unaudited Balance Sheet as at September 30, 2015 except: (a) to the extent disclosed or reserved against in the
Parent Unaudited Balance Sheet, or (b) for liabilities and obligations that were incurred after the date of the Parent Unaudited Balance Sheet in the ordinary course of the Business consistent in amount and kind with past practice and not
individually or in the aggregate material to the Parent. 
 3.3 Representations and Warranties of the Company. The Company hereby
represents and warrants to Merger Sub and the Parent that as of the Closing Date: 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

22 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 3.3.1 Authorization. The execution, delivery and performance of this Agreement and the
Ancillary Agreements to which it is or will be a party have been duly authorized by the Board of Directors and stockholders of the Company. No other action or approval on the part of the Company or its Affiliates is required for the execution,
delivery and performance of this Agreement by the Company. 
 3.3.2 Organization. The Company is a corporation duly incorporated and
organized, validly existing and in good standing under the laws of the State of Delaware. The Company has all requisite power and authority to own, lease and operate the properties and assets it currently owns, leases and operates and to carry on
its business and is duly qualified to transact business and is in good standing in each jurisdiction wherein the nature of the business conducted by the Company as of the Closing Date or the ownership of its assets makes such qualification
necessary. The Company has previously made available to the Parent true, correct and complete copies of the certificate of incorporation, bylaws and any other governing documents of the Company. 

3.3.3 Capitalization; Subsidiaries. 

(a) The authorized and issued and outstanding shares of capital stock of the Company are as set forth on Schedule 3.3.3(a). The Company
Shares constitute all of the issued and outstanding shares of capital stock of the Company. The Company Shares have been duly authorized, are validly issued, fully paid, and non-assessable, and are held of
record and beneficially by the Sellers in the proportions as set forth on Schedule 3.3.3(a), in each case, free and clear of all Encumbrances. The Company Shares were issued in conformity with all Applicable Laws, including federal and state
securities Applicable Laws, and were not issued in violation of, and are not subject to, any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any Applicable Law, any provision of
the certificate of incorporation, bylaws and any other governing documents of the Company or any Contract to which the Company is or was a party or by which it is or was otherwise bound. Except as set forth on Schedule 3.3.3(a), there are no
outstanding or authorized (i) options, warrants, purchase rights, subscription rights, conversion rights, exchange rights, or other contracts or commitments that could require the Company to issue, sell, or otherwise cause to become outstanding
any of the Company’s capital stock, or (ii) stock appreciation, phantom stock, profit participation, or similar rights with respect to the Company. The Company does not maintain any share option plan or any other plan or agreement
providing for equity compensation to any Person. Neither the Company nor any Seller is a party to any voting trusts, proxies, or other shareholder, member, investor or similar agreements or understandings with respect to the voting, repurchase, or
transfer of shares of the capital stock of the Company. 
 (b) The Company has no, and has never had, Subsidiaries and does not have, and
has never had, any interest in, or obligation or right to acquire, purchase or subscribe for, directly or indirectly, any outstanding capital stock of, or other equity interests in, any Person. 

3.3.4 Power and Authority. The Company has the power and authority to execute and deliver this Agreement and the Ancillary Agreements to
which it is or will be a party and to perform its obligations hereunder and thereunder. This Agreement and the Ancillary Agreements have been duly executed and delivered by the Company, and constitute the legal, valid and binding 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

23 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
obligations of the Company, enforceable against it in accordance with their terms except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar
laws affecting creditors’ rights generally and by general principles of equity. 
 3.3.5
Non-Contravention. The execution, delivery and performance of this Agreement by the Company and the Ancillary Agreements to which it is or will be a party and the consummation of the transactions
contemplated by this Agreement and the Ancillary Agreements to which it is or will be a party do not: (a) violate, conflict with, result in any material breach of, or constitute a default (or an event that, with notice or lapse of time or both,
would constitute a default) under any Contract of the Company, including the License Agreement; (b) result in the creation of any Encumbrance on any of the Company Shares; (c) violate any Applicable Laws; or (d) give any party to any
Contract to which the Company is a party, including the License Agreement, the right to terminate, modify or accelerate any rights, obligations or performance under such Contract. Except for the filing of the Certificate of Merger, there is no
consent, approval, order and authorization of or from, and registration, notification, declaration or filing to or with, any Person, including any Governmental Authority that is required by the Company in connection with the execution, delivery or
performance by the Company of this Agreement and the Ancillary Agreements to which it is or will be a party or the consummation of the transactions contemplated hereby and thereby. 

3.3.6 Title to Assets. The Company has the sole and exclusive right, title and interest in and to, or a valid lease or license to, all
of its assets used or usable in the conduct of its business as conducted as of the Closing Date (“Company Assets”) free and clear of all Encumbrances. Except as set forth in the License Agreement, no portion of the Company Assets
has been licensed from or to any Third Party. The license grants under the License Agreement comprise all of the assets and rights that are used or held for use by the Company prior to the Closing. 

3.3.7 Intellectual Property. 

(a) Except as described on Schedule 3.3.7(a), the Company owns exclusively all right, title and interest in and to, or has valid and
enforceable exclusive license rights to all of the Licensed Patent Rights and valid and enforceable non-exclusive license rights to all of the Licensed Know-How
(“Company Intellectual Property Rights”). The Company Intellectual Property Rights are the only Intellectual Property Rights Controlled by the Company. The Licensed Patent Rights were developed with federal funding from the U.S.
government. The Company has made available true and complete copies of all Patent Files in its possession to the Parent. Neither the Company nor any of its Affiliates Controls or otherwise uses any trademarks, trademark registrations, trademark
applications, service marks, service mark registrations or service mark applications. Other than the Licensed Know-How included in the Company Intellectual Property Rights, there is no know-how, techniques, processes, methods, formulations, specifications, chemical materials, biologic materials, assays, marketing plans and strategies, software (including source code and related documentation) or
other data and information (and all copyrights, trademarks, trade secret rights and other Intellectual Property Rights relating to any of the foregoing) Controlled by the Company in written, electronic or any other form. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

24 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 (b) Other than the License Agreement, there are no license agreements in respect of any of
Company Intellectual Property Rights either licensed by the Company as licensor to Third Parties or any of its Affiliates or licensed from Third Parties or any of its Affiliates to the Company as licensee. The License Agreement is in full force and
effect, all payments through the Closing Date required to be made thereunder by the Company have been made, and the Company is in compliance in all material respects with its respective obligations thereunder. 

(c) (i) To the Company’s Knowledge, there are no facts that should reasonably support a finding of invalidity or infringement with
respect to the Company Intellectual Property Rights, (ii) to the Company’s Knowledge, no actions or omissions have occurred in connection with the pending patent applications comprising the Patent Rights which would reasonably be likely to
render any Licensed Patent Rights unenforceable, and (iii) none of such Company Intellectual Property Rights has been or is the subject of any pending proceeding (including, with respect to the Licensed Patent Rights, inventorship challenges,
interferences, reissues, reexaminations and oppositions or similar proceedings) or any order or other agreement restricting or any order or other agreement (other than the License Agreement) restricting (1) the use of any such Company
Intellectual Property Rights or (2) the assignment or license thereof by the Company (or any of its Affiliates, as applicable). 
 (d)
Other than the License Agreement, there are no Contracts to which the Company or any of its Affiliates is a party that include royalty, license fee and other similar payment obligations of the Company (or any of its Affiliates) with respect to the
Licensed Patent Rights or otherwise in connection with the exploitation of the Company Patents Rights. 
 (e) To the Company’s
Knowledge, there is no unauthorized use, infringement, misappropriation or violation of any of the Company Intellectual Property Rights by any Person. To the Company’s Knowledge, the exploitation (including the manufacture, use, sale, offer for
sale or importation thereof) of the Company Intellectual Property Rights, including the Licensed Patent Rights, in the Territory does not and will not infringe or misappropriate or otherwise violate, as applicable, the Intellectual Property Rights
of any Person. The Company has not received any written notice from any Person regarding, and has no Knowledge of, any claim or assertion of, any infringement, misappropriation or violation with respect to Intellectual Property Rights of any Person
in connection with any of the Company Intellectual Property Rights, including the Licensed Patent Rights. 
 (f) To the Company’s
Knowledge, all issuance, renewal, maintenance and other payments that are or have become finally due with respect to the Company Intellectual Property Rights, including the Licensed Patent Rights, have been paid by or on behalf of the Company as of
the Effective Date. To the Company’s Knowledge, all documents, certificates and other material in connection with the Company Intellectual Property Rights, including the Licensed Patent Rights, have, for the purposes of maintaining such Company
Intellectual Property Rights, been filed in a timely manner with the relevant Governmental Authorities. The Company and to the Company’s Knowledge, its Affiliates or its licensors, as applicable, have filed, prosecuted and maintained all
Licensed Patent Rights and have filed, maintained or otherwise protected all other Company Intellectual Property Rights. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

25 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 (g) The Company has taken reasonable measures to maintain in confidence all Company trade
secrets and Company Confidential Information. 
 3.3.8 Product Sales; Inventory. The Company has not developed, manufactured or
Commercialized any Products in the Territory. Neither the Company or its Affiliates, nor any Third Party on behalf of The Company or its Affiliates, owns, possesses and/or is control of any inventory of finished Product for sale or use in the
Territory. 
 3.3.9 Company Compliance with Legal Requirements; Regulatory Matters. 

(a) The Company is, and has been since its formation, in compliance with all Applicable Laws in all material respects. The Company has not
received any written notice of any asserted violation of Applicable Laws. The Company is not aware of any pending investigation of any Governmental Authority. 

(b) The Company possesses all Registrations from Governmental Authorities, or required by Governmental Authorities to be obtained, in each
case, necessary for the lawful conduct of its business as now conducted. All such Registrations are in full force and effect in all material respects and the Company has filed all reports, notifications and filings with, and have paid all regulatory
fees to, the applicable Governmental Authority necessary to maintain all of such Registrations in full force and effect. The Company is in compliance in all material respects with the terms of all such Registrations. The Company has not received
written notice to the effect that a Governmental Authority was considering the amendment, termination, revocation or cancellation of any Registration. The consummation of the transactions contemplated under this Agreement, in and of itself, will not
cause the revocation or cancellation of any Registration. 
 (c) The Company is not a party to any corporate integrity agreements,
monitoring agreements, consent decrees, settlement orders or similar agreements with or imposed by any Governmental Authority. The Company has not been placed under or otherwise made subject to the FDA’s Application Integrity Policy pursuant to
FDA’s Compliance Policy Guide (CPG) 7150.09, 56 FR 46191 (September 10, 1991). 
 (d) Neither the Company nor any of its current
officers or agents, nor, to the Knowledge of the Company, any of its Affiliates, have ever been, are currently, or are the subject of a proceeding that could lead to the Company, any Seller or such employees or agents becoming, as applicable, a
Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual or a Convicted Entity or Convicted Individual. For purposes of this provision, the following definitions shall apply: (i) a “Debarred Individual” is an
individual who has been debarred by the FDA pursuant to 21 U.S.C. §335a(a) or barred from providing services in any capacity to a person that has an approved or pending drug or injectable product application; (ii) a “Debarred
Entity” is a corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. §335a(a) or barred from submitting or assisting in the submission of any abbreviated drug application, or a subsidiary or
affiliate of a Debarred Entity; (iii) an “Excluded Individual” or “Excluded Entity” is (A) an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in
federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department of Health and Human Services, or (B) is an individual or entity, as applicable, who has been excluded, debarred,
suspended or is otherwise ineligible to participate in federal 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

26 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 procurement and non-procurement programs, including those produced by
the U.S. General Services Administration (GSA); and (iv) a “Convicted Individual” or “Convicted Entity” is an individual or entity, as applicable, who has been convicted of a criminal offense that falls within the ambit of
21 U.S.C. §335a(a) or 42 U.S.C. §1320a—7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible, and in each case any foreign equivalents thereof, as applicable. 

(e) Neither the Company nor any of its current officers, employees or agents, nor, to the Knowledge of the Company, any of its Affiliates, has
made an untrue statement of a material fact or fraudulent statement to any Pharmaceutical Product Regulatory Authority, failed to disclose a material fact required to be disclosed to any Pharmaceutical Product Regulatory Authority, or committed any
act, made any statement, or failed to make any statement, that would reasonably be expected to provide a basis for the FDA to invoke its policy respecting “Fraud, Untrue Statements of Material Fact, Bribery, and Illegal Gratuities”, set
forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar Applicable Law in any other country in the Territory. 
 (f) The Company has
no Knowledge of any scientific or technical fact or circumstance that would reasonably be expected to materially and adversely affect the scientific, therapeutic or commercial viability of the Licensed Patent Rights or any Product, including the
ability to obtain a Registration for any Product. 
 (g) The Company has not been notified in writing by any Third Party or any Governmental
Authority of any material failure (or any material investigation with respect thereto) by them or any licensor, licensee, partner or distributor to comply with, or maintain systems and programs to ensure compliance with, any Applicable Laws. 

(h) All personal data collected, processed and disclosed by the Company or any of its Affiliates, including any information or data collected
during any clinical trials conducted during the development, Preclinical Studies and clinical testing, manufacture, storage, distribution, supply and administration of the Licensed Patent Rights or any Product, have been, and are being, collected,
processed, transferred, stored, used and disclosed in material compliance with (A) all Applicable Laws and industry standards, including the Health Insurance Portability and Accountability Act of 1996 and the implementing regulations of the
U.S. Department of Health and Human Services, Directive 95/46/EC of 24 October 1995 and the implementing laws of the individual European Union countries and (B) the Company’s privacy, data protection and information security policies
and practices (collectively “Privacy Practices”). Neither the Company nor any of its Affiliates have received any: (i) written notice or complaint alleging non-compliance with any
Applicable Laws or the Privacy Practices relating to the collection, processing and disclosure of information or data; (ii) written claim for compensation for loss or unauthorized collection, processing or disclosure of data; or
(iii) written notification of an application for rectification, erasure or destruction of information or data that is still outstanding. 

(i) No claims have been asserted nor, to the Company’s Knowledge, are threatened against the Company or its Affiliates by any person,
regulator, law enforcement agency or entity alleging a violation of any privacy, personal or confidentiality rights under any of the Privacy Practices or Applicable Laws. With respect to all personal or user information collected

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

27 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 by the Company, the Company has at all times taken all commercially reasonable steps
necessary (including, without limitation, implementing and monitoring compliance with reasonable measures with respect to administrative safeguards and technical and physical security) to (i) protect such information against loss and against
unauthorized access, use, modification, disclosure or other misuse and (ii) comply with Applicable Law and the Privacy Practices in its collection, processing, storage, use, disclosure and transfer of such information. 

To the Knowledge of the Company, there has been no unauthorized access to, theft, breach or disclosure of or other misuse of that information.
To the Knowledge of the Company, there has been no unauthorized disclosure, whether pursuant to Applicable Law or the Privacy Practices, of electronic communications, patient data, clinical data or protected health information to any Third Party,
including any Governmental Authority. 
 (j) The Company has made available to the Parent (i) complete and correct copies of the
Registrations, including all supplements and amendments thereto, (ii) all correspondence sent to and received from any Governmental Authority or any Institutional Review Board, and (iii) all existing written records relating to all
discussions and meetings between or involving the Company and any Governmental Authority or Institutional Review Board. 
 (k) The Company
has made available, or has caused its Affiliates to make available, to the Parent all Technical Information and Regulatory Documentation, and any other data, clinical studies and Preclinical Studies in the Company’s or the Company’s
Affiliates’ Control, and all such Technical Information and Regulatory Documentation were and are true, complete and correct at such time and as of the date hereof. The Company has prepared, maintained and retained all Regulatory Documentation
that is required to be maintained or reported pursuant to and, to the extent applicable, in accordance with Applicable Laws and, to the Knowledge of the Company, all such information is true, complete and correct in what it purports to be. 

(l) The Company is not now, and has never have been, party to a Government Contract. Neither the Company nor any of its Subsidiaries are now,
and have never been, a Contractor or Subcontractor as those terms are defined and used in the U.S. federal procurement law and regulation, including but not limited to the Federal Acquisition Regulation (“FAR”) and the U.S.
Department of Defense Supplement to the FAR (“DFAR”). 
 (m) No “bad actor” disqualifying event described in Rule
506(d)(1)(i)- (viii) of the Securities Act (a “Disqualification Event”) is applicable to the Company or, to the Company’s knowledge, any Covered Person (as defined in this Section 3.3.9(m)), except for
a Disqualification Event as to which Rule 506(d)(2)(ii-iv) or (d)(3) of the Securities Act is applicable. “Covered Person” means, with respect to the Company or Parent as an “issuer”
for purposes of Rule 506 promulgated under the Securities Act, any person listed in the first paragraph of Rule 506(d)(1) of the Securities Act. 

(n) The Company is not required to register as an “investment company” under the Investment Company Act of 1940. 

3.3.10 Litigation. There is no litigation or proceeding (including, but not limited to arbitration), in law or in equity, and there are
no proceedings or governmental investigations before any commission or other administrative authority or Governmental Authority, pending, or, to the Company’s Knowledge, threatened, against the Company or with respect to the consummation of the
transactions contemplated hereby. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

28 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 3.3.11 Contracts. The License Agreement and Investment Agreements comprise all of the
Contracts between the Company or its Affiliates and Third Parties pursuant to which the Company has rights and/or obligations (the “Company Contracts”). The Company has made available to the Parent a true and correct copy of the
Company Contracts. The Company Contracts are in full force and effect and constitute valid and binding obligations of the Company and, to the Knowledge of the Company, the other parties thereto. Neither the Company nor, to the Knowledge of the
Company, the other parties to the Company Contracts are in default thereunder, and the Company has not received or given notice of any default thereunder from or to any of the other parties thereto, and, to the Knowledge of the Company, there exists
no event which upon notice or the passage of time, or both, would reasonably be expected to give rise to any default by the Company or the other parties thereto. The Company has not received any written notice, nor does the Company have any
Knowledge that any party to any Company Contract intends to cancel or terminate any Company Contract. 
 3.3.12 Employee Matters. 

(a) The Company does not have, and has never had, any employees. 

(b) The Company does not maintain, sponsor, or contribute to, has never maintained, sponsored or contributed to (and is not, and has never
been, required to contribute to) any Employee Benefit Plan, and the Company has no liability and has never had any liability (joint, several, contingent or otherwise) with respect to any Employee Benefit Plan maintained, operated or otherwise
contributed to by Seller or an ERISA Affiliate from and after the Closing. 
 (c) The Company is not a party to nor has any Contract with
any independent contractor, consultant or advisor. 
 3.3.13 Brokers. No broker, investment banker, agent, finder or other
intermediary acting on behalf of the Company or under the authority thereof, is or will be entitled to any broker’s or finder’s fee or any other commission or similar fee directly or indirectly in connection with the transactions
contemplated under this Agreement. 
 3.3.14 Taxes. 

(a) All U.S. federal, state, local, and non-U.S. Tax Returns relating to any and all Taxes concerning
or attributable to the Company, have been timely filed, and such Tax Returns are true and correct in all material respects and have been completed in accordance with applicable law in all material respects. The Company has provided to the Parent
copies of all Tax Returns filed by or on behalf of the Company since its incorporation on July 11, 2012. The Company was not required in accordance with applicable law to file any Tax returns in respect of the years ended December 31, 2012
and 2013. 
 (b) All Taxes (whether or not shown on any Tax Return) required to be paid by or on behalf of the Company have been timely
paid. There are no Encumbrances for Taxes upon the Company or any of its assets. There is no reasonable basis for the assertion of any claim relating or attributable to Taxes which, if adversely determined, would result in any Encumbrances for Taxes
on the Company or any of its assets. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

29 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 (c) There is no Tax deficiency outstanding, assessed, or proposed against or with respect to
the Company or any of its assets, nor has there been executed or requested any outstanding waiver of any statute of limitations on or extension of the period for the assessment or collection of any Tax of or with respect to the Company or any of its
assets. 
 (d) Neither the Company nor any of its Affiliates has been notified of any request for an audit, examination, or proceeding with
respect to any Tax Return that relates to or concerns the Company, nor is any such audit, examination, or proceeding presently in progress. No adjustment relating to any Tax Return filed by or with respect to the Company has been proposed by any
Taxing Authority. No claim has ever been made that the Company is or may be subject to taxation in a jurisdiction in which it does not file Tax Returns. 

(e) None of the Company Shares is a “United States real property interest” within the meaning of Section 897(c)(1) of the Code.

 3.3.15 Real Property. The Company (i) does not own or lease any real property and (ii) has not (nor has any predecessor
thereof) owned or leased in the past any real property. 
 3.3.16 Financial Statements; Indebtedness; No Material Adverse Effect. 

(a) Attached to Schedule 3.3.16(a) is the Tax Return of the Company on Form 1120 containing an unaudited balance sheet of the Company
as of December 31, 2014. Other than as attached to Schedule 3.3.16(a), the Company has not prepared any other financial statements of the Company as of or for the periods ended December 31, 2014 or as of any date, or for any period
ended, after December 31, 2014. The unaudited balance sheet of the Company as of December 31, 2014 attached to Schedule 3.3.16(a) is accurate in all material respects, is consistent, in all material respects, with the books and
records of the Company, has been prepared in accordance with U.S. GAAP, and presents fairly, in all material respects, the financial condition of the Company as of December 31, 2014. Since December 31, 2014, the Company’s assets and
liabilities as would be reflected on an unaudited balance sheet of the Company as of the Closing Date prepared in accordance with U.S. GAAP have not changed. Schedule 3.3.16(a) sets forth the Company’s historical expenditures, if any,
since its incorporation on July 11, 2012 on a quarterly basis (or if no such expenditures have been so incurred, so states). 
 (b) The
Company (i) has no (A) indebtedness for borrowed money or other interest-bearing indebtedness owed under any under credit agreement or facility, (B) indebtedness evidenced by any note, bond, debenture or other debt security or
instrument, (C) indebtedness secured by a security interest, pledge or mortgage on its assets, indebtedness for the deferred purchase price of property or services with respect to which it is liable, contingently or otherwise, as obligor or
otherwise, (D) capitalized lease obligations, synthetic lease obligations and sale leaseback obligations, whether secured or unsecured, or (E) obligations under interest rate cap, swap, collar or similar transactions or currency hedging
transactions; (ii) is not party to any letters of credit, performance bonds or bankers acceptances; and (iii) has not guaranteed, directly or indirectly, in any manner any indebtedness of any type described in the foregoing clauses
(i) and (ii) of any other Person. All indebtedness of any type described in the foregoing sentence has been paid or otherwise discharged in full at or prior to the Closing. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

30 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 (c) Since January 31, 2015, no Material Adverse Effect has occurred or is continuing.

 3.3.17 Interested Party Transactions. None of the Sellers or their respective Affiliates or Affiliates of the Company
(collectively, the “Interested Parties”) (a) except for (i) the License Agreement to which Brandeis is a party, and (ii) the Investment Agreements to which each Seller is a party, is presently a party to any Contract or
other arrangement with the Company, or (b) except for the Licensed Patent Rights owned by Brandeis and licensed to the Company under the License Agreement, owns any interest in any assets used by the Company. There are no outstanding
Liabilities, notes payable to, receivables from or advances by the Company to, and the Company is not otherwise a creditor of, an Interested Party, each of which Liabilities, notes payable, receivables or advances shall be paid or otherwise
discharged in full at or prior to the Closing. 
 3.3.18 Environmental Matters. The Company has complied in all material respects with
all Applicable Laws intended to protect the environment and/or human health or safety (collectively, “Environmental Laws”). The Company has not released, handled, generated, used, stored, transported or disposed of any material,
substance or waste which is regulated by Environmental Laws (“Hazardous Materials”). The Company has no Knowledge of any environmental investigation, study, test or analysis, the purpose of which was to discovery, identify, or
otherwise characterize the condition of the soil, groundwater, air or the presence of Hazardous Materials at any location at which the business of the Company has been conducted. The Company does not have Environmental Liabilities that would
reasonably be expected to have a Material Adverse Effect. As used herein, “Environmental Liabilities” are any claims, demands, or liabilities under Environmental Law which arise out of or in any way relate to the operations or
activities of the Company, or any real property at any time owned, operated or leased by the Company, whether contingent or fixed, actual or potential, and arise from or relate to actions occurring (including any failure to act) or conditions
existing on or before the Closing Date. 
 3.3.19 Undisclosed Liabilities. The Company does not have any Liability (whether known or
unknown, whether absolute or contingent, whether liquidated or unliquidated and whether due or to become due), except for contractual liabilities incurred in the ordinary course of business under the Company Contracts. 

3.3.20 Full Disclosure. None of the representations or warranties made by the Company in this Agreement or any Ancillary Agreement to
which it is or will be a party, nor statements made in the Company and Seller Disclosure Schedules or any certificate furnished by the Company pursuant to this Agreement or any Ancillary Agreement to which it is or will be a party, when taken
together, contain any untrue statement of a material fact, or omits to state any material fact necessary in order to make the statements contained herein or therein, in the light of the circumstances under which they were made, not misleading. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

31 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 3.4 Representations and Warranties of the Sellers. Except with respect to the
representations and warranties contained below in Section 3.4.7 as to which Brandeis makes no such representations and warranties, each Seller, severally as to such Seller, hereby represents and warrants to Merger Sub and
the Parent that as of the Closing Date: 
 3.4.1 Authorization. The execution, delivery and performance of this Agreement and the
Ancillary Agreements to which it is or will be a party have been duly authorized by such Seller or, if applicable, the board of directors or similar governing body of such Seller. No other action or approval on the part of such Seller is required
for the execution, delivery and performance of this Agreement by such Seller and the Ancillary Agreements to which it is or will be a party. 

3.4.2 Organization. Such Seller, if such Seller is an entity, is validly existing and in good standing under the laws of the state of
its organization and has the requisite power and authority necessary to enter into, deliver and perform its obligations pursuant to each of the Transaction Documents to which it is or will be a party. Such Seller, if such Seller is an individual,
has all necessary legal capacity to enter into each of the Transaction Documents to which it is or will be a party and to perform all of his or her obligations pursuant to each of the Transaction Documents to which such Seller is or will be a party.

 3.4.3 Title to Company Shares. Such Seller (a) is the sole record and beneficial owner of, the Company Shares set forth
opposite such Seller’s name on Schedule 3.3.3(a); (b) except as set forth in the Investment Agreements, is not a party to any voting trust, proxy or other agreement or understanding with respect to the voting of such Company Shares;
(c) except as set forth in the Investment Agreements, is not a party to any option, warrant, purchase right or other Contract that could require such Seller to sell, transfer or otherwise dispose of any of such Seller’s Company Shares
(other than this Agreement); (d) has full power, right and authority, and any approval required by Applicable Laws, to make and enter into this Agreement; and (e) has good, valid and marketable title to such Seller’s Company Shares set
forth opposite such Seller’s name on Schedule 3.3.3(a), free and clear of all Encumbrances. Upon consummation of the transactions contemplated by this Agreement, and, assuming that the other Seller’s party to this Agreement have
good and marketable title to such Seller’s Company Shares set forth opposite such Seller’s name on Schedule 3.3.3(a), free and clear of all Encumbrances, the Parent will acquire good and marketable title to 100% of the capital stock
of the Company, free and clear of all Encumbrances. Such Seller has consented to the Merger in accordance with Section 228 of Delaware Law and/or by conduct by tendering such Seller’s Company Shares and thereby forfeits all of such
Seller’s appraisal rights in respect of the Merger under Section 262 of Delaware Law. 
 3.4.4 Power and Authority. Such
Seller has the power and authority to execute and deliver this Agreement and the Ancillary Agreements to which it is or will be a party and to perform its obligations hereunder and thereunder. This Agreement and the Ancillary Agreements to which
such Seller is a party have been duly executed and delivered by such Seller, and constitute the legal, valid and binding obligations of such Seller, enforceable against such Seller in accordance with their respective terms except as such
enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and by general principles of equity. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

32 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 3.4.5 Non-Contravention. The execution,
delivery and performance by such Seller of this Agreement and the Ancillary Agreements to which it is or will be a party and its compliance with the terms and provisions hereof and thereof do not conflict with or result in a breach of any of the
terms and provisions of or constitute a default under: (a) a loan agreement, guaranty, financing agreement, agreement affecting a product or other agreement or instrument binding or affecting it or its property that would adversely affect such
Seller’s ability to consummate the transactions contemplated by this Agreement and the Ancillary Agreements to which it is or will be a party; (b) if an entity, the provisions of such Sellers certificate or articles of incorporation,
bylaws or similar governing documents; or (c) any order, writ, injunction or decree of any Governmental Authority entered against such Seller or by which any of such Seller’s property is bound that would adversely affect such Seller’s
ability to consummate the transactions contemplated by this Agreement and the Ancillary Agreements to which such Seller is a party. 
 3.4.6
Litigation. There is no litigation or proceeding (including, but not limited to arbitration), in law or in equity, and there are no proceedings or governmental investigations before any commission or other administrative authority or
Governmental Authority, pending, or, to such Seller’s Knowledge, threatened, against such Seller with respect to this Agreement or the consummation of the transactions contemplated hereby. 

3.4.7 Regulatory Matters. 

(a) None of Fidelity, Petsko or Ringe, nor, solely with respect to Fidelity, any of Fidelity’s current officers, directors or employees,
nor, to the actual knowledge of Fidelity, any independent contractor or agent of Fidelity involved in preparing or submitting any Regulatory Documentation, has ever been, is currently, or is the subject of a proceeding that could lead to the
Company, such Seller or any such employees or agents becoming, as applicable, a Debarred Entity or Debarred Individual, an Excluded Entity or Excluded Individual or a Convicted Entity or Convicted Individual. For purposes of this provision, the
following definitions shall apply: (i) a “Debarred Individual” is an individual who has been debarred by the FDA pursuant to 21 U.S.C. §335a(a) or barred from providing services in any capacity to a person that has an approved or
pending drug or injectable product application; (ii) a “Debarred Entity” is a corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. §335a(a) or barred from submitting or assisting in the
submission of any abbreviated drug application, or a subsidiary or affiliate of a Debarred Entity; (iii) an “Excluded Individual” or “Excluded Entity” is (A) an individual or entity, as applicable, who has been
excluded, debarred, suspended or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department of Health and Human Services, or (B) is
an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal procurement and non-procurement programs, including those produced by the
U.S. General Services Administration (GSA); and (iv) a “Convicted Individual” or “Convicted Entity” is an individual or entity, as applicable, who has been convicted of a criminal offense that falls within the ambit of 21
U.S.C. §335a(a) or 42 U.S.C. §1320a—7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible, and in each case any foreign equivalents thereof, as applicable. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

33 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 (b) None of Fidelity, Petsko or Ringe, nor, solely with respect to Fidelity, any of
Fidelity’s current officers, directors or employees, nor, to the actual knowledge of Fidelity, any independent contractor or agent of Fidelity involved in preparing or submitting any Regulatory Documentation, has made an untrue statement of a
material fact or fraudulent statement to any Pharmaceutical Product Regulatory Authority, failed to disclose a material fact required to be disclosed to any Pharmaceutical Product Regulatory Authority, or committed any act, made any statement, or
failed to make any statement, that would reasonably be expected to provide a basis for the FDA to invoke its policy respecting “Fraud, Untrue Statements of Material Fact, Bribery, and Illegal Gratuities”, set forth in 56 Fed. Reg. 46191
(September 10, 1991) or any similar Applicable Law in any other country in the Territory. 
 3.4.8 Brokers. No broker, investment
banker, agent, finder or other intermediary acting on behalf of such Seller or under the authority thereof, is or will be entitled to any broker’s or finder’s fee or any other commission or similar fee directly or indirectly in connection
with the transactions contemplated under this Agreement. 
 3.4.9 Investor Representations. 

(a) Such Seller is an “accredited investor” as such term is defined in Rule 501(a) of Regulation D under the United States
Securities Act of 1933, as amended (the “Securities Act”), and has such knowledge and experience in financial and business matters that such Seller is capable of evaluating the merits and risks of the investment in such
Seller’s portion of the Parent Shares. Such Seller believes he or it has received all the information regarding Parent and Merger Sub that he or it considers necessary or appropriate for deciding whether to acquire such Seller’s portion of
the Parent Shares. 
 (b) Such Seller is acquiring such Seller’s portion of the Parent Shares solely for such Seller’s own account
(not as a nominee or agent) for investment purposes and does not have any Contract with any person to sell, transfer or grant participations to any third person with respect to any portion of the Parent Shares for such Seller. 

(c) The Parent has made available to such Seller all material that has been requested by such Seller and has provided answers to all questions
of such Seller regarding the terms and conditions of the offering of the Parent Shares and the business, properties, prospects, and financial condition of the Parent and its Subsidiaries, including Merger Sub, and such additional information (to the
extent the Parent possessed such information or could acquire it without unreasonable effort or expense) necessary to verify the accuracy of any information furnished or made available to such Seller by the Parent. Such Seller has had an opportunity
to inspect such books and records and material contracts as such Seller deemed necessary to its determination to acquire such Seller’s portion of the Parent Shares. Such Seller believes he or it has received all the information it considers
necessary or appropriate for deciding whether to purchase the Parent Shares. 
 (d) Such Seller understands that an investment in the Parent
Shares is highly speculative and that there can be no assurance as to what return, if any, there may be. Such Seller further understands that no public market now exists for all or any portion of the shares comprising the Parent Shares, that there
can be no assurance that a public market will ever exist for the shares comprising the Parent Shares and that the Parent is under no obligation to register 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

34 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
any portion of the Parent Shares for such Seller. Such Seller (i) has no need for liquidity in its investment in such Seller’s portion of the Parent Shares, (ii) is able to bear
the substantial economic risks of an investment in such Seller’s portion of the Parent Shares for an indefinite period, and (iii) at the present time, can afford a complete loss of such investment in such Seller’s portion of the
Parent Shares. If an individual, such Seller’s current commitments to illiquid investments is not disproportionate to such Seller’s net worth and such Seller’s investment in such Seller’s portion of the Parent Shares will not
cause such commitment to become disproportionate. Such Seller acknowledges that no federal, state or other governmental agency has made any findings or determination as to the fairness of the offering for investment, nor any recommendation or
endorsement of the Parent Shares. The offering of the Parent Shares has not been reviewed for accuracy or completeness by any federal, state or other securities commissioner or agency. 

(e) Such Seller was not offered or sold the Parent Shares, directly or indirectly, by means of any form of general solicitation or general
advertisement, including (i) any advertisement, article, notice or other communication published in any newspaper, magazine or similar medium or broadcast over television or radio or (ii) any seminar or other meeting whose attendees had
been invited by general solicitation or general advertising. 
 (f) Such Seller acknowledges and understands that the Parent Shares have not
been registered under the Securities Act or any other securities laws by reason of a specific exemption thereunder, and that any certificates evidencing such Seller’s portion of the Parent Shares will be imprinted with legends restricting their
transfer other than in compliance with the Securities Act and other applicable securities laws. Such Seller acknowledges that such Seller’s portion of the Parent Shares must be held indefinitely unless subsequently registered under the
Securities Act or the Parent receives an opinion of counsel satisfactory to the Parent that such registration is not required. 
 (g) Such
Seller understands that the Parent Shares have not been registered under the Securities Act on the ground that the sale provided for in this Agreement and the issuance of securities hereunder is exempt from registration under the Securities Act
pursuant to Section 4(2) thereof, Regulation D or other specific exemption thereunder, and that the Company’s reliance on such exemption is predicated on the accuracy of such Seller’s representations set forth herein. 

(h) To the extent that such Seller is a Covered Person (as defined in Section 3.3.9(m) of this Agreement), no
Disqualification Event (as defined in Section 3.3.9(m) of this Agreement) is applicable to such Seller, except for a Disqualification Event as to which Rule 506(d)(2)(ii-iv) or (d)(3)
of the Securities Act is applicable. 
 (i) Such Seller is a US person (as provided for by the Securities Act 1933) and acknowledges no
offer of the Parent Shares has been made to such Seller in any jurisdiction other than the United States of America. 
 3.5 Additional
Representations and Warranties of Brandeis. Brandeis hereby represents and warrants to Merger Sub and the Parent that as of the Closing Date: 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

35 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 3.5.1 Validity of the License Agreement. The License Agreement (a) is the legal,
valid and binding license to the Licensed Patent Rights, enforceable against Brandeis in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
creditors’ rights generally and by general principles of equity, and (b) represents the complete agreement and understanding between Brandeis and the Company relating to the Licensed Patent Rights as of the Closing Date. The License
Agreement has not been amended, modified or supplemented as of the Closing Date, other than the amendment contemplated to be entered into simultaneously with the Closing pursuant to the terms of this Agreement. The License Agreement is in full force
and effect, all payments through the Closing Date required to be made thereunder by the Company have been made, and the Company is in compliance in all material respects with its respective obligations thereunder. 

3.5.2 Rights to Licensed Patent Rights. All rights, title and interest of Ringe, Petsko and Xu Simon (collectively, the
“Inventors”) in the Licensed Patent Rights have been assigned to Brandeis and Brandeis has delivered copies of the patent assignments to the Parent. To the Knowledge of Brandeis’s Office of Technology Licensing (after inquiry
with Brandeis’s Office of General Counsel), Brandeis has not received any written notice from any Person claiming or asserting any infringement, misappropriation or violation with respect to Intellectual Property Rights of any Person in
connection with any of the Licensed Patent Rights. To the Knowledge of Brandeis’s Office of Technology Licensing (after inquiry with Brandeis’s Office of General Counsel), no event has occurred or circumstance exists that (with or without
notice or lapse of time) would cause or would be reasonably expected to cause Brandeis not to be able to license the Licensed Patent Rights in accordance with terms of the License Agreement, provided, however, that nothing in this sentence is
intended to be (nor shall it be construed as) a representation or warranty that the use of the Company Intellectual Property Rights does not infringe the Intellectual Property Rights of another Person. All issuance, renewal, maintenance and other
payments that are or have become finally due with respect to the Licensed Patent Rights have been paid as of the Closing Date. All documents, certificates and other material in connection with the Licensed Patent Rights have, for the purposes of
maintaining such Licensed Patent Rights, been filed in a timely manner with the relevant Governmental Authorities. Brandeis has filed, prosecuted and maintained or caused to be filed, prosecuted and maintained on its behalf, all Licensed Patent
Rights. 
 3.5.3 Use of Government Funding. The Licensed Patent Rights were developed at least in part with federal funding from the
U.S. government. 
 3.5.4 No Right to Additional Company Shares of Parent. Except for the portion of the Parent Shares set forth
opposite Brandeis’s name on Schedule 2.1.5, immediately after the consummation of the transactions contemplated by this Agreement, Brandeis is not, and will not be, entitled to, credited as fully paid, any A ordinary shares of
£0.0001 in the capital of the Parent or any other ordinary shares or securities convertible into or exercisable or exchangeable for ordinary shares of Parent pursuant to the License Agreement or otherwise. Brandeis acknowledges that neither
Parent nor any of its Affiliates is, nor will be, obligated to issue Brandeis any Anti-Dilution Protection Adjustment Shares (as defined in the License Agreement) pursuant to Exhibit A of the License Agreement, any other provision of the License
Agreement or otherwise. 
 4. CLOSING DELIVERIES 

4.1 Deliveries of the Company and Sellers. At the Closing, the Company and each of the Sellers shall deliver, or cause to be delivered,
to the Parent the following: 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

36 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 4.1.1 Ancillary Agreements. The Company and each Seller shall have delivered to Merger
Sub or the Parent each Ancillary Agreement listed on Schedule 4.1.1 to which it is or will be a party, each of which shall have been validly executed by a duly authorized representative of the Company or such Seller, as applicable. 

4.1.2 Resignations. The Company shall have delivered to the Parent, the resignations and releases, effective as of the Closing Date, of
the officers and directors of the Company. 
 4.1.3 Corporate Certificate. The Company shall have delivered to the Parent a
certificate dated as of the Closing Date and signed on the Company’s behalf by an officer of the Company certifying as follows: (a) the Company’s Certificate of Incorporation and bylaws, or equivalent organizational documents,
attached to such certificate is true, correct and complete, in full force and effect in the form attached to such certificate from and after the date of the adoption of the resolutions referred to in clause (b) below, and no amendment to such
Certificate of Incorporation has occurred from and after the date of the last amendment annexed thereto; (b) the resolutions of the stockholders, if applicable, and the Board of Directors of the Company attached to such certificate authorizing
this Agreement, the Ancillary Agreements and the transactions contemplated by this Agreement and the Ancillary Agreements were duly adopted at a duly convened meeting thereof or by written consent, remain in full force and effect, and have not been
amended, rescinded or modified; and (c) the incumbency of its directors and officers as of the Closing. 
 4.1.4 FRPTA
Certification. The Company shall have delivered to the Parent a certificate that meets the requirements of Treasury Regulations Section 1.1445-2(c)(3) dated as of the Closing Date, certifying that the
Company has not been a “United States real property holding corporation” within the meaning of Section 897(c)(2) of the Code at any time during the five year period ending on the Closing Date. 

4.1.5 Amendment to License Agreement. The License Agreement shall be amended in form and substance satisfactory to the Parent in the
form attached hereto as Exhibit C (the “License Agreement Amendment”). 
 4.1.6 Termination of the Investment
Agreements. The Company and the Sellers shall have delivered a termination agreement in form and substance satisfactory to Parent with respect to the termination as of the Effective Time of the Investment Agreements as set forth on Schedule
4.1.1. 
 4.2 Deliveries of the Parent. At the Closing, the Parent and Merger Sub shall deliver, or cause to be delivered, to the
Sellers’ Representative the following: 
 4.2.1 Ancillary Agreements. The Parent shall have delivered to the Sellers’
Representative each Ancillary Agreement listed on Schedule 4.2.1, each of which shall have been validly executed by a duly authorized representative of Parent. 
  

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

37 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 4.2.2 Corporate Certificate. The Parent shall deliver to the Seller’s
Representative a certificate dated as of the Closing Date and signed on the Parent’s behalf by an authorized director or officer of the Parent certifying as follows: (a) the Parent’s articles of association are true, correct and
complete, in full force and effect in the form attached to such certificate from and after the date of the corporate approvals referred to in clause (b) below, and no amendment to such Certificate of Incorporation has occurred from and after
the date of the last amendment annexed thereto; (b) that this Agreement, the Ancillary Agreements and the transactions contemplated by this Agreement and the Ancillary Agreements were duly authorized by all necessary corporate action and have
not been amended, rescinded or modified; and (c) the incumbency of its directors and officers as of the Closing. 
 4.2.3 Corporate
Certificate. Merger Sub shall have delivered to the Sellers’ Representative a certificate dated as of the Closing Date and signed on the Company’s behalf by an officer of the Company certifying as follows: (a) Merger Sub’s
certificate of incorporation and bylaws, or equivalent organizational documents, attached to such certificate is true, correct and complete, in full force and effect in the form attached to such certificate from and after the date of the adoption of
the resolutions referred to in clause (b) below, and no amendment to such Certificate of Incorporation has occurred from and after the date of the last amendment annexed thereto; (b) the resolutions of the sole stockholder, if applicable,
and the Board of Directors of Merger Sub attached to such certificate authorizing this Agreement, the Ancillary Agreements and the transactions contemplated by this Agreement and the Ancillary Agreements were duly adopted at a duly convened meeting
thereof or by written consent, remain in full force and effect, and have not been amended, rescinded or modified; and (c) the incumbency of its directors and officers as of the Closing. 

5. COVENANTS. 
 5.1
Confidentiality. 
 5.1.1 Fidelity. From and after the Closing, Fidelity shall, and shall cause its Affiliates to, hold, and
shall use its reasonable best efforts to cause its and their respective Representatives to hold, in confidence and not use any and all Company Confidential Information, whether written or oral, concerning the Company or any Confidential Information
of Parent disclosed to Fidelity. 
 5.1.2 Brandeis, Petsko and Ringe. From and after the Closing, each of Brandeis, Petsko and Ringe
shall, and shall cause its Affiliates to, hold, and shall use its reasonable efforts to cause its and their respective Representatives to hold, in confidence, and not use, (a) any and all Company Confidential Information, whether written or
oral, concerning the Company or (b) any Confidential Information of Parent disclosed to Brandeis, Petsko or Ringe, except that, with respect to Company Confidential Information, (x) Brandeis and its Affiliates and their respective
Representatives shall (i) be permitted to use the subject matter described and claimed in the Patent Rights for non-commercial purposes to the extent permitted by Section 2.3 of the License Agreement
(as amended by the License Agreement Amendment), (ii) retain all rights to the Licensed Know-How, except to the extent licensed under Section 2.1 of the License Agreement (as amended by the License
Agreement Amendment), and (y) Petsko and Ringe shall be permitted to use (i) the Licensed Patent Rights (A) for or on behalf of the Parent or its Affiliates, or (B) for non-commercial,
academic purposes in his or her capacity as a faculty member of Brandeis or other academic institution disclosed in writing to Parent, or (ii) the Licensed Know-How as permitted by Brandeis (except to the
extent licensed under Section 2.1 of the License Agreement (as amended by the License Agreement Amendment)). 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

38 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 5.1.3 Company Confidential Information. As used herein, “Company Confidential
Information” is Confidential Information of the Company except to the extent that such Confidential Information (a) is generally available to and known by the public through no fault of such Seller, any of its Affiliates or their
respective Representatives; or (b) is lawfully acquired by such Seller, any of its Affiliates or their respective Representatives from and after the Closing from sources which are not prohibited from disclosing such information by a legal,
contractual or fiduciary obligation. Solely for the purposes of applying this Section 5.1 to Brandeis and notwithstanding anything to the contrary in this Agreement, information that is or has been independently developed by Brandeis, any of
its Affiliates, or any of their respective Representatives shall not constitute Company Confidential Information. 
 5.1.4 Disclosure
Required under Applicable Law. If any Seller or any of its Affiliates or their respective Representatives are compelled to disclose any Company Confidential Information or Confidential Information of Parent by judicial or administrative process
or by other requirements of Applicable Law, such Seller shall promptly notify the Parent or the Company in writing and shall disclose only that portion of such Company Confidential Information or Confidential Information of Parent, as applicable,
which such Seller is advised by its counsel in writing is legally required to be disclosed, provided that such Seller, at Parent’s cost, shall use reasonable best efforts to obtain (or to permit Parent to obtain) an appropriate protective order
or other reasonable assurance that confidential treatment will be accorded such Company Confidential Information or Confidential Information of Parent, as applicable. 

5.2 Noncompetition and Nonsolicitation. For a period commencing on the Closing Date and (x) with respect to Fidelity, ending thirty-six months following the Closing Date, and (y) with respect to Petsko and Ringe, thirty-six months following the first Registration in the United States, no
Restricted Party shall, and no Restricted Party shall permit any of its Affiliates to, directly or indirectly: 
 (a) Consult with, render
services for or otherwise engage in any business, endeavor or activity anywhere in the Territory for the development, manufacture, use or Commercialization of any Competing Technology; provided, that, (y) Petsko and Ringe shall be permitted to
use the Licensed Patent Rights and Licensed Know-How (i) for or on behalf of the Parent or its Affiliates, or (ii) for non-commercial, academic purposes in his
capacity as a faculty member of Brandeis or other academic institution disclosed in writing to Parent; 
 (b) Hire or solicit any employee
of the Company or its Affiliates or encourage any such employee to leave such employment or hire any such employee who has left such employment; provided, that nothing in this Section 5.2 shall prevent any Restricted
Party or any of its Affiliates from hiring (i) any employee whose employment has been terminated by the Company or its Affiliates or (ii) after 180 days from the date of termination of employment, any employee whose employment has been
terminated by the employee; or 
 (c) solicit or entice, or attempt to solicit or entice, any clients or customers of the Company or
potential clients or customers of the Company for purposes of diverting their business or services from the Company. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

39 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 For the avoidance of doubt, the restrictions contained in this
Section 5.2 shall not apply to Brandeis, which shall be subject in all respects to the rights and restrictions with respect to the Licensed Patent Rights and Licensed Know-How as set
forth in the License Agreement (as amended). 
 5.2.2 Right to Equitable Relief. Each Restricted Party acknowledges that a breach or
threatened breach of this Section 5.2 would give rise to irreparable harm to the Parent and its Affiliates, for which monetary damages would not be an adequate remedy, and hereby agrees that in the event of a breach or a
threatened breach by any Restricted Party of any such obligations, the Parent or its Affiliates shall, in addition to any and all other rights and remedies that may be available to it in respect of such breach, be entitled to equitable relief,
including a temporary restraining order, an injunction, specific performance and any other relief that may be available from a court of competent jurisdiction (without any requirement to post bond). 

5.2.3 Reasonableness of Restrictions. Each Restricted Party acknowledges that the restrictions applicable to such Restricted Party
contained in this Section 5.2 are reasonable in duration and scope (geographic and otherwise) and necessary to protect the legitimate interests of the Parent and its Affiliates and constitute a material inducement to the
Parent and Merger Sub to enter into this Agreement and consummate the transactions contemplated by this Agreement. In the event that any covenant contained in this Section 5.2 should ever be adjudicated to exceed the time,
geographic, product or service, or other limitations permitted by Applicable Law in any jurisdiction, then any court is expressly empowered to reform such covenant, and such covenant shall be deemed reformed, in such jurisdiction to the maximum
time, geographic, product or service, or other limitations permitted by Applicable Law. The covenants contained in this Section 5.2 and each provision hereof is severable and distinct covenants and provisions. The
invalidity or unenforceability of any such covenant or provision as written shall not invalidate or render unenforceable the remaining covenants or provisions hereof, and any such invalidity or unenforceability in any jurisdiction shall not
invalidate or render unenforceable such covenant or provision in any other jurisdiction. 
 5.3 Further Assurances. Following the
Closing, each of the Parties shall, and shall cause their respective Affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the
provisions hereof and give effect to the transactions contemplated by this Agreement. 
 5.4 Tax Covenants. 

5.4.1 Tax Returns and Payment of Taxes. Without the prior written consent of the Parent (which consent shall not be unreasonably
withheld), no Seller shall, to the extent it may affect, or relate to, the Company, make, change or rescind any Tax election or amend any Tax Return or take any action or omit to take any action that would have the effect of increasing the Tax
liability or reducing any Tax asset of the Company in respect of any Post-Closing Tax Period. 
 (a) All transfer, documentary, sales, use,
stamp, registration, value added and other such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement and the other Transaction Documents (including any stamp or transfer Tax in respect of the Company
Shares and any other similar Tax) shall be borne and paid by Fidelity when due. Fidelity shall, at its own expense, timely file any Tax Return or other document with respect to such Taxes or fees (and the Company shall reasonably cooperate with
respect thereto as necessary). 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

40 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 (b) The Company shall prepare, or cause to be prepared, all Tax Returns required to be filed
by the Company after the Closing Date with respect to a Pre-Closing Tax Period. Any such Tax Return shall be prepared in a manner consistent with past practice (unless otherwise required by Law) and without a
change of any election or any accounting method and shall be submitted by the Company to Fidelity (together with schedules, statements and, to the extent requested by Fidelity, supporting documentation) at least forty-five (45) days prior to
the due date (including extensions) of such Tax Return. If Fidelity objects to any item on any such Tax Return, it shall, within ten days after delivery of such Tax Return, notify the Company in writing that it so objects, specifying with
particularity any such item and stating the specific factual or legal basis for any such objection. If a notice of objection shall be duly delivered, the Company and Fidelity shall negotiate in good faith and use their reasonable best efforts to
resolve such items. If the Company and Fidelity are unable to reach such agreement within ten (10) days after receipt by the Company of such notice, the disputed items shall be resolved by the Accounting Firm and any determination by the
Accounting Firm shall be final. The Accounting Firm shall resolve any disputed items within twenty (20) days of having the item referred to it pursuant to such procedures as it may require. If the Accounting Firm is unable to resolve any
disputed items before the due date for such Tax Return, the Tax Return shall be filed as prepared by the Company and then amended to reflect the Accounting Firm’s resolution. The costs, fees and expenses of the Accounting Firm shall be borne
equally by the Company and Fidelity. The preparation and filing of any Tax Return of the Company that does not relate to a Pre-Closing Tax Period shall be exclusively within the control of the Company. 

5.4.2 Straddle Period. In the case of Taxes that are payable with respect to a taxable period that begins before and ends after the
Closing Date (each such period, a “Straddle Period”), the portion of any such Taxes that are treated as Pre-Closing Taxes for purposes of this Agreement shall be: 

(a) in the case of Taxes based upon, or related to, income or receipts, deemed equal to the amount which would be payable if the taxable year
ended with the Closing Date; and 
 (b) in the case of other Taxes, deemed to be the amount of such Taxes for the entire period multiplied
by a fraction the numerator of which is the number of days in the period ending on the Closing Date and the denominator of which is the number of days in the entire period. 

5.4.3 Contests. The Company agrees to give written notice to Fidelity of the receipt of any written notice by the Company, the Parent or
any of the Company’s Affiliates which involves the assertion of any claim, or the commencement of any audit or other proceeding in respect of Taxes of the Company, in respect of which an indemnity may be sought by any Parent Indemnified Party
pursuant to this Section 5.4 (a “Tax Claim”); provided, that failure to comply with this provision shall not affect any Parent Indemnified Party’s right to indemnification hereunder. The Company or its
Affiliates shall control the contest or resolution of any Tax Claim; provided, however, that the Company shall obtain the prior written consent of Fidelity (which 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

41 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 consent shall not be unreasonably withheld or delayed) before entering into any settlement of a claim or
ceasing to defend such claim; Fidelity shall be entitled to participate in the defence of such claim and to employ counsel of its choice for such purpose, the fees and expenses of which separate counsel shall be borne solely by Fidelity. 

5.4.4 Cooperation and Exchange of Information. Each Seller and the Company shall provide each other with such cooperation and
information as either of them reasonably may request of the other in filing any Tax Return pursuant to this Section 5.4 or in connection with any audit or other proceeding in respect of Taxes of the Company. Such
cooperation and information shall include providing copies of relevant Tax Returns or portions thereof, together with accompanying schedules, related work papers and documents relating to rulings or other determinations by Taxing Authorities. Each
Seller and the Company shall retain all Tax Returns, schedules and work papers, records and other documents in its possession relating to Tax matters of the Company for any taxable period beginning before the Closing Date until the date seven
(7) years following the expiration of the statute of limitations of the taxable periods to which such Tax Returns and other documents relate, without regard to extensions except to the extent notified by the other Parties in writing of such
extensions for the respective Tax periods. Prior to transferring, destroying or discarding any Tax Returns, schedules and work papers, records and other documents in its possession relating to Tax matters of the Company for any taxable period
beginning before the Closing Date, each Seller or the Parent (as the case may be) shall provide the other Party with reasonable written notice and offer the Company or the Sellers’ Representative, as the case may be, the opportunity to take
custody of such materials. 
 5.4.5 Tax Indemnification. Fidelity shall indemnify the Company, and each Parent Indemnified Party and
hold them harmless from and against (a) any Loss attributable to any breach of or inaccuracy in any representation or warranty made in Section 3.3.14; (b) any Loss attributable to any breach or violation of, or failure
to fully perform, any covenant, agreement, undertaking or obligation in Section 5.4; (c) all Pre-Closing Taxes and all Taxes of the Company arising out of or relating to the business
of the Company for all Pre-Closing Tax Periods; (d) all Taxes of any member of an affiliated, consolidated, combined or unitary group of which the Company (or any predecessor of the Company) is or was a
member on or prior to the Closing Date by reason of a liability under Treasury Regulation Section 1.1502-6 or any comparable provisions of foreign, state or local Law; and (e) any and all Taxes of
any person imposed on the Company arising under the principles of transferee or successor liability or by Contract, relating to an event or transaction occurring before the Closing Date. In each of the above cases, together with any out-of-pocket fees and expenses (including attorneys’ and accountants’ fees) incurred in connection therewith. Fidelity shall reimburse the Company for any Taxes of
the Company that are the responsibility of Fidelity pursuant to this Section 5.4 within ten Business Days after payment of such Taxes by the Parent or the Company. To the extent that any obligation or responsibility
pursuant to Section 5.4 may overlap with an obligation or responsibility pursuant to Article 6, the provisions of this Section 5.4 shall govern. 

5.4.6 Refunds. Any refunds of Taxes of the Company plus any interest received with respect thereto (net of any Taxes actually imposed on
Parent or its Affiliates with respect to such interest) from an applicable Taxing Authority with respect to any Pre-Closing Tax Period shall be for the account of the Sellers, and shall be paid by Parent to
the Fidelity (for disbursement to the Sellers) within twenty (20) Business Days after Parent, the Surviving Corporation or any of 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

42 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 their Affiliates receives such refund. If any refunds or any related interest previously paid to the Sellers
pursuant to this Section 5.4.6 is required to be repaid to a Taxing Authority or is subsequently disallowed by a Taxing Authority, the Sellers shall be required to repay to Parent such previously paid amounts, together with
any interest and penalties due to such Taxing Authority. 
 5.4.7 Tax Treatment of Payments. Any Contingent Payment actually paid
pursuant to Section 2.3 or indemnification payments pursuant to this Section 5.4 shall be treated as an adjustment to the Merger Consideration by the parties for Tax purposes, unless otherwise
required by Applicable Law. 
 5.4.8 Survival. Notwithstanding anything in this Agreement to the contrary, the provisions of
Section 3.3.14 and this Section 5.4 shall survive for the full period of all applicable statutes of limitations (giving effect to any waiver, mitigation or extension thereof) plus 60 days. 

5.5 Public Disclosures. No disclosure of the existence, or the terms, of this Agreement may be made by any Party, and no Party shall use
the name, trademark, trade name or logo of any other Party, its Affiliates or their respective employee(s) in any publicity, promotion, press release or disclosure relating to this Agreement or its subject matter, or any Ancillary Agreement without
the prior express written permission of the other Parties, except as may be required by Applicable Law. Notwithstanding the foregoing, the Parties have agreed to (a) allow disclosure of this Agreement and the Ancillary Agreements to each
Party’s insurers and to existing or potential equity investors and debt providers, provided that such Third Parties are bound by confidentiality restrictions at least as stringent as those contained in this Section 5.1,
and (b) allow disclosure of the existence of this Agreement to its employees and vendors and for internal communications. 
 6. INDEMNIFICATION.

 6.1 Survival. The representations and warranties of the Parties contained in this Agreement, or in any certificate or other
writing delivered pursuant hereto or thereto or in connection herewith or therewith shall survive until eighteen months from the Closing Date (the “Expiration Date”), except that the representations and warranties in Sections
3.1.1, 3.1.2, 3.1.6, 3.2.1, 3.2.2, 3.2.3, 3.2.7, 3.3.1, 3.3.2, 3.3.3, 3.3.6, 3.3.13, 3.4.1, 3.4.2, 3.4.3, 3.4.8 and 3.5.4, (the
“Special Representations”) shall survive until 30 days following expiration of all statutes of limitation applicable to the matters referred to therein. Notwithstanding the preceding sentence, any representation or warranty in
respect of which indemnification may be sought under Sections 6.2 or 6.3 herein shall survive the time at which it would otherwise terminate pursuant to the preceding sentence if notice of the inaccuracy or breach or
potential liability thereof giving rise to such right to indemnity, with reasonable detail to allow the receiving Party to make an assessment thereof, shall have been given to the Party against whom such indemnity may be sought prior to the
Expiration Date. Except for the Special Representations, no claim for indemnity for breaches of representations and warranties under this Agreement may be made after the Expiration Date. The covenants, agreements and other provisions contained in
this Agreement shall survive the Closing for the full period of all applicable statutes of limitations plus 60 days. The representations and warranties and covenants and agreements contained in this Agreement (and any right to indemnification for
breach thereof) shall not be affected by any investigation conducted by or on behalf of an Indemnified Party or any knowledge acquired (or capable of being acquired) by an Indemnified Party, whether before or after the Closing Date, with respect to
the inaccuracy or breach of any such representation or warranty or covenant or agreement. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

43 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 6.2 Indemnification by the Parent. Subject to the limitations set forth in
Section 6.4, the Parent shall indemnify, defend and hold harmless each Seller, severally as to such Seller, their respective Affiliates, and, as applicable, their respective employees, officers, directors and agents (each,
an “Seller Indemnified Party”) from and against any and all Losses to the extent resulting from or arising out of (a) (i) any misrepresentation or breach of warranty made by Merger Sub or the Parent pursuant to the provisions
of this Agreement (other than Special Representations), the Ancillary Agreements or any certificate or other writing delivered pursuant hereto or thereto and (ii) any misrepresentation or breach of any Special Representation made by Merger Sub
or the Parent, or (b) any failure by Merger Sub or the Parent to fully perform, fulfill or comply with any covenant or agreement set forth herein, in the Ancillary Agreements or any certificate or other writing delivered pursuant hereto or
thereto; provided that no Seller Indemnified Party shall be entitled to any duplicative recovery for the same Loss under this Section 6.2 to the extent that any Seller Indemnified Party has been actually compensated for
such Loss. 
 6.3 Indemnification by the Sellers. 

6.3.1 Fidelity. Subject to the limitations set forth in Section 6.4, Fidelity shall indemnify, defend and hold
harmless Merger Sub (and, following the Effective Time, its successor, the Company), the Parent and their respective employees, officers, directors, agents and Affiliates (each, a “Parent Indemnified Party”) from and against any and
all Losses to the extent resulting from or arising out of (a) (i) any misrepresentation or breach of warranty made by the Company or Fidelity pursuant to the provisions of this Agreement (other than Special Representations), the Ancillary
Agreements or any certificate or other writing delivered pursuant hereto or thereto and (ii) any misrepresentation or breach of any Special Representation made by the Company or Fidelity, (b) any failure by the Company or Fidelity at or
prior to the Closing to fully perform, fulfill or comply with any covenant or agreement set forth herein, in the Ancillary Agreements or any certificate or other writing delivered pursuant hereto or thereto, and (c) the Company’s ownership
of any of the Company Assets or the operation of the business of the Company prior to the Closing; provided that no Parent Indemnified Party shall be entitled to any duplicative recovery for the same Loss under this
Section 6.3.1 to the extent that any Parent Indemnified Party has been actually compensated for such Loss. 
 6.3.2
Brandeis. Subject to the limitations set forth in Section 6.4, Brandeis shall indemnify and hold harmless the Parent Indemnified Parties from and against any and all Losses to the extent resulting from or arising out
of (a) (i) any misrepresentation or breach of warranty made by Brandeis pursuant to the provisions of this Agreement (other than Special Representations), the Ancillary Agreements or any certificate or other writing delivered pursuant hereto or
thereto and (ii) any misrepresentation or breach of any Special Representation made by Brandeis, or (b) any breach or nonperformance of any covenant or agreement of Brandeis contained herein or the Transaction Documents to which it is or
will be a party; provided that no Parent Indemnified Party shall be entitled to any duplicative recovery for the same Loss under this Section 6.3.2 to the extent that any Parent Indemnified Party has been actually
compensated for such Loss. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

44 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 6.3.3 Petsko. Subject to the limitations set forth in
Section 6.4, Petsko shall indemnify and hold harmless the Parent Indemnified Parties from and against any and all Losses to the extent resulting from or arising out of (a) (i) any misrepresentation or breach of
warranty made by Petsko pursuant to the provisions of this Agreement (other than Special Representations), the Ancillary Agreements or any certificate or other writing delivered pursuant hereto or thereto and (ii) any misrepresentation or
breach of any Special Representation made by Petsko, or (b) any breach or nonperformance of any covenant or agreement of Petsko contained herein or the Transaction Documents to which he is or will be a party; provided that no Parent Indemnified
Party shall be entitled to any duplicative recovery for the same Loss under this Section 6.3.3 to the extent that any Parent Indemnified Party has been actually compensated for such Loss. 

6.3.4 Ringe. Subject to the limitations set forth in Section 6.4, Ringe shall indemnify and hold harmless the
Parent Indemnified Parties from and against any and all Losses to the extent resulting from or arising out of (a) (i) any misrepresentation or breach of warranty made by Ringe pursuant to the provisions of this Agreement (other than Special
Representations), the Ancillary Agreements or any certificate or other writing delivered pursuant hereto or thereto and (ii) any misrepresentation or breach of any Special Representation made by Ringe, or (b) any breach or nonperformance
of any covenant or agreement of Ringe contained herein or the Transaction Documents to which she is or will be a party; provided that no Parent Indemnified Party shall be entitled to any duplicative recovery for the same Loss under this
Section 6.3.4 to the extent that any Parent Indemnified Party has been actually compensated for such Loss. 
 6.3.5
For purposes of this Article 6, “Material Adverse Effect” qualifications and other qualifications based on the word “material” or similar phrases contained in such representations and warranties shall be disregarded for
all purposes with respect to any indemnity pursuant to this Section 6.3, including for determining whether there is a claim and the amount of any Loss. 

6.3.6 No Seller Indemnified Party will make any claim for indemnification against the Company, the Parent or any other Affiliate of the Company
(determined after the Closing) under the certificate of incorporation or bylaws of the Company, Delaware Law, any insurance policy or otherwise by reason of the fact that such Seller Indemnified Party was a stockholder, director, manager, officer,
employee or agent of the Company or is or was serving at the request of any of the Company as a partner, member, manager, trustee, director, officer, employee or agent of another entity (whether such claim is for judgments, damages, penalties,
fines, costs, amounts paid in settlement, losses or expenses) with respect to any action, suit, proceeding, complaint, claim or demand brought by a Parent Indemnified Party against any Seller or the Sellers collectively (in each case, if such
action, suit, proceeding, complaint, claim or demand arises under this Agreement). Each Seller Indemnified Party hereby acknowledges that it will have no claims or right to contribution or indemnity from the Company, the Parent or any other
Affiliate of the Company (determined after the Closing) under the certificate of incorporation or bylaws of the Company, Delaware Law, any insurance policy or otherwise with respect to amounts payable by any Seller Indemnified Party pursuant to this
Agreement (including pursuant to Sections 2.3 or the applicable provision of this Section 6.3) or any of the other Transaction Documents. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

45 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 6.4 Limitation of Indemnification. The term “Indemnified Party” as
used in this Section 6.4 shall refer to Seller Indemnified Party or Parent Indemnified Party as applicable. 

6.4.1 Threshold Amount; Limitations. No claim may be made by any Indemnified Party for indemnification pursuant to
Section 6.2(a)(i), Section 6.3.1(a)(i), Section 6.3.2(a)(i), Section 6.3.3(a)(i), or Section 6.3.4(a)(i) herein unless and until the
aggregate amount of Losses for which the Indemnified Party seeks to be indemnified exceeds ten thousand dollars ($10,000.00), and then, only to the extent of such excess. 

6.4.2 Cap. 
 (a)
Parent. The maximum liability of Parent for all claims of the Seller Indemnified Parties made pursuant to Section 6.2(a)(i) shall not exceed five hundred thousand dollars ($500,000.00). 

(b) Fidelity. The maximum liability of Fidelity for all claims made pursuant to Section 6.3.1(a)(i) shall not
exceed five hundred thousand dollars ($500,000.00). 
 (c) Brandeis; Ringe; Petsko. The maximum liability for each of Brandeis, Ringe
and Petsko for any liability under this Agreement (including indemnification liability under this Article 6) shall not exceed the value of the portion of the Parent Shares received by such Seller (as hereinafter determined) plus the
amount of Contingent Payments, if any, actually received by such party under Section 2.3, after reducing such amount by any Tax payment made by such party in connection with such Contingent Payment (including any amount
withheld with respect to such Contingent Payments pursuant to Section 2.5). 
 6.4.3 Insurance. Any Losses
as to which indemnification provided for in Section 6.2 and Section 6.3 may apply shall be determined net of any cash recovery actually received by an Indemnified Party with respect to insurance
specifically with respect to the specific matter for which indemnification is sought, less any costs actually incurred in obtaining such recovery (including premium adjustments and similar charges). 

6.4.4 Exclusive Remedy. Except for actions or claims for fraud, actions or claims brought under the provisions of
Section 5.4, or actions or claims in respect of breaches of Sections 5.1, 5.2, 5.3 or 5.5 after the Closing, this Article 6 shall provide the sole and exclusive remedy for any misrepresentation or
breach of any representation and warranty pursuant to the provisions of this Agreement or any certificate or other writing delivered pursuant hereto. 

6.4.5 Payment of Claims. 
 (a)
Fidelity. Any claims made by a Parent Indemnified Party against Fidelity shall be satisfied by a cash payment from Fidelity. 

(b) Brandeis, Petsko and Ringe. Any claims made by a Parent Indemnified Party against Brandeis, Petsko or Ringe shall be
satisfied first by the transfer of the Parent Shares held by Brandeis, Petsko or Ringe, respectively, back to Parent at the fair market value of the Parent Shares as of the date (the “Return Date”) the amount of Losses in respect of
which any Parent Indemnified Party is entitled to indemnification from such Seller pursuant to the 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

46 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
applicable subsection of Section 6.3 applicable to such Seller has been finally determined pursuant to the provisions of Section 6.5 or
Section 6.6, as applicable, in accordance with the provisions set forth in the following sentence, with the balance, if any, satisfied pursuant to the setoff, recoupment or deduction of any Milestone Payment or Royalty
Payment in accordance with the provisions of Section 6.4.6 below. The fair market value of the Parent Shares as of the Return Date shall be determined as follows: 

(i) If the Return Date is within 180 days of the closing of a Qualified Financing, then the fair market value of the Parent Shares as of the
Return Date shall be equal to the value of the shares offered in the Qualified Financing. 
 (ii) If the Return Date is more than 180 days
after the closing of a Qualified Financing, then the fair market value of the Parent Shares as of the Return Date shall be determined as follows: 

(A) If a 409A Valuation (as herein defined) is available as of the Return Date, then the fair market value of the Parent Shares as of the
Return Date shall equal the value of the Parent Shares determined by an independent Third Party valuation that satisfies the safe harbor requirements under section 409A of the Code (a “409A Valuation”); or 

(B) If there is no 409A Valuation of the Parent Shares available as of the Return Date, then Brandeis, Petsko or Ringe (as applicable), on the
one hand, and the Parent, on the other, shall propose in writing within thirty (30) days after the Return Date his, her or its determination of the fair market value of the Parent Shares as of the Return Date, and 

(1) If the difference between the fair market value as determined by Brandeis, Petsko or Ringe, as applicable, and the Parent is 20% or less,
then the fair market value of the Parent Shares as of the Return Date shall be mid-point between the two valuations; 

(2) If the difference between the fair market value as determined by Brandeis, Petsko or Ringe, as applicable, and the Parent is more than
20%, then (i) either Party may submit the disputed fair market value of the Parent Shares as of the Return Date to the Accounting Firm for a determination pursuant to the procedures of Section 2.3.3(b) of this
Agreement, the provisions of which shall apply hereto mutatis mutandis, (ii) Brandeis, Petsko or Ringe (as applicable), on the one hand, and the Parent, on the other, may agree in writing to use the
mid-point between their applicable valuations, or (iii) the applicable Parties may otherwise agree in writing to a value for the Parent Shares as of the Return Date, in each case, with respect to clauses
(ii) and (iii), which agreement shall be made within ten (10) Business Days after the expiration of the 30-day period pursuant to Section 6.4.5(b)(ii)(B) (or such longer
period as the applicable Parties may mutually agree upon). To the extent any Party submits a matter to the Accounting Firm pursuant to clause (i) above, Brandeis and not Fidelity shall serve as Sellers’ Representative with respect to such
matter and Fidelity shall not have any obligation under Section 2.3.3 of this Agreement to pay any fees, costs or expenses of the Accounting Firm with respect to such matter (in which case, such obligations, if any, shall become the obligations
of Brandeis, Petsko and Ringe, subject to and in accordance with the provisions of Section 2.3.3). 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

47 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 (c) Parent. Any claims made by a Seller Indemnified Party against
Parent shall be satisfied by a cash payment from Parent. 
 6.4.6 Setoff Against Milestone Payment and Royalty Payments. The Parent
Indemnified Parties may, at their election, setoff, recoup and deduct from all or any portion of any Milestone Payment or Royalty Payment payable to a particular Seller (directly or through the Sellers’ Representative on behalf of all of the
Sellers under Section 2.3 of this Agreement), the amount of Losses in respect of which any Parent Indemnified Party is entitled to indemnification from such Seller pursuant to Section 5.4 (solely
with respect to Fidelity) or the applicable subsection of Section 6.3 applicable to such Seller and, in each case, as has been finally determined pursuant to the provisions of Section 6.5 or
Section 6.6, as applicable, or is being contested in good faith by the Parent Indemnified Parties and such Seller (up to the entire amount of the portion of such Milestone Payment or Royalty Payment that becomes payable to
such Seller, but in no event in excess of the amount of Losses in respect of which any Parent Indemnified Party is entitled to or seeking indemnification). The Parent Indemnified Parties shall exercise the foregoing rights by notifying the
Sellers’ Representative or the applicable Seller that it is reducing the amount of any Milestone Payment or Royalty Payment payable to the Sellers or a Seller under Section 2.3 of this Agreement and specifying in
reasonable detail (i) the nature of the claim and (ii) the amount of the claimed Losses in respect of each such claim. The setoff, recoupment and deduction of any Milestone Payment or Royalty Payment payable to the Sellers under
Section 2.3 of this Agreement shall not be the Parent Indemnified Parties sole method of collection or payment for any Losses in respect of which any Parent Indemnified Party is entitled to indemnification from the Sellers
pursuant to this Article 6. If the Parent Indemnified Parties setoff, recoup, or deduct under this section and it is determined that the Parent Indemnified Parties did not have a right to setoff, recoup or deduct part or all of such funds
payable to a Seller or Sellers, then, immediately upon such a determination, the Parent Indemnified Parties shall pay to the aggrieved Seller the amount it did not have a right to set-off, recoup, or deduct.

 6.4.7 Limited Consequential Loss Exclusion. (a) No Parent Indemnified Party shall be entitled to indemnification from
Brandeis, Petsko or Ringe pursuant to Section 6.3.2, Section 6.3.3, or Section 6.3.4, respectively, and (b) neither Brandeis, Petsko or Ringe nor any of their respective
Affiliates, employees, officers, directors, heirs and agents (collectively, the “Brandeis Indemnified Parties”), shall be entitled to indemnification from Parent pursuant to Section 6.2, in each case, with
respect to clauses (a) and (b), for any Losses under this Agreement that constitute special, exemplary, incidental, indirect, punitive or consequential damages (including lost profits), except for any such Losses under this Agreement that
constitute special, exemplary, incidental, indirect, punitive or consequential damages (including lost profits) incurred by Third Parties and for which an Indemnified Party is entitled to indemnification for a Third Party Claim under
Section 6.3.2 Section 6.3.3, Section 6.3.4 or Section 6.2 of this Agreement, as applicable. For the avoidance of doubt, nothing set forth in this
Section 6.4.7 shall limit or be construed to affect the indemnification obligations of the Parent to Fidelity or any of its Affiliates, employees, officers, directors, or agents pursuant to
Section 6.2 or Fidelity pursuant to Section 6.3.1. 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

48 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 6.5 Third Party Claims. 

6.5.1 Procedure. Promptly after the discovery by the Party seeking indemnification under Section 6.2 or
Section 6.3 herein (the “Indemnified Party”) of any Loss, claim or breach, including any claim by a Third Party (a “Third Party Claim”) that would reasonably be expected to give rise to a
claim for indemnification hereunder, the Indemnified Party shall give written notice to the Party against whom indemnity is sought (the “Indemnifying Party”); provided that, no delay on the part of the Indemnified Party in notifying
the Indemnifying Party shall relieve the Indemnifying Party of any liability or obligation hereunder, except to the extent that the Indemnifying Party has been prejudiced thereby, and then only to such extent. The Indemnifying Party shall assume the
defense of the Third Party Claim and retain reputable counsel reasonably satisfactory to the Indemnified Party to represent the Indemnifying Party and the Indemnifying Party shall pay the fees and expenses of such counsel related to such proceeding.
In any such proceeding, the Indemnified Party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of the Indemnified Party unless (a) the Parties shall have mutually agreed to the
retention of such counsel, (b) the named parties to any such proceeding (including any impleaded parties) include the Parties and representation of both Parties by the same counsel would be inappropriate due to actual or potential differing
interests between them or (c) the Indemnified Party assumes the defense of a Third Party Claim after the Indemnifying Party has failed to diligently defend a Third Party Claim it has assumed per the Indemnified Party’s request. All such
fees and expenses incurred pursuant to this Section 6.5 shall be reimbursed as they are incurred. In the event that the Indemnified Party assumes the defense of any Third Party Claim, the Indemnified Party’s right to
indemnification for a Third Party Claim shall not be adversely affected by assuming the defense of such Third Party Claim. The Indemnifying Party shall not be liable for any settlement of any proceeding without its prior written consent (which shall
not be unreasonably withheld, conditioned or delayed). The Indemnifying Party shall not, without the written consent of the Indemnified Party, effect any settlement of any Third Party Claim unless (a) such settlement includes an unconditional
release of the Indemnified Party from all liability on claims to which the indemnity relates that are the subject matter of such proceeding and (b) it would not result in (i) the imposition of a consent order, injunction or decree that
would restrict the future activity or conduct of the Indemnified Party or any of its Affiliates, (ii) a finding or admission of a violation of Applicable Law or violation of the rights of any Person by the Indemnified Party or any of its
Affiliates or (iii) any monetary liability of the Indemnified Party arising from such Third Party Claim that shall not be promptly paid or reimbursed by the Indemnifying Party. 

6.5.2 Confidential Information. The Indemnified Party and the Indemnifying Party shall use Commercially Reasonable Efforts to avoid
production of Confidential Information (consistent with Applicable Law), and to cause all communications among employees, counsel and others representing any party to a Third Party Claim to be made so as to preserve any applicable attorney-client or
work-product privileges. 
 6.6 Direct Claims. If an Indemnified Party wishes to make a claim for indemnification hereunder for a Loss
that does not result from a Third Party Claim (a “Direct Claim”), the Indemnified Party shall notify the Indemnifying Party in writing of such Direct Claim promptly after first learning of such Direct Claim, the amount or the
estimated amount of Losses sought thereunder to the extent then ascertainable (which estimate shall not be conclusive of the final 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

49 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
amount of such Direct Claim), any other remedy sought thereunder, any relevant time constraints relating thereto and, to the extent practicable, any other material details pertaining thereto. The
Indemnifying Party shall have a period of thirty (30) business days within which to respond to such Direct Claim. If the Indemnifying Party does not respond within such thirty (30) business day period or rejects all or any part of the
Direct Claim, the Indemnified Person shall be free to seek enforcement of its rights to indemnification under this Agreement with respect to such Direct Claim. 

6.7 Treatment of Indemnity Payments. Any payment made pursuant to this Article 6 shall be treated as an adjustment to the Merger
Consideration to the extent permitted by Applicable Law. 
 7. MISCELLANEOUS. 

7.1 Sellers’ Representative. 

7.1.1 The Sellers’ Representative is hereby appointed and authorized to have full power and authority to represent and take actions for
and on behalf of each Seller with respect to the Authorized Actions, and (x) all such actions taken by the Sellers’ Representative shall be binding upon each Seller and such Seller’s successors, assigns and, if applicable, heirs, as
if expressly confirmed and ratified in writing by each of them and (y) no Seller shall have a right to object, dissent, protest or otherwise contest the same. Any action to be taken by any Seller or the Sellers collectively pursuant to
Section 2.3 shall be authorized to be taken solely by the Sellers’ Representative, except that if Fidelity shall elect in writing not to pursue a claim or objection pursuant to Section 2.3 of
this Agreement that Brandeis wishes to pursue, then Brandeis shall be permitted upon written notice to Parent to assume the role of Sellers’ Representative pursuant to this Section 7.1, with all of the duties,
obligations, liability, rights, power and authority of the Sellers’ Representative, solely to pursue and resolve such claim or objection in accordance with the terms and conditions of this Agreement. For the avoidance of doubt, to the extent
Brandeis assumes the role of Sellers’ Representative with respect to a claim or objection pursuant to this Section 7.1, Fidelity shall not serve as Sellers’ Representative with respect to such claim or objection
and Fidelity shall not have any obligation under Section 2.3.3 of this Agreement to pay any fees, costs or expenses of the Accounting Firm with respect to such claim or objection (in which case, such obligations, if any, shall become the
obligations of Brandeis, Petsko and Ringe, subject to and in accordance with the provisions of Section 2.3.3). 
 7.1.2 The
Sellers’ Representative is hereby authorized to (the “Authorized Actions”): 
 (a) receive all notices or documents
given or to be given to any of the Sellers or the Sellers’ Representative pursuant hereto or any other Transaction Document or in connection herewith or therewith and to receive and accept service of legal process in connection with any suit or
proceeding arising under this Agreement or any other Transaction Document; 
 (b) after the date of this Agreement, take such action as the
Sellers’ Representative may, in its sole discretion, deem appropriate in respect of: (A) receiving all documents or certificates or notices required under this Agreement or any Ancillary Agreement; and (B) all such actions as may be
necessary to carry out any of the transactions contemplated by 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

50 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
this Agreement or any other Transaction Document, excluding any waiver of any obligation of Merger Sub or the Parent (except that the Sellers’ Representative shall be authorized to waive any
obligation of Parent or its Affiliates under Section 2.3 or Section 5.4, provided, however, that Seller’s Representative shall not be entitled to waive the obligations of Parent or Affiliates
under Section 2.3 with respect to Brandeis, Petsko or Ringe without obtaining Brandeis’ prior written consent); and 
 (c) engage
counsel and such accountants (including the Accounting Firm) and other advisors for the purpose of carrying out the obligations of the Sellers and/or the Sellers’ Representative under Section 2.3 or
Section 5.4 and incur such expenses in connection with the foregoing. 
 7.1.3 The Sellers’ Representative
shall have no duties or liability to the Sellers with respect to any action taken, decision made or instruction given by the Sellers’ Representative in connection with this Agreement or any instruments, documents and agreements executed and
delivered in connection with this Agreement. 
 7.1.4 The Sellers, in proportion to their respective holdings of Company Shares as set forth
on Schedule 2.1.5, agree to indemnify, defend and hold the Sellers’ Representative and any of its Affiliates and any of their respective heirs, successors, assigns, partners, directors, officers, employees, agents, stockholders,
consultants, attorneys, accountants, advisors, brokers, representatives or controlling persons, in each case relating to the Sellers’ Representative’s conduct as Sellers’ Representative, harmless against all Losses incurred by them,
other than Liabilities resulting from the Sellers’ Representative’s gross negligence, fraud or willful misconduct in connection with its performance under this Agreement or any instruments, documents and agreements executed and delivered
in connection with this Agreement. This indemnification shall survive the termination of this Agreement. The costs of such indemnification (including the costs and expenses of enforcing this right of indemnification) shall be paid by the Sellers and
no Parent Indemnified Party shall have any liability therefor. In no event shall the Sellers’ Representative solely with respect to its actions or omissions in its capacity as Sellers’ Representative be liable hereunder or in connection
herewith for any indirect, punitive, special or consequential damages. 
 7.1.5 In the performance of its duties hereunder, the Sellers’
Representative shall be entitled to (i) rely upon any document or instrument reasonably believed by its to be genuine, accurate as to content and signed by any Seller or any other Party hereunder and (ii) assume that any Person purporting
to give any notice in accordance with the provisions hereof has been duly authorized to do so. 
 7.1.6 The Seller or Sellers collectively
holding over a majority of the outstanding Company Shares immediately prior to the Closing shall have the right at any time following the Closing to remove the then-acting Sellers’ Representative provided such Sellers appoint a successor
Sellers’ Representative upon the resignation or removal of the Sellers’ Representative; provided, however, that neither the removal/resignation of the then acting Sellers’ Representative nor the appointment of a successor
Sellers’ Representative shall be effective until the delivery to the Company of executed counterparts of a writing signed by the Sellers collectively holding over a majority of the Company Shares outstanding immediately prior to the Closing
with respect to 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

51 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
such removal, resignation and appointment, together with an acknowledgement signed by the successor Sellers’ Representative appointed in such writing that he or it accepts the responsibility
of successor Sellers’ Representative and agrees to perform and be bound by all of the provisions of this Agreement applicable to the Sellers’ Representative. Each successor Sellers’ Representative shall have all of the power,
authority, rights and privileges conferred by this Agreement upon the original Sellers’ Representative, and in this Agreement or any instruments, documents and agreements executed and delivered in connection with this Agreement and shall be
deemed to include any interim or successor Sellers’ Representative. 
 7.1.7 Subject to the right of removal under
Section 7.16, the appointment of the Sellers’ Representative hereunder is irrevocable and any action taken by the Sellers’ Representative pursuant to the authority granted in this
Section 7.1.9 shall be effective and absolutely binding as the action of the Sellers’ Representative under this Agreement or any instruments, documents and agreements executed and delivered in connection with this
Agreement. 
 7.2 Governing Law, Jurisdiction; Specific Performance. 

7.2.1 Governing Law. The interpretation and construction of this Agreement shall be governed by the laws of the State of New York,
excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

7.2.2 Jurisdiction. With respect to any dispute, claim, controversy or proceeding arising out of or relating to this Agreement, any
Ancillary Agreement or any of the transactions contemplated hereby or thereby (each, an “Action”), each Party irrevocably (i) agrees and consents to be subject to the jurisdiction of the United States District Court for the
Southern District of New York or any New York State court sitting in New York City and (ii) waives any objection which it may have at any time to the laying of venue of any such Action brought in any such court, waives any claim that such
dispute, claim, controversy or proceeding has been brought in an inconvenient forum and further waives the right to object, with respect to such Action, that such court does not have any jurisdiction over such Party. 

7.2.3 WAIVER OF JURY TRIAL. THE PARTIES HERETO HEREBY IRREVOCABLY WAIVE, AND AGREE TO CAUSE THEIR RESPECTIVE SUBSIDIARIES TO WAIVE, THE
RIGHT TO TRIAL BY JURY IN ANY ACTION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT, ANY ANCILLARY AGREEMENT OR ANY TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. 

7.2.4 Specific Performance. Notwithstanding anything in Agreement to the contrary, the Parties agree that irreparable damage would occur
and that the parties would not have any adequate remedy at law in the event that the obligations of the parties to effect, on the terms and conditions set forth herein, the covenants and agreements set forth in Article V of this Agreement
were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to seek an injunction or injunctions to prevent such (and only such) actual or threatened breaches of
this Agreement and to enforce specifically (without proof of actual damages or harm, and not subject to any requirement 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

52 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 for the securing or posting of any bond in connection therewith) such terms and provisions of this Agreement
in the United States District Court for the Southern District of New York or any New York State court sitting in New York County, this being in addition to any other remedy to which they are entitled at law or in equity, including money damages.

 7.3 Waiver. A Party’s failure to enforce, at any time or for any period of time, any provision of this Agreement, or to
exercise any right or remedy shall not constitute a waiver of that provision, right or remedy or prevent such Party from enforcing any or all provisions of this Agreement and exercising any rights or remedies. To be effective any waiver must be in
writing. 
 7.4 Notices. 

7.4.1 Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication permitted or required under
this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by facsimile transmission (with transmission confirmed) or by internationally recognized overnight delivery
service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section 7.4.2 or to such other address as the Party to whom notice is to be given may have provided to the
other Party in accordance with this Section 7.4.1. Such Notice shall be deemed to have been given as of the date delivered by hand or on the second Business Day (at the place of delivery) after deposit with an
internationally recognized overnight delivery service. 
 7.4.2 Address for Notice. 

For Parent: 
 MeiraGTx Limited

 450 East 29th Street, 5th Floor 

New York, New York 10016 
 Attn:
Richard Giroux, Chief Operating Officer 
 Fax: (646) 666-7978 

with a copy to: 
 DLA Piper LLP
(US) 
 1251 Avenue of the Americas 

27th Floor 
 New York, New York
10020 
 Attn: Penny J. Minna, Esq. 

Fax: (410) 580-3228 

and 
 MeiraGTx Limited 

450 East 29th Street, 5th Floor 

New York, New York 10016 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

53 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 Attn: Office of the Chief Counsel 

Fax: (646) 666-7978 

For the Sellers’ Representative: 

F-Prime Inc. 

(f/k/a Fidelity Biosciences Corp.) 

One Main Street 
 Cambridge, MA
02142 
 Attn: Stacie Weninger Barnes 

Facsimile: (617) 231-2425 

with a copy to: 
 Allan S.
Galper 
 Senior Legal Counsel 

FMR LLC (Fidelity Investments) 

82 Devonshire St., MZ EPC 13A 

Boston, Massachusetts 02109 

Fax: (617) 385-2001 

For the Sellers: 
 The address
of such Seller set forth on the signature pages to this Agreement. 
 7.5 Entire Agreement. This Agreement, the Schedules and the
Ancillary Agreements constitute the entire agreement between the Parties with respect to the subject matter of this Agreement and the Ancillary Agreements. This Agreement and the Ancillary Agreements supersede all prior agreements, whether written
or oral, with respect to the subject matter hereof and thereof (provided that, for the avoidance of doubt, the foregoing shall not affect the Confidentiality Agreements or the Parent Shareholder Agreement). All Schedules or Exhibits referred to in
this Agreement are intended to be and are hereby specifically incorporated into and made a part of this Agreement. In the event of any inconsistency between any such Schedules or Exhibits and this Agreement, the terms of this Agreement shall govern.

 7.6 Amendment. Any amendment or modification of this Agreement must be in writing and signed by authorized representatives of both
Parties. 
 7.7 Assignment. No Party may assign its rights or delegate its obligations under this Agreement, in whole or in part
without the prior written consent of the other Parties, except that the Parent and, following the Effective Time, the Company may make such an assignment or delegation without the consent of the Sellers or the Sellers’ Representative
(i) to Affiliates, provided that such assignment or delegation shall not relieve such assigning Party from its obligations hereunder, or (ii) to a successor to substantially all of the business to which this Agreement pertains, whether in
a merger, sale of stock, sale of assets, spin-off or other transaction (provided that, for the avoidance of doubt, any assignment following the Effective Time of the obligations of the Company under this
Agreement without a corresponding assignment of the 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

54 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 obligations of Parent hereunder shall not affect any of the then-remaining rights and obligations of Parent
under this Agreement). Any permitted successor or assignee of rights and/or obligations hereunder shall, in writing to the other Parties, expressly assume performance of such rights and/or obligations. Any attempted assignment or delegation in
violation of this Section 7.7 shall be void. 
 7.8 No Benefit to Others. The provisions of this Agreement
are for the sole benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights in any other Persons, except as otherwise expressly provided in this Agreement. 

7.9 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of
which taken together shall be deemed to constitute one and the same instrument. An executed signature page of this Agreement delivered by facsimile or PDF transmission shall be as effective as an original executed signature page. 

7.10 Severability. To the fullest extent permitted by Applicable Law, the Parties waive any provision of law that would render any
provision in this Agreement invalid, illegal or unenforceable in any respect. If any provision of this Agreement is held to be invalid, illegal or unenforceable, in any respect, then such provision will be given no effect by the Parties and shall
not form part of this Agreement. To the fullest extent permitted by Applicable Law and if the rights or obligations of any Party will not be materially and adversely affected, all other provisions of this Agreement shall remain in full force and
effect and the Parties will use their best efforts to negotiate a provision in replacement of the provision held invalid, illegal or unenforceable that is consistent with Applicable Law and achieves, as nearly as possible, the original intention of
the Parties. 
 7.11 Expenses. Except as otherwise provided herein, all costs and expenses incurred in connection with this Agreement
shall be paid by the Party incurring such cost or expense. 
 7.12 Interpretation and Construction. 

7.12.1 Unless otherwise provided herein, all monetary values stated herein are expressed in United States currency and all references to
“dollars” or “$” will be deemed references to the lawful money of the United States. Each accounting term set forth herein and not otherwise defined shall have the meaning accorded it under U.S. GAAP. For the avoidance of doubt,
in the event of any discrepancy between U.S. GAAP and the provisions of this Agreement, the provisions of this Agreement shall control. Whenever conversion of values from any Foreign Currency for a particular date or period shall be required, such
conversion shall be made using the closing exchange rate for the date that is three Business Days prior to the applicable date or dates, as the case may be, as reported by Bloomberg L.P. (the “Exchange Rate”) on the close of
business in New York, New York three Business Days prior to the applicable date or dates. 
 7.12.2 The parties have participated jointly in
the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise
favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement. Any reference to any federal, state, local or foreign Law shall be deemed also to refer to all rules and regulations promulgated thereunder,
unless the context requires otherwise. When a reference is made in this Agreement to a party or to a Section, Exhibit or Schedule, such reference 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

55 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 shall be to a Party to, a Section of, or an Exhibit or Schedule to, this Agreement, unless otherwise
indicated. All terms defined in this Agreement shall have their defined meanings when used in any Exhibit or Schedule to this Agreement or any certificate or other document made or delivered pursuant hereto, unless otherwise defined therein. 

7.12.3 Whenever the words “include”, “includes”, “including” or “such as” are used in this Agreement,
they shall be deemed to be followed by the words “without limitation”. The word “will” shall be construed to have the same meaning and effect as the word “shall”. The words “hereof”, “herein” and
“hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. Except where the context otherwise requires, wherever used, the singular
shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The word “extent” in the phrase “to the extent”
means the degree to which a subject or other thing extends, and such phrase shall not mean simply “if”. The words “asset” and “property” shall be construed to have the same meaning and effect. 

7.12.4 The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent
of this Agreement or the intent of any provision contained in this Agreement. 
 7.12.5 Any agreement, instrument or statute defined or
referred to herein means such agreement, instrument or statute as from time to time amended, supplemented or modified, including (a) (in the case of agreements or instruments) by waiver or consent and (in the case of statutes) by succession of
comparable successor statutes and (b) all attachments thereto and instruments incorporated therein. 
 7.12.6 References to a Person are
also to its permitted successors and assigns. 
 7.13 Opportunity to Consult Counsel. Each Party represents that it has had the
opportunity to consult with independent legal counsel or other advisors of its own choosing concerning this Agreement and the Ancillary Agreements to which it is or will be a party. 

[Signature Page Follows] 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

56 

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this
Agreement to be effective as of the Effective Date. 
  

			
	MERGER SUB:
	
	MEIRAGTx ACQUISITION CORPORATION
		
	By	 	 /s/ Richard Giroux

	Name:	 	Richard Giroux
	Title:	 	COO
	
	PARENT:
	
	MEIRAGTx LIMITED
		
	By	 	 /s/ Zandy Forbes

	Name:	 	Zandy Forbes
	Title:	 	CEO and Director

 [Signatures continued on the following page.] 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
			
	COMPANY:
	
	BRI-ALZAN, INC.
		
	By	 	 /s/ Stacie Weninger Barnes

	Name:	 	Stacie Weninger Barnes
	Title:	 	President
	
	SELLERS:
	
	F-PRIME INC
	(f/k/a FIDELITY BIOSCIENCES CORP.)
		
	By	 	 /s/ Mary Pendergast

	Name:	 	Mary Pendergast
	Title:	 	CFO
		
	Address:	 	One Main Street, 13th Floor
		 	Cambridge, Massachusetts 02142
	
	 /s/ Gregory Petsko

	Name: Gregory Petsko
		
	Address:	 	308 East 72nd St., Apt 14C
		 	New York, New York 10021
	
	 /s/ Dagmar Ringe

	Name: Dagmar Ringe
		
	Address:	 	983 Memorial Drive
		 	Cambridge, Massachusetts 02138
	
	BRANDEIS UNIVERSITY
		
	By	 	 /s/ Rebecca Menapace

	Name:	 	Rebecca Menapace
	Title:	 	Associate Provost for Innovation
		 	Executive Director, OTL
		
	Address:	 	415 South Street
		 	Waltham, Massachusetts 02453

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 [Signatures continued on the following page.] 

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. 
  

 Confidential Treatment Requested by MeiraGTx Holdings plc 

 

 
			
	SELLERS’ REPRESENTATIVE:
	
	F-PRIME INC
	(f/k/a FIDELITY BIOSCIENCES CORP.) solely in its capacity as the Sellers’ Representative,
		
	By	 	 /s/ Mary Pendergast

	Name:	 	Mary Pendergast
	Title:	 	CFO
		
	Address:	 	One Main Street, 13th Floor
		 	Cambridge, Massachusetts 02142

  
 Confidential Portions of this Exhibit
marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00283-of-00352.parquet"}]]